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CHAPTER 1 - INTRODUCTION 
Trophoblast cells are a major embryonic component of the placenta that mediate its major 
functions (Chaddha et al., 2004).  As placentation proceeds the trophoblast cells differentiate and 
change to accommodate the growing placenta and fetus that it supports.  The goal of this project 
was to better understand mechanisms that regulate trophoblast survival in both normal and 
pathological human pregnancies.  This chapter reviews the existing literature on growth factors 
and molecular mechanisms governing blastocyst implantation and placentation. 
The first 10 weeks of pregnancy are a period when O2 is low within the conceptus 
(Burton and Jauniaux, 2004; Burton et al., 1999).  Intrauterine measurements report low O2 
concentrations in placental tissues (~2%) compared to the surrounding decidua (~8%) and other 
adult tissues (Jauniaux et al., 2001; Rodesch et al., 1992).  This environment favors the 
proliferation of the trophoblast cells, while repressing invasion (Genbacev et al., 1996; Genbacev 
et al., 1997).  As a result, trophoblast cells accumulate and occlude the maternal blood vessels, 
which maintains the relatively hypoxic state (Burton and Jauniaux, 2004).  The most distal 
trophoblast cells contact maternal blood, exposing them to higher O2 concentrations, which 
promotes the invasive extravillous trophoblast (EVT) phenotype.  As gestation progresses 
beyond 10 weeks, the spiral arteries are remodeled by EVT cells to an extent that reperfuses and 
fully oxygenates the placenta by dislodging the occluding trophoblast cells and removing the 
arterial smooth muscle (Norwitz et al., 2001).  The placenta is programmed to survive this rapid 
increase in O2 tension after Week 10 to meet the demands of a growing fetus.  Prolonged 
hypoxia beyond Week 10 is associated with perinatal disease arising from aberrant placental 
development (Soleymanlou et al., 2005).  If reoxygenation does not take place in timely manner, 
or if the trophoblast cells are deficient in their ability to adjust to O2 fluctuation (Hung and 
Burton, 2006), uteroplacental insufficiency could result. 
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Uteroplacental insufficiency, the sub-optimal perfusion of the developing placenta due to 
reduced uterine artery blood flow, contributes to several perinatal disorders, including early 
pregnancy loss (EPL), fetal growth restriction (FGR), and preeclampsia (PE) (Hossain and 
Paidas, 2007; Papageorghiou et al., 2004).  The incidence of EPL approaches 15% (Larsen et al., 
2013). FGR occurs in 4-8% of all pregnancies in developed countries, depending on the infant 
size percentile used for inclusion (Kramer, 1987).  PE has a frequency of about 5-7%, while the 
most severe forms occur at 0.5-1%.  PE is clinically defined by the presence of maternal 
hypertension and proteinuria occurring after 20 weeks of pregnancy in a previously 
normotensive, non-proteinuric patient (Davey and MacGillivray, 1988).  Maternal death or 
serious long-term morbidity can occur, while abruption, preterm delivery and FGR contribute to 
perinatal fetal death and infant morbidity, with the associated costs of extensive neonatal 
hospitalization, and lifelong disabilities (Roberts et al., 1998).  Until recently, PE could be 
alleviated only by removal of the placenta (Roberts et al., 1998), requiring delivery of the fetus 
and accounting for 15% of premature deliveries and the associated infant morbidity and 
mortality (Meis et al., 1998).  More recently, interventional efforts such as the introduction of a 
low dose aspirin (Bujold et al., 2014) or Pravastatin (Ramma and Ahmed, 2014) regimen prior to 
16 weeks of gestation have shown promise in reducing the rate of PE in high-risk patients, 
providing a course of action when diagnosed early.  
Histological features of placentas delivered by women with EPL, PE and FGR suggest a 
prior disruption of EVT function in the first trimester (Burton and Jauniaux, 2004), characterized 
by reduced trophoblast invasion, insufficient remodeling of the spiral arteries, and EVT cell 
death (Brosens et al., 1972; DiFederico et al., 1999; Ishihara et al., 2002; Khong et al., 1986).  
Evidence strongly indicates that remodeling of the uterine arteries becomes deficient before PE 
and FGR are diagnosed, yet direct confirmation of early EVT dysfunction is lacking, and the 
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underlying etiologic cellular and molecular mechanisms are unknown due largely to our inability 
to interrogate the gestational period of interest.  A large number of predictors for FGR and PE 
have been proposed with variable results (Bastek and Elovitz, 2013; Hossain and Paidas, 2007; 
Papageorghiou et al., 2004; Staff et al., 2013).  First trimester screening of multiple predictors 
remains uninformative even when combined in a multivariable model (Myatt et al., 2012).  At 
best, screening at any GA is limited to predicting early severe PE.  Therefore, no reliable 
biomarkers are available to alert clinicians in the first trimester to identify pregnancies that will 
eventually develop FGR or PE, impeding progress toward targeted management of at-risk 
pregnancies to lessen the impact on women and their fetuses. 
While access to fetal cells for prenatal diagnosis is technically complex and in some cases 
high risk (Wapner, 2005), a relatively simple solution to this challenge has been advanced over 
the past forty years (Adinolfi and Sherlock, 2001; Bischoff and Simpson, 2006; Imudia et al., 
2010; Shettles, 1971).  Trophoblast cells shed into the lower uterine pole accumulate within the 
cervix.  Scientists and clinicians have tried to harness the information of trophoblast cells in the 
endocervical canal, but were largely unsuccessful due to the inability to purify these cells.  
Trophoblast retrieval and isolation from the cervix (TRIC) (Bolnick et al., 2014) efficiently 
separates maternal cells from fetal cells that resemble EVT cells in endocervical specimens.  
TRIC provides ample amounts of fetal DNA, RNA and protein for molecular analyses.  Fetal 
cells obtained by TRIC as early as 5 weeks of gestation can be used in genomic, epigenomic, 
transcriptomic, metabolomic or other global discovery paradigms.  Therefore, TRIC provides the 
opportunity to investigate the molecular profiles of trophoblast cells in the first trimester from 
pregnancies with known outcomes.  Indeed, a pilot study using TRIC has demonstrated 
significant differences between protein biomarkers produced by the fetal cells before 10 weeks 
of gestation in normal control pregnancies and those that ended with an EPL (Fritz et al., 2015a).  
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The survival and extravillous differentiation of trophoblast cells is crucial for normal 
pregnancy, and deficiencies are linked to diseases of placental insufficiency (e.g. EPL, FGR, 
PE).  Heparin-binding EGF-like growth factor (HBEGF) acts as a trophoblast survival factor, 
protecting the first trimester trophoblast cells from apoptosis during exposure to low O2 levels 
(Armant et al., 2006), and promoting their invasion of maternal tissues (Leach et al., 2004).  
Conversely the hypertensive disease, PE, in which trophoblast invasion of the uterine arteries is 
reduced (Khong et al., 1986) and apoptosis elevated (Allaire et al., 2000), is associated with a 
dramatic reduction in HBEGF expression (Leach et al., 2002a).  This suggests that the survival 
of trophoblast cells at the beginning of pregnancy might be disrupted by reduced HBEGF in 
women who later develop PE.  However, it is not known whether the decreased expression of 
HBEGF in preeclamptic placentas occurs prior to delivery, which would indicate whether 
dysregulation is a cause or result of disease.  Recently, these findings were confirmed and 
extended to other components of the epidermal growth factor (EGF) family (Armant et al., 
2015), of which HBEGF is a member. 
Epidermal growth factor (EGF) signaling system 
The EGF family of growth factors and their receptors regulate a variety of biological 
processes that include proliferation, differentiation and survival.  Growth factors in the EGF 
superfamily include EGF, HBEGF, transforming growth factor-alpha (TGFA), amphiregulin 
(AREG), betacellulin (BTC), epiregulin (EREG), epigen and the neuregulins (NRG) (Holbro and 
Hynes, 2004; Riese and Stern, 1998).  Recent studies have examined the roles of each EGF 
family member in implantation and placentation. 
The EGF-like growth factors activate receptor tyrosine kinases in the plasma membrane 
that include epidermal growth factor receptor (EGFR/ERBB1) and related ERBB family proteins 
(ERBB2, ERBB3, ERBB4).  Growth factor binding initiates an intrinsic protein-tyrosine kinase 
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activity, autophosphorylation of the cytoplasmic domain and receptor dimerization to generate a 
downstream signaling cascade (Holbro and Hynes, 2004).  The EGF-like growth factors are 
synthesized as membrane bound proteins that signal to their receptors on adjacent cells, through 
juxtacrine signaling, or they are secreted through proteolytic cleavage of their extracellular 
domain, carried out by metalloproteinases, for autocrine or paracrine signaling (Riese and Stern, 
1998).  
Mouse implantation 
The importance of the EGF signaling system for blastocyst implantation is suggested by 
the EGFR knockout (Miettinen et al., 1995; Sibilia and Wagner, 1995; Threadgill et al., 1995), 
which, depending on the genetic background of host mice, has a perinatal-lethal phenotype.  
However, the picture is less clear from studies of embryos with deletion of EGF family growth 
factors where several knockouts produce mice that are viable and fertile, while others have roles 
in early post-implantation embryonic development that make interpretation difficult.  It remains 
to be determined whether the EGF signaling system has a specific role in the process of 
implantation, or if it is more involved in embryonic survival and differentiation.  Alternative 
approaches provide evidence to support the hypothesis that this complex signaling system 
directly influences the success of blastocyst implantation. 
Experiments in mice establish that HBEGF is present in the uterus shortly before embryo 
implantation, providing the earliest known signaling between the blastocyst and maternal cells 
(Lim and Dey, 2009).  In situ hybridization demonstrates that HBEGF is expressed in the 
luminal epithelium specifically at sites surrounding blastocysts 6-7 hours prior to the attachment 
reaction (Das et al., 1994).  HBEGF is also expressed by blastocysts prior to implantation (Liu 
and Armant, 2004), suggesting its role in a two-way dialogue.  Experimentally induced delayed 
implantation in ovariectomized mice reveals no HBEGF expression at implantation sites; 
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however, HBEGF becomes upregulated in both the uterus (Das et al., 1994) and blastocyst 
(Hamatani et al., 2004) with administration of estrogen to activate the blastocyst to implant.  Its 
receptors ERBB1 and ERBB4 are concomitantly regulated by estrogen along with HBEGF in the 
blastocyst (Paria et al., 1993; Paria et al., 1999).  HBEGF signaling between the trophoblast and 
uterine epithelial cells is most likely initiated by embryonic HBEGF shedding, as depicted in 
Figure 1A.Crosstalk with other signaling pathways mobilizes HBEGF from intracellular stores in 
the trophectoderm and demonstrates the complexity of the maternal-embryo dialogue.  
Lysophosphatidic acid (LPA) produced in the maternal reproductive tract accelerates blastocoel 
formation at the morula stage and trophoblast differentiation at the early blastocyst stage through 
downstream intracellular Ca2+ signaling (Liu and Armant, 2004; Stachecki and Armant, 1996).  
LPA activates cognate G protein-coupled receptors that signal through phospholipase C to 
generate inositol-1,4,5-trisphosphate and diacylglycerol that, in turn, mobilize cytoplasmic free 
Ca2+ and activate protein kinase C (PKC), respectively (Contos et al., 2000).  Signaling by both 
cytoplasmic Ca2+ and PKC is known to stimulate HBEGF shedding (Dethlefsen et al., 1998; 
Dong and Wiley, 2000) and the subsequent transactivation of ERBB signaling (Umata et al., 
2001).  Immunofluorescence microscopy demonstrates that HBEGF is sequestered from the 
plasma membrane during blastocyst development, but accumulates transiently at the embryo 
surface in response to LPA-induced intracellular Ca2+ release (Liu and Armant, 2004).  
Therefore, uterine LPA secretion could activate HBEGF shedding from blastocysts in opposition 
to the uterine wall, signaling its presence to the adjacent uterine epithelium (Figure 1A). 
Several studies support the hypothesis that expression of HBEGF in the peri-implantation 
endometrial epithelium is induced by embryo derived HBEGF signaling.  HBEGF is expressed 
in both mouse and hamster preimplantation blastocysts (Hamatani et al., 2004; Liu and Armant, 
2004; Wang et al., 2002).  Interestingly, when growth factor-soaked beads the approximate size 
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of blastocysts are transferred into the uteri of pseudo pregnant mice only HBEGF and insulin-
like growth factor-1 (IGF1) provoke discrete implantation-like responses (Paria et al., 2001).  
Furthermore, highly localized expression of HBEGF occurs in the uterine epithelium adjacent to 
apposition stage blastocysts (Das et al., 1994).  These studies suggest a positive feed-forward 
regulation of uterine HBEGF expression initiated by the blastocyst during the apposition stage of 
implantation.  While HBEGF secreted by the embryo is sufficient to induce HBEGF expression 
in the luminal epithelium, other factors secreted by embryos (e.g., IGF1) could have equivalent 
Figure 1. Heparin binding EGF-like growth factor (HBEGF)- signaling and cell differentiation
during implantation in mice. Blastocyst-uterine interactions shown at the top of the diagram illustrate
the (A) apposition, (B) attachment and (C) invasion stages of implantation. The regions within the green
boxes are expanded below to summarize signaling pathways that orchestrate trophoblast and uterine
epithelial cell differentiation at each stage, as discussed in the text. Arrows depict growth factor secretion
or shedding, binding to receptors, intracellular trafficking, ion influx, and de-repression in the case of
TRO and ERBB4. Double lines indicate juxtacrine signaling and/or cell-cell adhesion. ECM,
extracellular matrix; HBEGF, heparin-binding EGF-like growth factor; ITGA, integrin alpha subunit;
ITGB, integrin beta subunit; LPA, lysophosphatidic acid; LPAR, LPA receptor; N, N-type voltage-gated
Ca2+ channel; PKC, protein kinase C; PLC, phospholipase C; TRO, trophinin; X, indicates apoptosis
induced by nuclear localization of PKCδ 
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activity and perhaps compensate in HBEGF deficient embryos, which are able to implant 
normally when transferred to wild type pseudopregnant dams (Xie et al., 2007). 
HBEGF protein appears on the surface of the uterine epithelium early on gestation day 5 
in mice as the attachment reaction commences (Das et al., 1994).  The primary target of HBEGF 
in the luminal epithelium is the trophoblast (Figure 1B).  Late on day 4, HBEGF signaling in the 
blastocyst becomes robust as a result of ERBB4 trafficking to the trophoblast surface (Wang et 
al., 2000).  ERBBs 1-3 are already localized at the apical surface as the blastocyst forms.  
However, ERBB4 is the preferred receptor for HBEGF in blastocysts (Paria et al., 1999).  Thus, 
ERBB1 and ERBB4 both become available on the trophoblast at approximately the time when 
uterine HBEGF first appears.  These events position HBEGF and its receptors to mediate 
blastocyst adhesion and trophoblast differentiation.  
HBEGF-induced ERBB autophosphorylation advances trophoblast adhesive 
differentiation (Das et al., 1994; Paria et al., 1999; Wang et al., 2000).  In blastocysts cultured 
serum-free, HBEGF induces trafficking of integrin subunits, including ITGA5 (Figure 1B), into 
the plasma membrane of trophoblast cells approximately 24 hours earlier than in control 
embryos, which promotes their adhesion to fibronectin in the maternal extracellular matrix 
(Wang et al., 2000).  In vitro experiments suggest that after apoptosis of the opposing luminal 
epithelial cells, ligation of the integrin ITGA5/ITGB1 by the exposed basement membrane 
activates phospholipase Cg (Wang et al., 2007), leading to trafficking of ITGA2B into the 
plasma membrane (Rout et al., 2004), which strengthens cell adhesion as trophoblast invasion 
commences (Figure 1C).  
Experiments have been reported suggesting that HBEGF supports the attachment reaction 
during implantation in addition to its ability to advance hatching and trophoblast differentiation.  
Using engineered cells that express membrane bound HBEGF to simulate receptive uterine 
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epithelial cells, it has been demonstrated that cell surface HBEGF binds to day 4 mouse 
blastocysts, but not to delayed blastocysts (Raab et al., 1996).  HBEGF signaling activates Ca2+ 
influx across the plasma membrane through N-and calmodulin, consequently accelerating 
trophoblast invasion (Wang et al., 2000).  It appears that there are complex autocrine, paracrine 
and juxtacrine pathways that integrate HBEGF signaling with input from other growth factors, as 
well as through cell-cell interactions between the trophectoderm and uterine epithelium during 
implantation (Figure 1). 
Maternal HBEGF deficiency targeted to the uterus defers the window of implantation and 
compromises pregnancy outcome, thus, implicating the importance of two-way communication 
between the embryo and the uterus (Xie et al., 2007).  However, another heparin-binding 
member of the EGF family, AREG, partially compensates for HBEGF loss.  Progesterone 
upregulates AREG throughout the uterine luminal epithelium of the mouse early on gestation 
day 4 independently of the blastocyst (Das et al., 1995), but it becomes restricted to the 
implantation site by day 5.  Studies conducted to clarify the mechanism of AREG signaling at 
the embryonic-maternal interface suggest that the presence of fertilized embryos in the 
reproductive tract elevates expression of AREG on day 4 (Lee et al., 2006).  Therefore, the 
presence of embryos in an HBEGF-deficient uterus could induce partially-compensating 
production of AREG, which can activate only ERBB1 (Riese and Stern, 1998). 
Another EGF family member, TGFA, has extensive sequence homology to EGF and 
comparable affinity for ERBB1, its only receptor.  Immunohistochemical, in situ hybridization, 
northern blot and RT-PCR analyses clearly demonstrate TGFA expression in the uterus and 
embryo (Rappolee et al., 1988; Tamada et al., 1991).  Additionally, a reduction in the number of 
implantation sites in rats after administration of intraluminal anti-TGFA injections supports the 
involvement of TGFA in implantation (Tamada et al., 1997).  Addition of TGFA to in vitro 
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culture medium is favorable for preimplantation embryo development and trophoblast 
differentiation (Haimovici and Anderson, 1993; Machida et al., 1995).  However, this 
involvement is controversial, as TGFA knock out mice have normal implantation (Luetteke et 
al., 1993; Mann et al., 1993).  Similarly, AREG and EGF are not essential for implantation, 
indicated by mice deficient in AREG and triple knockout mice lacking TGFA, AREG and EGF, 
which are all fertile (Luetteke et al., 1999).  These studies support the concept of a compensatory 
response by other EGF family members, perhaps HBEGF, during implantation. 
Another group of EGF-like growth factors that mediate cell-cell interactions, the NRGs, 
are encoded by four distinct genes, NRG-1, NRG-2, NRG-3 and NRG-4 (Burden and Yarden, 
1997; Falls, 2003).  There is evidence for 15 splice variants of NRG-1 that are grouped into three 
subtypes (Ben-Baruch and Yarden, 1994; Meyer et al., 1997).  Of the three subtypes, Type 1 is 
comprised of neu differentiation factor (NDF), heregulin and acetylcholine receptor-inducing 
activity (Ben-Baruch and Yarden, 1994).  Type 2 consists of the glial growth factor (GGF) and 
type 3 comprises the sensory and motor neuron derived factor (SMDF) (Brown et al., 2004).  
NDF and its isoforms are expressed in the preimplantation mouse uterus (Reese et al., 1998).  
Mice with delayed implantation do not express NDF; however, upon administration of estrogen, 
the expression of NDF returns.  Alternately there is evidence that SMDF has a similar cellular 
distribution to NDF and its expression becomes prominent at the time of implantation (Brown et 
al., 2004).  However, no significant expression of GGF is observed in the peri-implantation 
uterus.  In the blastocyst, both ERBB3 and ERBB4 are present on trophoblast cells, suggesting 
the capacity for signaling with NRG family members (Wang et al., 2000).  A parallel study 
observed a similar expression pattern of the EGF family members BTC and EREG (Das et al., 
1997), suggesting that optimal expression of NDF, BTC and EREG requires an activated 
blastocyst.  Therefore, it remains possible that these EGF family members contribute to mouse 
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implantation.  
Human implantation 
In contrast to its regulation in mice that have a short estrus cycle, HBEGF is regulated 
independently of the presence of an embryo in the stromal and epithelial compartments during 
the menstrual cycle of the human endometrium (Chobotova et al., 2002a; Leach et al., 1999; Yoo 
et al., 1997).  There is evidence that HBEGF mediates maternal-blastocyst signaling and 
attachment in humans as it does in rodents owing to the switch in expression of HBEGF mRNA 
and protein from the subepithelial stroma during early secretory phase to glandular and luminal 
epithelium in the mid-secretory phase (Leach et al., 1999).  ERBB4 is expressed by the 
trophoblast cells of human peri-implantation blastocysts, suggesting that HBEGF present in the 
luminal epithelium could stimulate the blastocyst through paracrine or juxtacrine signaling 
(Chobotova et al., 2002b).  HBEGF not only accelerates the development of human embryos to 
the blastocyst stage, but also aids in hatching from the zona pellucida (Martin et al., 1998). 
Evidence indicates that proliferation in human endometrial stromal cells is regulated by 
both the soluble and transmembrane forms of HBEGF, along with other EGF family members, 
EGF and BTC, suggesting key functions for the EGF family of growth factors in regeneration 
and maturation of the human endometrium and to prepare the embryo for implantation 
(Chobotova et al., 2002a).  However, this induction is under the cooperative effect of TNF.  
Another study shows that the endometrial stromal cells produce both the soluble and 
transmembrane forms of HBEGF to regulate TNF and TGFB (Chobotova et al., 2005).  This 
provides a survival function that prevents apoptosis of endometrial cells exposed to apoptotic 
factors, which highlights the importance of HBEGF and its receptors in the human endometrium. 
HBEGF appears to participate in a broader dialogue that includes other molecules, 
exemplified by trophinin-bystin signaling.  Both human trophoblast cells and the uterine 
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epithelium express the transmembrane protein trophinin that mediates cell adhesion through 
homophilic binding (Suzuki et al., 1999).  Trophinin forms a complex with its cytoplasmic 
partner bystin and ERBB4, which inhibits ERBB tyrosine phosphorylation required for invasive 
trophoblast differentiation (Figure 1B).  However, during the attachment reaction between the 
blastocyst and luminal epithelium, homophilic trophinin binding releases bystin, thus 
derepressing ERBB4, which can then become activated by HBEGF to promote trophoblast dif-
ferentiation (Sugihara et al., 2007; Tamura et al., 2011).  Meanwhile, in the luminal epithelium, 
homophilic trophinin binding disrupts its tethering of protein kinase Cδ to the plasma membrane, 
freeing the latter to enter the nucleus where it induces apoptosis (Tamura et al., 2011).  Thus, 
trophinin signaling removes the cellular barrier to blastocyst implantation as it licenses activation 
of trophoblast adhesion competence. 
Human placentation 
Most components of the EGF signaling system are present throughout pregnancy.  
Transcripts from placental tissues obtained in all three trimesters demonstrate expression of 
HBEGF, with the highest abundance in first trimester decidua (Yoo et al., 1997).  Strong staining 
for HBEGF is observed in villous and EVT cells in both normal placentas and those delivered 
preterm (Leach et al., 1999; Leach et al., 2002a).  Other EGF family members and ERBB 
receptor tyrosine kinases are expressed in placental trophoblast populations (Hofmann et al., 
1992; Tanimura et al., 2004), indicating that the EGF signaling system is highly active during 
placental development.  
There is evidence to support the hypothesis that HBEGF, and possibly other EGF family 
members, promote trophoblast invasion (Jessmon et al., 2009).  The capacity for invasion 
weakens as gestation progresses (Damsky et al., 1994; Librach et al., 1991), indicating the 
importance of the EGF signaling system in first trimester trophoblast cells (Bass et al., 1994).  
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EGF, TGFA and HBEGF can stimulate first trimester trophoblast cells to become invasive and 
differentiate to the extravillous phenotype (Bass et al., 1994; Leach et al., 2004).  However, the 
effectiveness of EGF diminishes with trophoblast cells obtained from the second or third 
trimester (Bass et al., 1994), suggesting that their loss of invasion competence is intrinsic rather 
than a product of their environment.  Invading EVT cells are necessary for adequate remodeling 
of the uterine spiral arteries that perfuse the developing placenta (Norwitz et al., 2001). 
The widespread expression of HBEGF in placental trophoblast cells and surrounding 
decidua (Leach et al., 1999) could facilitate invasion and contribute to remodeling of the spiral 
arteries.  It has been demonstrated that when the HTR-8/SVneo human first trimester 
cytotrophoblast cell line is cultured at 2% O2, HBEGF, but not other EGF family members, is 
upregulated and secreted (Armant et al., 2006).  However, trophoblast cells in villous explants 
from term placentas do not elevate HBEGF in response to low oxygen and their survival is 
compromised by hypoxia (Imudia et al., 2008).  Addition of HBEGF to term villous explants 
cultured at 2% O2 inhibits apoptosis, demonstrating its capacity as a survival factor.  
Because the placenta is programmed to survive at a low O2 tension during the first 
trimester, trophoblast invasion progresses slowly at the vascular interface, delaying the full onset 
of placental perfusion for ten weeks (Norwitz et al., 2001).  However, if reoxygenation does not 
occur on time, placental insufficiency ensues, and, depending on severity, can result in EPL, 
FGR or PE (Burton and Jauniaux, 2004).  These disorders are associated with poor trophoblast 
invasion and increased apoptosis (Brosens et al., 1972; DiFederico et al., 1999), two functions 
that are strongly regulated by HBEGF signaling (Jessmon et al., 2009).  Placental tissues from 
preeclamptic pregnancies have reduced expression of HBEGF compared to gestational age-
matched normotensive placentas, as well as reduced HBEGF mRNA expression (Leach et al., 
2002a).  There are also deficiencies in EGF and TGFA, as well as increased production of a 
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secreted form of EGFR that binds EGF-like growth factors to antagonize signaling through 
ERBB receptors (Armant et al., 2015).  These findings suggest the hypothesis that reduced 
HBEGF expression could contribute to the shallow trophoblast invasion and poor survival 
observed in preeclampsia.  It remains to be established whether the reduced expression of 
HBEGF precedes the onset of preeclampsia, or if it is merely associated with late placental 
demise.  There is also clinical evidence of HBEGF disruption associated with infertility in 
women (Aghajanova et al., 2008).  The decreased HBEGF expression in infertile couples was 
not confirmed in a larger clinical study, but it was noted that a significant increase between the 
early and mid-secretory phases was absent in the infertile patients (Leach et al., 2012).  
Significant advancements have been made in unraveling the molecular mechanisms 
governing growth factors involved in implantation and trophoblast invasion.  The mouse has 
provided a powerful experimental model; however, its correlation with human implantation and 
trophoblast development is not entirely consistent.  In the mouse trophoblast invasion is shallow 
(Redline and Lu, 1989), the arteries and blood vessels of the decidua are lined by endothelium 
rather than trophoblast (Adamson et al., 2002; Redline and Lu, 1989).  In humans, trophoblasts 
are responsible for vascular remodeling (Pijnenborg et al., 2006), while uterine natural killer 
cells are more important in the mouse (Monk et al., 2005).  The differences in trophoblast 
invasion and vascular remodeling in humans compared to the mouse make it a suboptimal model 
for studying placental insufficiencies.  
A better understanding of the molecular mechanisms governing the expression of growth 
factors in implantation and placentation could better define the window of implantation.  
Furthermore, this additional information could provide a foundation for development of new 
treatments for clinical pathologies such as recurrent pregnancy loss and placental insufficiencies 
that reduce fetal growth or contribute to PE.  In considering the signaling pathways disrupted by 
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obstetric disease it might be possible to devise new strategies for pharmaceutical intervention to 
improve maternal-fetal care.  Therefore, continued investigation of growth factors and the 
molecular mechanisms that ensure successful implantation and placentation has significant 
clinical relevance.  The significance of HBEGF signaling during human pregnancy will not be 
fully appreciated without more sophisticated experimental approaches that take into account its 
interactions with other signaling pathways.  Other pathways that regulate HBEGF and alter its 
expression in obstetric disease might lie closer to the root cause of placental insufficiencies, and 
would provide superior targets for intervention strategies.  Therefore, global approaches to this 
subject are needed in addition to a targeted analysis of the role for HBEGF in placental 
development and pathology. 
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CHAPTER 2 - TROPHOBLAST SURVIVAL SIGNALING DURING HUMAN 
PLACENTATION REQUIRES HIF-INDUCED TRANSCRIPTION OF HSP70 
Abstract 
Survival of trophoblast cells in the low oxygen environment of human placentation 
requires metalloproteinase-mediated shedding of HBEGF and downstream signaling.  A matrix 
metalloproteinase (MMP) antibody array and quantitative RT-PCR revealed upregulation of 
MMP2 post-transcriptionally in human first trimester HTR-8/SVneo trophoblast cells and 
placental explants exposed to 2% O2.  Specific MMP inhibitors established the requirement for 
MMP2 in HBEGF shedding and upregulation.  Hypoxia inducible factors, HIF1A and EPAS1 
(HIF2A), accumulated at 2% O2, and HIF target genes were identified by next-generation 
sequencing of RNA from trophoblast cells cultured at 2% O2 for 0, 1, 2 and 4 hrs.  Of nine genes 
containing HIF-response elements upregulated at 1 hour, only HSPA6 (HSP70B’) remained 
elevated after 4 hours.  The HSP70 chaperone inhibitor VER155008 blocked upregulation of 
both MMP2 and HBEGF at 2% O2, and increased apoptosis.  However, both HBEGF 
upregulation and apoptosis were rescued by exogenous MMP2.  We propose that MMP2-
mediated shedding of HBEGF, initiated by HSP70, contributes to trophoblast survival at the low 
O2 levels encountered during the first trimester, and is essential for successful pregnancy 
outcomes. 
Introduction 
In humans, the placenta is not fully perfused with oxygenated maternal blood until after 
the tenth week of pregnancy, rendering the implantation site a low O2 environment (Burton, 
2009; Burton et al., 1999; Jauniaux et al., 1991).  Atypical of most cells, human trophoblast cells 
not only survive at low O2, but also proliferate more rapidly (Genbacev et al., 1996; Genbacev et 
al., 1997; Kilburn et al., 2000).  The epidermal growth factor (EGF) family member, heparin-
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binding EGF-like growth factor (HBEGF) is highly expressed in the uteroplacental compartment 
during implantation and early placentation (Jessmon et al., 2009).  We previously reported that 
HBEGF prevents death of human trophoblast cells exposed to low O2 concentrations (Armant et 
al., 2006).  Although HBEGF is upregulated ~100-fold in trophoblast cells after exposure to 2% 
O2, HBEGF mRNA remains unchanged and is abundant (2500 copies/cell) at both O2 
concentrations (Armant et al., 2006).  Survival of trophoblast cells at low (2%) O2 requires 
metalloproteinase-mediated shedding of membrane-bound proHBEGF and HBEGF downstream 
signaling (Armant et al., 2006).  HBEGF is synthesized as transmembrane proHBEGF, and 
secreted through shedding from the plasma membrane by proteolytic cleavage, allowing it to 
activate ERBB receptor tyrosine kinases, including its cognate receptors, EGF receptor/ERBB1 
and ERBB4 (Holbro and Hynes, 2004).  As O2 increases with the full perfusion of the 
intravillous space after 10 weeks of gestation (Burton, 2009; Burton et al., 1999; Jauniaux et al., 
1991), HBEGF positively regulates trophoblast motility and invasion (Jessmon et al., 2010; 
Leach et al., 2004).  The hypertensive pregnancy disorder, preeclampsia, in which trophoblast 
invasion is reduced and apoptosis elevated, is characterized by a reduction in HBEGF and other 
components of the EGF signaling system (Armant et al., 2015; Jessmon et al., 2009; Leach et al., 
2002a).  It can, therefore, be hypothesized that HBEGF production could be a factor in 
trophoblast dysfunction associated with placental insufficiency disorders. 
In human trophoblast cells, HBEGF activates p38 (MAPK14), ERK (MAPK1), and JNK 
(MAPK8) (Jessmon et al., 2010).  During hypoxia, HBEGF upregulates its biosynthesis through 
an autocrine feedback mechanism, and prevents apoptosis through a parallel signaling pathway 
(Armant et al., 2006; Jessmon et al., 2010).  Activation of ERBB receptor tyrosine kinase by 
HBEGF prevents apoptosis through a mechanism mediated by p38 MAPK, while autocrine 
upregulation of HBEGF appears to be mediated by any one of the MAPKs, p38, ERK, or JNK, 
18 
 
based on experiments using specific inhibitors (Jessmon et al., 2010).  However, it is unclear 
whether the MAPKs specifically function downstream of HBEGF in its autocrine upregulation, 
or also operate further upstream in the cascade initiated by hypoxia to regulate proHBEGF 
shedding. 
It is well established that metalloproteinases contribute to invasion and tissue remodeling 
(Loffek et al., 2011; Stamenkovic, 2003).  Successful implantation and trophoblast invasion are 
closely linked to the expression of matrix metalloproteinases (MMPs) that degrade basement 
membranes (Librach et al., 1991).  The gelatinases (gelatinase A/MMP2; 72-kDa, and gelatinase 
B/MMP9; 92-kDa), which target major components of basement membranes (e.g., collagen IV), 
are expressed by trophoblast cells, and therefore, regarded as key to the invasion process (Isaka 
et al., 2003).  MMP2 and MMP9 are differentially expressed in first trimester trophoblast cells, 
with MMP2 more prominently secreted until 9 weeks (Staun-Ram et al., 2004; Xu et al., 2000).  
MMP2 is constitutively expressed in trophoblast cells throughout pregnancy, but its activity is 
diminished in the full-term placenta.  MMP9 is mainly expressed by trophoblast cells during the 
period after Week 9, and also decreases at term.  Thus, MMP2 and MMP9 are expressed and 
functioning throughout the periods of low and then elevated O2 in the reproductive tract, 
characterized by high trophoblast proliferation and then elevated invasion, respectively 
(Jovanovic et al., 2010; Librach et al., 1991).  While their role in tissue remodeling is well 
known (Loffek et al., 2011; Stamenkovic, 2003), emerging evidence reveals that MMPs also 
participate in shedding of membrane-anchored signaling molecules, which contributes to 
chemokine and growth factor activation (Burton, 2009; Chow and Fernandez-Patron, 2007; 
Powell et al., 1999).  
Shedding is mediated by membrane-type MMPs and MMPs bound to membrane 
receptors, including MMP2 and MMP9 (Sternlicht and Werb, 2001).  Cheng et al reported that 
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bradykinin-induced proliferation of rabbit corneal cells is blocked by an inhibitor of both MMP2 
and MMP9, as well as an inhibitor of HBEGF, suggesting that an MMP could contribute to the 
cleavage of proHBEGF (Cheng et al., 2012).  MMP2 participates in a proteolytic cascade in 
αT3-1 cells that directs both proHBEGF shedding and EGFR transactivation (Roelle et al., 
2003).  In addition, its rapid release in CMTC9 cells after E2 stimulation is correlated with 
cleavage of proHBEGF (Torres et al., 2009).  We previously found that treatment with a general 
metalloproteinase inhibitor blocks HBEGF accumulation in human trophoblast cells at low O2, 
causing apoptosis that is rescued with recombinant HBEGF, but not other EGF-like ligands 
(Armant et al., 2006).  Autocrine HBEGF activity in trophoblast cells requires, in addition to 
metalloproteinase-mediated shedding of HBEGF, binding to either EGFR or ERBB4.  Blocking 
HBEGF signaling prevents its upregulation at 2% O2, suggesting that low levels of resident 
proHBEGF are cleaved through activation of metalloproteinases to initiate its autocrine 
accumulation downstream of ERBB receptors in a positive feedback loop.  
To understand the molecular mechanism of trophoblast survival at low O2, the HTR-
8/SVneo human trophoblast cell line (Graham et al., 1993) was used.  The HTR-8/SVneo cell 
line is an immortalized cell line (Graham et al., 1998) that was established from human first-
trimester cytotrophoblast cells (Graham et al., 1993).  HTR-8/SVneo cells express cytokeratin 
(KRT7), a marker for trophoblast and other epithelial cells, as well as the beta subunit of human 
chorionic gonadotropin (β-hCG), which is trophoblast-specific (Kilburn et al., 2000).  This cell 
line possesses the ability to invade Matrigel basement membrane without being tumorigenic, and 
expresses the trophoblast-specific major histocompatibility protein, HLA-G, when induced by 
Matrigel differentiate (Kilburn et al., 2000).  In response to Matrigel, HTR-8/SVneo cells switch 
integrin expression (Damsky) in association with invasive differentiation, while in response to 
hypoxia, proliferation increases and extravillous differentiation is inhibited (Kilburn et al., 2000).  
20 
 
To examine the hypothesis that MMPs contribute to the shedding and upregulation of HBEGF at 
low O2 concentrations required for trophoblast survival in the first trimester, we used HTR-
8/SVneo human trophoblast cells, with confirmatory experiments using first trimester villous 
explants (Castellucci et al., 1990; Genbacev et al., 1992). 
Materials and Methods 
Cell Culture and Treatments 
The first trimester human TB cell line, HTR-8/SVneo (Graham et al., 1993), was grown 
in either 96-well culture plates (approx. 500,000 cells) or T25 tissue culture flasks (approx. 85% 
confluency) during experiments in sterile DMEM/F-12 with 1 mg/ml BSA at either 20% O2 or 
2% O2.  Cells were treated by adding to the culture medium 1-10 μg/ml α-amanitin (Sigma-
Aldrich), 250 μM CoCl2 (Sigma-Aldrich), inhibitors (EDM Chemicals, Inc., Gibbstown, NJ) 
specific for MMP2 and MMP9 (BiPS; (2R)-[(4-Biphenylylsulfonyl)amino]-N-hydroxy-3-
phenylpropionamide; 100 nM; MMP-2 (IC50 = 310 nM) and MMP-9 (IC50 = 240 nM)) (Tamura 
et al., 1998), MMP2 only [(2-((isopropoxy)-(1,1′-biphenyl-4-ylsulfonyl)-amino))-N-
hydroxyacetamide; 250 nM; IC50 = 12 nM (at high concentration inhibits MMP-9 and MMP-3 
(IC50 = 0.2 and 4.5 µM, respectively)] (Rossello et al., 2004), or MMP9 only [MMP9 Inhibitor I; 
100 nM MMP-9; IC₅₀ = 5 nM (at high concentration inhibits MMP-1 (IC₅₀ = 1.05 µM) & MMP-
13 (IC₅₀ = 113 nM)] (White et al., 2006), specific inhibitors for ERK, JNK, and p38 (Jessmon et 
al., 2010), HSP70 inhibitor (VER-155008, Santa-Cruz Biotech; 0.05-100 μM), and 10 nM 
recombinant MMP2 (R&D Systems; rMMP2;).  For protein analysis, attached cells were 
extracted using cell lysis buffer (Cell Signaling), and total cellular protein concentrations were 
determined using Pierce BCA protein assay kit (ThermoFisher Scientific).  The HTR-8/SVneo 
cell line was maintained in DMEM/F12 with 10% donor calf serum at 20% O2 between passages 
30-50, and routinely checked for production of β-hCG, KRT7, and when cultured on Matrigel, 
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HLA-G (Graham et al., 1993; Kilburn et al., 2000).  Serum was replaced with BSA 24 h before 
all experiments. 
Villous Explant Culture 
Placental tissues were obtained with Wayne State University Institutional Review Board 
approval and patient informed consent from first trimester terminations at a Michigan family 
planning facility.  Within a 2-hr period, fresh tissue was collected, placed on ice in PBS, 
transported to the laboratory, and villous explant cultures were prepared (Bolnick et al., 2015).  
The chorionic villi were dissected into pieces of approximately 5 mg wet weight and transferred 
individually into DMEM/F12 culture medium supplemented with 10% donor calf serum, 100 
I.U. penicillin and 100 μg/ml streptomycin in a 24-well culture plate (Costar, Corning, NY).  The 
explants were culture overnight at either 8% or 2% O2 then treated as described for the cell line.  
Antibody Arrays  
Cell lysates (1 mL) were incubated overnight with antibody array membranes, using a 
human MMP antibody array kit (Abcam, Cat # ab134004).  The membranes were washed and 
incubated with a secondary biotin-conjugated antibody, followed by incubation with horseradish 
peroxidase conjugated streptavidin, according to the manufacturer’s direction.  The arrays were 
developed, using enhanced chemiluminescence, and imaged on the ChemiDoc Imaging System 
(BioRad).  Labeling of each protein in the array was quantified using ImageJ software (NIH 
http://rsbweb.nih.gov/ij/).  The mean of six negative controls was subtracted for background 
correction, and the mean of six positive controls was used to normalize the data and calculate the 
relative expression levels. 
Western Blotting  
Western blots were performed as previously described (Kilburn et al., 2000).  Briefly, 
cellular lysates were diluted in SDS sample buffer containing 5% β-mercaptoethanol, run on 
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precast 4%–20% Tris-HCl gradient gels (BioRad), and blotted with antibodies against MMP2, 
MMP9, HIF1A (R&D Systems), HIF2A/EPAS1 (Novus Biologicals) and HSPA6 (Abcam) 
diluted 1:1000 in TTBS and 5% milk.  Densitometry was used to quantify grey levels of protein 
bands of interest, using image analysis software (SimplePCI, Hamamatsu).  Background grey 
levels, determined in a blank lane, were subtracted to obtain the specific grey level for each 
band. Band intensities were below saturation, although linearity was not determined. 
ELISA 
Cells were cultured and treated in six-well plates. ELISA was conducted using HBEGF, 
MMP2, HIF1A and HIF2A DuoSet ELISA Development kits (R&D Systems).  The optical 
density of the final reaction product was determined at 450 nm using a programmable multiplate 
spectrophotometer (Power Wave Workstation; Bio-Tek Instruments) with automatic wavelength 
correction.  Data are presented as nanograms (ng) of HBEGF or MMP2 per microgram (μg) of 
total protein, determined using standard curves generated with the respective recombinant 
proteins (R&D Systems). 
Immunohistochemistry 
Immunohistochemistry was performed using a DAKO (Carpinteria, CA) Autostainer 
Universal Staining System, as previously described (Leach et al., 2002a).  Rehydrated sections of 
cultured explants were labeled for 1 h at 25°C with 5 μg/ml goat polyclonal antibody against 
human recombinant HBEGF (R&D Systems) that recognizes both membrane and secreted forms 
of the protein and 2.5 μg/ml antibody against cytokeratin (KRT7) (DAKO) specific for 
trophoblast.  Controls were incubated with 10 μg/ml non-immune goat IgG (Jackson 
Immunoresearch Laboratories, West Grove, PA).  Tissues were then incubated 1 h at 25°C with 
0.1 μg/ml rabbit anti-goat IgG (Jackson Immunoresearch).  Slides were viewed at 400 × 
magnification using a Leica (Wetzlar, Germany) DM IRB inverted microscope and imaged with 
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spot camera.  Trophoblast cells were labeled with monoclonal antibodies HSPA6 (Abcam) 
diluted 1:400.  To visualize and quantify bound primary antibody, an Envision System 
peroxidase anti-mouse/rabbit kit (DAKO) was used. Staining (grey level) was imaged using a 
Leica DM IRB epifluorescence microscope, and images were captured using a Hamamatsu Orca 
digital camera.  Images were semi-quantified using SimplePCI (Hamamatsu) imaging software, 
as previously described (Leach et al., 2012).  
qPCR 
RNA from HTR-8/SVneo cells was collected using the miRNeasy kit (Qiagen) that 
included DNase treatment, according to the manufacturer’s protocol.  RNA concentration was 
determined using the NanoDrop spectrophotometer and purity was ascertained with a 
microfluidic Bioanalyzer (Agilent Technologies - 2100 Electrophoresis Bioanalyzer Instrument).  
RNA was used in subsequent qPCR (Bustin et al., 2009) analysis.  Reverse transcription was 
performed using the Quantitect Reverse Transcription kit (Qiagen), and qPCR for MMP2, 
HBEGF and HSPA6 was conducted with the Quantitect SYBR Green PCR kit without UNG 
(Qiagen), in a final volume of 25 μl.  GAPDH and SDHA were used as housekeeping genes to 
normalize the data.  Semi-quantitative analysis was performed according to the ΔΔCt method 
(Pfaffl, 2001).  Primers for GAPDH, SDHA, HBEGF, MMP2 and HSPA6 were obtained from 
Qiagen. 
LongRNA (LnRNA) Library Prep for Next Generation Sequencing (NGS) 
LnRNA was isolated using the miRNeasy mini kit (Qiagen).  The RNA was quantified 
and its purity assessed with an Agilent 2100 Electrophoresis Microfluidics Analyzer.  RNA was 
converted into an adapter-ligated cDNA library (Figure 2), using the Ovation & Encore Library 
Preparation Kit (NuGen), according to the manufacturers protocol.  Each cDNA sample was bar-
coded, and the resulting 12 libraries (three replicate libraries for each of the four O2 conditions) 
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were combined for NGS.  Paired-end sequencing was performed for 50 cycles using the Illumina 
HiSeq-2500 sequencer.  
Data Alignment & Mapping 
RNA sequencing data was first processed with demultiplexing software (Casava 1.8.2, 
Illumina).  It was then aligned to the human genome build HG19, and to the ribosomal sequences 
18s and 28s, using bioinformatics tool Novoalign (Novocraft, 2010).  Novoalign determined 
unique alignments that were used to generate an average of 1000 reads per coding segment per 
sample.  The reads thus generated were converted into bed files and imported to the Genomatix 
Genome Analyzer (GGA) (Genomatix Software GmbH).  The GMS, using RNA-seq analysis, 
generated data in the form of Reads per Kilobase of exon per Million fragments mapped 
(RPKM) for 25,000 genes in the database. 
Promoter Extraction 
The Genomatix Genome Analyzer (GGA) MatInspector program (Cartharius et al., 2005) 
was used to extract the promoter regions for the differentially regulated genes. MatInspector 
utilizes a large library of matrix descriptions for transcription factor binding sites to locate 
matches in DNA sequences.  For the purpose of this study it was used to identify hypoxia 
response elements (HRE) in differentially regulated genes. 
Statistics 
All statistics were performed with GraphPad Prism 6 software.  One-way ANOVA with 
Figure 2. An example is shown for 
the size distribution of an individual 
library using the Agilent 
Bioanalyzer. A. Peak size (~250 bp) 
B. Sample (S) size on gel projection, 
as compared to a base pair (bp) ladder 
(L). 
A B 
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Student–Newman–Keuls post hoc comparisons was used to identify changes between controls 
and treatments.  Two-way ANOVA was used for experiments with multiple groups.  
Significance was defined as P < 0.05; all experiments were done three times (n=3) and data are 
expressed as mean ± SD.  For RNAseq data, adjusted p-values were calculated using Benjamin-
Hochberg, and threshold was set at 0.05 to account for false discovery rate. 
Results 
Upregulation of MMP2 at low O2 
Using a human MMP antibody array, we observed that relative expression of MMP2, but 
not MMP9 or other MMPs, increased 1.7-fold in HTR-8/SVneo trophoblast cells cultured for 4 
hrs at 2% O2 (Figure 3A), as compared to trophoblast cells cultured at 20 % O2.  The specific 
increase in expression of MMP2, and not MMP9, was confirmed by western blotting (Figure 3B 
and Figure 4A &B).  Cellular MMP2 was quantified temporally by ELISA in trophoblast cells 
after shifting to 2% O2.  The MMP2 concentration abruptly increased 164-fold (p<0.0001) after 2 
hours of culture at 2% O2 (Figure 3C).  These findings indicate that low O2 upregulates MMP2 
prior to the observed increase in HBEGF, which occurs at 4 hrs (Armant et al., 2006). 
Role of MMP2 in HBEGF upregulation 
To determine whether MMP2 has a functional role in HBEGF regulation by O2, specific 
inhibitors of MMP2 and MMP9 were supplemented in culture medium during manipulation of 
O2 levels.  HBEGF failed to accumulate in trophoblast cells cultured at 2% O2 for 4 h when 
MMP2 was inhibited (Figure 3D).  However, MMP9 inhibition had no effect on the normal 
accumulation of HBEGF at low O2.  A third inhibitor that targets both MMP2 and MMP9 (Inh. 
2/9) also inhibited HBEGF accumulation.  Additionally, TUNEL assays showed increased 
(p<0.0001) trophoblast cell death when both MMP2 and MMP9, or only MMP2, were inhibited 
(Figure 3E).  Inhibition of only MMP9 produced apoptosis levels similar to control.  We 
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conclude that MMP2, but not MMP9, either directly or indirectly, mediates the proteolytic 
cleavage of proHBEGF, and subsequent survival signaling. 
 
Figure 3. Upregulation of MMP2 at low O2, and its effects on HBEGF and cell survival. A.
Expression arrays for MMP-related proteins incubated with extracts of HTR-8/SVneo cells cultured at
20% (left) or 2% (right) O2. Arrows indicate elevated MMP2 at 2% compared to 20% O2. The key below
indicates the location of duplicate antibody probes for each protein according to the coordinates shown,
including both positive (Pos) and Negative (Neg) controls. B. Western blots of molecular weight
standards (Ladder), recombinant MMP2 or MMP9 (Control), and extracts of trophoblast cells cultured at
20% or 2% O2, as indicated. The upper blot was labeled with anti-MMP2, the middle blot was labeled
with anti-MMP9 and lower blot with anti-β-actin. C. MMP2 quantified by ELISA in trophoblast cells
cultured 0-4 h at 2% O2. D. HBEGF quantified by ELISA in trophoblast cells treated during culture for 4
h with the indicated MMP inhibitor or vehicle, and concentration of O2. E. Apoptosis was quantified in
trophoblast cells cultured as in D using the TUNEL assay. * p<0.05, compared to the control (0 h,
vehicle/20% O2). 
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MMP2 mRNA expression 
To determine whether MMP2 is transcriptionally upregulated at low O2, its expression 
was quantified by qPCR, using RNA extracted from HTR-8/SVneo cells cultured at 20 % and 2 
% O2 for 1-4 hrs.  Expression values, normalized to GAPDH, were calculated for both MMP2 
(Figure 5A) and HBEGF (Figure 5B).  MMP2 mRNA, like HBEGF message, did not change 
(p=0.8) at 2% O2, suggesting that their proteins are both regulated post-transcriptionally.  
Role of transcription in HBEGF upregulation 
Trophoblast cells were cultured at 2% O2 with or without α-amanitin, an inhibitor of 
RNA polymerase-II (Lindell et al., 1970; Stirpe and Fiume, 1967), to examine the role of de 
novo transcription in the upregulation of HBEGF. MMP2 and HBEGF mRNA expression was 
quantified by qPCR, using RNA extracted from HTR-8/SVneo cells cultured at 20 % and 2 % O2 
for 6h, and with 5 µg/ml α-amanitin for 6h, 8h and 24h at 2 % O2.  Expression values, 
normalized to GAPDH and SDHA, were calculated for both MMP2 (Figure 5C) and HBEGF 
(Figure 5D).  The presence of α-amanitin did not significantly alter the abundance of either 
MMP2 (p=0.4454) or HBEGF (p=0.1357) transcripts in trophoblast cells cultured at 2% O2 for 
up to 6h.  However, a time-dependent decrease in both MMP2 and HBEGF mRNA abundance 
was observed in α-amanitin-treated cells at 6-24 h that became significant at 24 h (p<0.05), 
indicative of MMP2 and HBEGF mRNA turnover.  Previous work done has shown that culturing 
Figure 4. Western blots of 
molecular weight standards 
(Ladder), recombinant MMP2 or 
MMP9 (Control), and extracts of 
trophoblast cells cultured at 20% or 
2% O2, as indicated. Blot A was 
labeled with anti-MMP2, blot B was 
labeled with anti-MMP9 
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HTR-8/SVneo cells at 2% O2 for 8h (Armant et al., 2006) and 24h (Kilburn et al., 2000) 
increases proliferation of trophoblast cells, based on nuclear expression of the cell proliferation 
marker, Ki-67.  This suggests that the decrease in MMP2 and HBEGF mRNA after 24 h of α-
amanitin treatment is not due to increased apoptosis, as the cells are alive and proliferating.  
Elevation of HBEGF protein after culture at 2% O2 for 6 h was abrogated in a dose-dependent 
manner by α-amanitin, with maximal inhibition attained at 5 μg/ml (Figure 5E).  Using ELISA, 
we demonstrated that MMP2 was not only required for HBEGF upregulation (Figure 3D), but 
that addition of rMMP2 was sufficient to increase (p<0.0001) HBEGF at 20% O2 to the same 
extent as trophoblast culture at 2% O2 (Figure 3F).  Furthermore, addition of rMMP2 rescued 
(p<0.0001) HBEGF biosynthesis in the presence of α-amanitin at 2% O2 (Figure 5F), suggesting 
that de novo transcription is required for MMP2 activity leading to the shedding and 
accumulation of HBEGF.   
CoCl2, a chemical mimic of hypoxia that stabilizes hypoxia inducible factor (HIF) by 
inhibiting ubiquitination of HIF (Jiang et al., 1997), was used to examine its effect on HBEGF 
regulation. At 20% O2, CoCl2 increased (p<0.0001) HBEGF levels. As expected, CoCl2 induced 
accumulation of HIF1A and HIF2A, similar to the effect of low O2, according to western blotting 
(Figure 6A, Figure 7A & B).  The CoCl2-induced accumulation of HIF1A (Figure 6B) and 
HIF2A (Figure 6C) was quantified by ELISA, establishing a significant increase comparable to 
low O2.  α-Amanitin blocked the CoCl2-mediated increase in HBEGF (Figure 6D).  The 
observed effects of α-amanitin on HBEGF accumulation suggest that transcription of genes, 
likely regulated by HIF1A or HIF2A, is required to initiate MMP2 accumulation and HBEGF 
shedding.  Additionally, immunohistochemical staining of both HIF1A and HIF2A indicated the 
localization of both HIF proteins to nucleus (indicated by arrows) as they accumulated after 
exposure to low O2 for 0.5 to 1 h (Figure 7C). 
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Figure 5. Expression of MMP2 and HBEGF at 2% O2 in HTR-8/SVneo cells. MMP2 (A, C) and
HBEGF (B, D) mRNA were measured by qPCR after culture for indicated time at 2% O2 (A, B) and
after culture with α-amanitin (2 µg/ml) at indicated time and O2 concentration (C, D). HBEGF protein
measured by ELISA in extracts of trophoblast cells cultured at the indicated concentrations of α-
amanitin and O2 (E) and in cellular extracts of trophoblast cells cultured for 4 h at either 20% or 2%
O2 in the presence of recombinant MMP2 (rMMP2) and α-amanitin, as indicated (F). *, p<0.05,
compared to no treatment/vehicle/20% O2, n=3.  
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Figure 6. Expression of HIF proteins and HBEGF in the presence of CoCl2 in HTR-8/SVneo cells
A. Western blots of HIF1A (~ 93 kDa), HIF2A (~96 kDa) and β-actin (~45kDa) in lysates of cells treated
at 20% O2 or 2% O2 for 4 h, or at 20% O2 in the presence of 250 μM CoCl2 for 0.5 - 2 h, as indicated in
the Key below gel images. HIF1A (B) and HIF2A (C) protein measured by ELISA in extracts of
trophoblast cells treated at 20% O2 or 2% O2 for 4h, or at 20% O2 in the presence of 250 μM CoCl2 for
0.5 - 2 h. D. HBEGF protein measured by ELISA in extracts of trophoblast cells cultured at the indicated
concentrations of α-amanitin and CoCl2 at 20% O2. * p < 0.05 compared to no treatment control, n=3. 
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Role of MAPKs in MMP2 upregulation  
We previously showed that upregulation of HBEGF at low O2 requires MAPK signaling 
Figure 7. Expression of HIF1A and HIF2A during altered O2 concentrations or simulated hypoxia
(CoCl2) in HTR-8/SVneo cells. Western blots showing the entire lanes for HIF1A (A, ~ 93 kDa) and
HIF2A (B, ~96 kDa) in TB cell lysates prepared after treatment at 20% O2 or 2% O2 for 4h, or at 20% O2
in the presence of 250 μM CoCl2 for 0.5 - 2 h, as indicated in the Key below gel images. C. TB cells
cultured at either 20%, or switched to 2% O2 for 0.5 or 1 h, as indicated. Cells were fixed and stained for
HIF1A (upper panel) and HIF2A (lower panel) using immunohistochemistry. Size bar, 50 µm. Arrows
indicate localization of HIF1A and HIF2A in nuclei. 
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(Jessmon et al., 2010).  MMP2 was quantified by ELISA in extracts of trophoblast cells cultured 
at 2% O2 for 4 hours, with or without specific inhibitors of ERK, p38 and JNK, or the 
corresponding inactive structural analogs (Table 1).  Inhibitors of MAPKs had no effect on the 
increased MMP2 expression at 2% O2, suggesting that the upregulation of MMP2 is independent 
of MAPK, and that MAPK signaling most likely functions exclusively downstream of ERBB 
activation.  
Table 1. MMP2 upregulation is independent of MAPKs 
% O2 Treatment MMP2 (ng/ml) 
20 Vehicle 0.03 ± 0.03 
2 Vehicle 7.27 ± 0.74 * 
2 U 0126/ERK inhibitor 6.07 ± 0.55 * 
2 U0124/ERK Negative control 7.40 ± 0.66 * 
2 JNK inhibitor 5.44 ± 1.98 * 
2 JNK Negative control 6.53 ± 1.23 * 
2 SB203580 P38 inhibitor 6.17 ± 0.87 * 
2 SB 202474 P38 Negative control 7.15 ± 089 * 
2 All 3 inhibitors 5.86 ± 1.51 * 
2 All 3 neg. controls 6.34 ± 0.68 * 
* p<0.0001 
Identification of differentially expressed transcripts 
Transcripts differentially expressed in trophoblast cells at the two O2 levels were 
identified, using a non-biased NGS approach.  RNA-seq analysis using the GGA revealed a total 
of 9 upregulated (Table 2) and 120 downregulated genes (Table 3) after 1 hr of exposure to 2% 
O2 (Figure 8A).  Of the 9 upregulated genes, HSPA6 was the most dramatically upregulated 
(870-fold) (Table 3), and the only gene that remained elevated at 2 h (Figure 8B) and 4 h (Figure 
8C).  The increase in HSPA6 expression at 2% O2 was validated using qPCR (18 fold, p<0.0001) 
and western blotting (2.3 fold, p<0.05) (Figure 8D, E).  Extraction of the promoter region using 
the GGA MatInspector (Cartharius et al., 2005) program revealed two overlapping HRE’s 2.4 
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kbp upstream of the 5’-most HSPA6 transcriptional start site (Figure 9), suggesting that HSPA6 
could operate downstream of hypoxia to regulate MMP2 and HBEGF biosynthesis at low O2.  
Interestingly, as expected RNAseq data showed that although HBEGF and HIF1A were not 
differentially regulated yet their transcripts were present and showed no change in RPKM values 
after shifting trophoblast cells from 20% to 2% O2.  Surprisingly, MMP2 was not detected 
possibly due to low abundance of its transcript, or a problem in the software used to map it to the 
human genome. 
Table 2. Upregulated transcripts from RNASeq analysis 
 
Table 3. Downregulated transcripts from RNASeq analysis 
Gene Symbol Gene ID Log 2 fold change 
  0h vs 1h 0h vs 2h 0h vs 4h 
HSPA6 3310 6.771 7.78 6.55 
FAP 2191 5.188 -- -- 
LOC100131607 100131607 5.043 -- -- 
SNORA5A 654319 4.826 -- -- 
RPS16P5 647190 4.794 -- -- 
ZNF319 57567 4.564 -- -- 
IL8 3576 4.435 -- -- 
VTRNA1-3 56662 4.039 -- -- 
CLK1 1195 3.687 -- -- 
Gene Symbol Gene ID Log 2 fold change 
  0h vs 1h 0h vs 2h 0h vs 4h 
ATG9A 79065 -9.071 -9.071 -9.028 
LOC100506361 100506361 -8.257 -8.969 -8.885 
WHSC2 7469 -8.225 -8.470 -8.737 
CCNF 899 -7.736 -8.450 -8.403 
RBPMS2 348093 -7.713 -8.306 -8.368 
RXRA 6256 -7.617 -8.265 -8.312 
PGPEP1 54858 -7.594 -8.234 -8.260 
TONSL 4796 -7.569 -8.173 -8.228 
RUSC1 23623 -7.518 -8.126 -8.215 
SOLH 6650 -7.518 -8.122 -7.867 
RPS6KA4 8986 -7.426 -8.015 -7.855 
CLEC16A 23274 -7.41 -7.914 -7.831 
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ZFPL1 7542 -7.365 -7.611 -7.764 
CAPG 822 -7.336 -7.595 -7.727 
SFSWAP 6433 -7.323 -7.570 -7.687 
TMEM184B 25829 -7.293 -7.474 -7.657 
BAD 572 -7.262 -7.367 -7.496 
SUN2 25777 -6.818 -7.381 -7.534 
CDC42EP1 11135 -6.494 -7.293 -7.521 
PKMYT1 9088 -6.466 -7.293 -7.465 
SCAMP5 192683 -5.818 -7.237 -7.345 
WDR6 11180 -5.782 -7.173 -7.147 
SMG6 23293 -5.677 -7.033 -6.976 
ESPL1 9700 -5.659 -7.020 -6.914 
DPYSL2 1808 -5.581 -6.953 -6.879 
SEC24D 9871 -5.5 -6.753 -6.791 
EPHB4 2050 -5.498 -6.747 -6.704 
SEC16A 9919 -5.443 -6.742 -6.685 
PLCD3 113026 -5.309 -6.701 -6.648 
GLI2 2736 -5.282 -6.688 -6.603 
ATXN2L 11273 -5.227 -6.606 -6.518 
POLR2A 5430 -5.14 -6.601 -6.488 
SLC19A1 6573 -5.13 -6.521 -6.322 
RANBP10 57610 -5.095 -6.520 -6.248 
SYNPO 11346 -5.043 -6.506 -6.241 
SMTN 6525 -5.042 -6.380 -6.188 
GYS1 2997 -5 -6.297 -6.148 
PTP4A3 11156 -4.964 -6.284 -6.083 
RAI1 10743 -4.955 -6.237 -5.994 
POM121 9883 -4.935 -6.212 -5.966 
PCNXL3 399909 -4.863 -6.146 -5.955 
PPDPF 79144 -4.82 -6.113 -5.949 
EIF4G1 1981 -4.755 -6.089 -5.933 
ZNF646 9726 -4.755 -6.039 -5.911 
NUMBL 9253 -4.667 -6.031 -5.837 
GPR56 9289 -4.665 -6.026 -5.834 
SPSB1 80176 -4.65 -6.435 -5.810 
SLC48A1 55652 -4.641 -5.915 -5.745 
SHKBP1 92799 -4.616 -5.880 -5.668 
ZNF703 80139 -4.585 -5.832 -5.637 
ORAI1 84876 -4.582 -5.659 -5.568 
TAPBP 6892 -4.58 -5.599 -5.544 
RNFT2 84900 -4.547 -5.457 -5.534 
SOX13 9580 -4.53 -5.450 -5.490 
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TMEM131 23505 -4.528 -5.387 -5.482 
PLXNB2 23654 -4.511 -5.379 -5.475 
CREB3L2 64764 -4.477 -5.163 -5.452 
ALG3 10195 -4.426 -5.110 -5.438 
MEN1 4221 -4.379 -5.045 -5.333 
TTLL4 9654 -4.327 -4.781 -5.305 
LLGL1 3996 -4.325 -4.759 -5.302 
CTTN 2017 -4.323 -4.755 -5.276 
BCL9L 283149 -4.311 -4.673 -5.193 
ATN1 1822 -4.286 -4.584 -5.070 
MYADM 91663 -4.265 -4.528 -5.040 
PHF1 5252 -4.229 -4.506 -4.993 
BCAR1 9564 -4.228 -4.432 -4.975 
MLXIP 22877 -4.219 -4.383 -4.966 
PRRC2B 84726 -4.219 -4.357 -4.962 
RNF31 55072 -4.213 -4.304 -4.895 
ZNF777 27153 -4.153 -4.233 -4.845 
SRRM2 23524 -4.088 -4.232 -4.825 
CBX6 23466 -4.084 -4.194 -4.796 
RAB1B 81876 -4.069 -4.189 -4.789 
COL6A1 1291 -4.035 -4.174 -4.740 
WBP2 23558 -4.032 -4.141 -4.707 
FOSL2 2355 -3.988 -4.044 -4.704 
PRRC2A 7916 -3.983 -4.033 -4.665 
TRIM26 7726 -3.962 -4.032 -4.640 
COTL1 23406 -3.959 -4.020 -4.522 
DBN1 1627 -3.933 -3.989 -4.498 
SEPN1 57190 -3.913 -3.964 -4.494 
PFKP 5214 -3.907 -3.900 -4.482 
RNF220 55182 -3.898 -3.936 -4.438 
RAVER1 125950 -3.894 -3.897 -4.422 
COL1A1 1277 -3.88 -3.866 -4.249 
TMEM109 79073 -3.875 -3.823 -4.239 
ACOT7 11332 -3.875 -3.799 -4.226 
SDC1 6382 -3.859 -3.781 -4.201 
NRSN2 80023 -3.856 -3.754 -4.161 
BGN 633 -3.842 -3.700 -4.109 
CIZ1 25792 -3.79 -3.677 -4.030 
DAG1 1605 -3.789 -3.643 -4.009 
NUP214 8021 -3.772 -3.642 -3.918 
CYB5R3 1727 -3.771 -3.615 -3.883 
NPRL3 8131 -3.762 -3.577 -3.864 
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COL4A2 1284 -3.748 -3.552 -3.811 
SLC7A5 8140 -3.722 -3.482 -3.794 
SRCAP 10847 -3.707 -3.460 -3.782 
FOSL1 8061 -3.691 -3.443 -3.773 
CYP2S1 29785 -3.676 -3.404 -3.762 
PLEC 5339 -3.662 -3.405 -3.733 
GIT1 28964 -3.657 -3.365 -3.722 
NACC1 112939 -3.595 -3.363 -3.710 
C20orf112 140688 -3.569 -3.348 -3.672 
MAP2K7 5609 -3.487 -3.341 -3.638 
C16orf57 79650 -3.475 -3.299 -3.425 
ZFP36L1 677 -3.447 -3.234 -3.400 
SLC25A23 79085 -3.426 -3.203 -3.395 
LDOC1 23641 -3.409 -3.190 -3.235 
AP2A1 160 -3.402 -3.180 -3.214 
APEX2 27301 -3.357 -3.136 -3.196 
PLOD1 5351 -3.312 -3.109 -3.176 
EHMT2 10919 -3.268 -3.069 -3.150 
SCAMP2 10066 -3.263 -3.037 -3.132 
HEATR2 54919 -3.252 -2.956 -3.086 
LRRC8A 56262 -3.246 -2.920 -3.079 
ZNF574 64763 -3.207 -2.916 -3.006 
PTRF 284119 -3.196 -2.892 -2.945 
PPARD 5467 -3.026 -2.789 -2.582 
MDH2 4191 -2.983 -2.7329 -2.564 
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Figure 8. Transcriptome graph analysis of trophoblast cells exposed to 2% O2. A-C. Abundance of
transcripts compared using GGA work station between cells cultured at 2% O2 for 0 h (x-axis) and 1 h (A,
y-axis), 2 h (B, y-axis) or 4 h (C, y-axis). Unchanged transcripts are indicated in blue, upregulated
transcripts are red, and downregulated transcripts are black. HSPA6 (red triangle) was the most highly
upregulated mRNA, and only transcript upregulated at 2 h and 4 h. D. HSPA6 mRNA was measured by
qPCR in trophoblast cells cultured for indicated time at 2% O2. E. Western blots of HSPA6 (~ 70 kDa)
and β-actin (~43 kDa) in lysates of trophoblast cells cultured for indicated time at 2% O2. 
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Figure 9. Transcriptome analysis of trophoblast cells exposed to 2% O2. MatInspector on the GGA
work station was used to extract promoter regions of upregulated genes between cells cultured at 2% O2
for 0 h and 1 h to identify HRE sites (Blue boxes). Splice variants (*) also shown. 
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HSP70 function in MMP2 and HBEGF upregulation 
Inhibition of HSP70 with a pharmacological inhibitor, VER 155008 (Schlecht et al., 
2013), in trophoblast cells cultured at 2% O2 caused a dose-dependent decrease in MMP2 
(Figure 10A) and HBEGF (Figure 10B).  VER 155008 acts by binding to the nucleotide binding 
site of HSP70 thereby arresting the nucleotide binding domain in a half open conformation.  
VER 155008 acts as an ATP-competitive inhibitor that prevents allosteric control between the 
Figure 10. Regulation of MMP2, HBEGF and cell survival by HSP70. HSP70 was inhibited using
the pharmacological inhibitor VER 155008 during culture of HTR-8/SVneo cells for 4 h at 20% or 2%
O2. At 2% O2, HSP70 inhibition caused a dose-dependent decrease in both MMP2 (A) and HBEGF (B),
measured by immunohistochemistry, and concomitantly increased cell death (C), measured by TUNEL.
Cells cultured at 20% O2 were unaffected. D. ELISA for HBEGF in cellular extracts of trophoblast cells
cultured for 4 h at either 20% or 2% O2 in the presence of recombinant MMP2 (rMMP2) and HSP70
inhibitor (VER 155008), as indicated. * p<0.05, compared to vehicle/20% O2. 
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nucleotide binding domain and the substrate binding domain (Schlecht et al., 2013).  TUNEL 
assays showed increased (p<0.0001) trophoblast cell death with HSP70 inhibition (Figure 10C), 
suggesting that survival at 2% O2, through upregulation of MMP2 and HBEGF, requires HSPA6 
activity.  Using ELISA, we demonstrated that MMP2 was not only required for HBEGF 
upregulation (Figure 3D), but that addition of rMMP2 was sufficient to increase (p<0.0001) 
HBEGF at 20% O2 to the same extent as trophoblast culture at 2% O2 (Figure 10D).  
Furthermore, addition of rMMP2 rescued (p<0.0001) HBEGF biosynthesis in the presence of 
HSP70 inhibitor at 2% O2 (Figure 10D).  These results demonstrate that upregulation of MMP2 
requires HSPA6 (HSP70B’) activity, while upregulation of HBEGF requires only shedding 
mediated by MMP2. 
Regulation of MMP2 in first trimester explants 
Using immunohistochemistry and ELISA, it was confirmed that HSP70 inhibitor 
prevents the upregulation of MMP2 (Figure 11A, B) and HBEGF (Figure 8C, D) in first 
trimester explants cultured at 2% O2 similar to the observed expression affects in HTR-8/SVneo 
(Figure 10).  In addition, rMMP2 alone increased (p<0.0001) HBEGF at 20% O2, and rescued 
(p<0.0001) HBEGF upregulation at 2% O2 during treatment with HSP70 inhibitor (Figure 11C, 
D).  Cell death assays showed increased (p<0.05) cell death during HSP70 inhibition that was 
rescued (p<0.05) by rMMP2 (Figure 11E, F), suggesting that survival at 2% O2, through 
upregulation of MMP2 and HBEGF, requires HSPA6 activity. 
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Discussion 
The regulation of HBEGF signaling during implantation and placentation is critical for 
trophoblast survival and invasion (Jessmon et al., 2009; Lim and Dey, 2009).  An autocrine, 
post-transcriptional mechanism induced at low O2 upregulates HBEGF synthesis and secretion, 
Figure 11. Regulation of MMP2 in first trimester chorionic villous explants. First trimester villous
explants cultured for 6 h at either 20% or 2% O2 in the presence of recombinant MMP2 (rMMP2) and
VER 155008 (HSP70 inh.), as indicated, were stained for MMP2 & Cytokeratin (KRT7) (A), HBEGF &
KRT7 (C) with counterstaining with Hematoxylin. Healthy nuclei counterstained with Hematoxylin
appear blue and dual staining with DAPI and TUNEL (E), using immunofluorescence microscopy. Size
bars indicating 10 µm are shown in A, C and 100 µm as shown in E. Cell extracts were assayed by
ELISA for MMP2 (B) and HBEGF (D), as well as for cell death by TUNEL (F). *, p<0.0001 in B and
D, p<0.05 in F, compared to vehicle/20% O2, n=3 
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providing an important survival factor during early gestation (Armant et al., 2006; Jessmon et al., 
2009).  The present study provides evidence that a transcriptional event is required to initiate 
HBEGF shedding downstream of HIF signaling.  In seeking a metalloproteinase responsible for 
HBEGF shedding, a human MMP antibody array, verified by western blot and ELISA, 
implicated a protease cascade that includes MMP2.  A functional role for MMP2 in the 
accumulation of HBEGF was established using a specific inhibitor.  The increase in apoptosis 
observed by using another specific inhibitor for both MMP2 and MMP9 was greater, but not 
significantly different than the increase by MMP2 inhibition alone.  The increase found with 
MMP2/9 inhibition could be additive; however, that is unlikely because apoptosis was 
unaffected by inhibition of MMP9 alone, compared to control.  MMP2 mRNA concentration was 
unaltered by reduced O2, suggesting that it was regulated post-transcriptionally.  Transcriptomic 
analysis identified HSPA6, a member of the HSP70 family, as a potential regulator upstream of 
MMP2.  Using an inhibitor of HSP70 and exogenous rMMP2, evidence was obtained supporting 
a mechanism wherein low O2 concentrations, as experienced by trophoblast cells during the first 
10 weeks of placentation, induce HIF-mediated transcription of HSP70, a chaperone that directly 
or indirectly facilitates MMP2 accumulation.  MMP2, in turn, appears to participate in a protease 
cascade that sheds HBEGF from the cell surface (Hitchon et al., 2002; Mohammad et al., 2010).  
The production of sHBEGF initiates autocrine signaling through its cognate receptors, EGFR 
and ERBB4 which activates its biosynthesis from constitutively-expressed, but latent HBEGF 
mRNA (Figure 12).   
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Supplementation with HBEGF and other EGF family members such as EGF or TGFα has 
little effect on proliferation rates, but is highly effective at converting trophoblast cells to an 
invasive phenotype (Leach et al., 2004).  The extensive expression of HBEGF in trophoblast 
cells, particularly within extravillous populations (Leach et al., 2002a), could be vital for their 
invasive activities during the establishment of pregnancy and physiological conversion of spiral 
arteries.  Therefore, it has been established that HBEGF regulates trophoblast survival and 
invasion, two crucial functions that are compromised in pregnancies complicated by 
Figure 12. Proposed Mechanism. Low (2%) O2 stabilizes cytoplasmic HIF1A and HIF2A (1) that
accumulate and translocate to the nucleus (2) where they dimerize to HIF1B and bind to hypoxia
response elements (HRE) in the regulatory regions of target genes, including HSPA6/HSP70B’ (3).
HSP70 regulates the accumulation of activated MMP2 at the cell surface (4), which is required and
sufficient for shedding (5) of the extracellular domain of proHBEGF. The released sHBEGF binds (6) to
its receptors, ERBB1 and ERBB4, through its EGF-like domain and to heparan sulfate proteoglycans
(HSPG) through its heparin-binding domain. ERBB downstream signaling activates MAPKs (7) required
for biosynthesis of proHBEGF from the pool of HBEGF mRNA (8). HBEGF autocrine signaling thereby
increases HBEGF secretion to achieve extracellular HBEGF concentrations (>1 nM) sufficient to inhibit
apoptosis at 2% O2. 
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preeclampsia (Brosens et al., 1972; DiFederico et al., 1999).  HBEGF and other components of 
the EGF signaling system are disrupted in placentas of women with preeclampsia (Armant et al., 
2015; Leach et al., 2002a).  Trophoblast invasion is shallow in preeclampsia, possibly due to a 
lack of HBEGF-induced cell migration and a rise in apoptosis, exacerbated by reduced 
cytoprotection.  The increased oxidative damage to trophoblast cells (Redman and Sargent, 
2005) and the decrease in HBEGF in preeclamptic placentas is consistent with the hypothesis 
that HBEGF is an important survival factor throughout gestation. In this study we are focused at 
the role of HBEGF in cell survival to better understand the underlying mechanism. 
Jessmon et. al showed that HBEGF activates ERK, p38 and JNK in human trophoblast 
cells, and treatment with specific inhibitors indicated that hypoxia upregulates HBEGF 
biosynthesis through any one of the three examined MAPKs (Armant et al., 2006; Jessmon et al., 
2010).  However, it was unclear whether this MAPK pathway was functional upstream or 
downstream of HBEGF shedding.  Therefore, MMP2 was quantified in human trophoblast cells 
cultured at 2% O2 with specific inhibitors of ERK, p38 and JNK.  These inhibitors did not 
influence the upregulation of MMP2 at low O2, suggesting that the MAPKs function only 
downstream of HBEGF signaling through the ERBB1/4 tyrosine kinases in human trophoblast 
cells, as indicated in Figure 12. 
MMP2 was not among the genes that were transcriptionally regulated at low O2, but 
nevertheless appears to participate in a proteolytic cascade that culminates in HBEGF shedding.  
Studies of early placentation suggest that MMP2 is important in trophoblast invasion (Staun-
Ram et al., 2004).  Interestingly, very low O2 (0.1%) increases MMP2 mRNA levels 1.7-fold in 
trophoblast cells isolated from first trimester placentae (Onogi et al., 2011), which was not found 
in our study.  However, culture at 2% O2 could differ significantly from 0.1% O2, and account 
for the different outcomes.  Using specific inhibitors and rMMP2, we showed that MMP2, but 
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not HBEGF, is regulated by HSP70.  It appears that HSP70 stabilizes either MMP2 or a protein 
regulating its accumulation at the cell surface for shedding of HBEGF.  
Although both MMP2 and HBEGF appear to be regulated by O2 post-transcriptionally, 
HBEGF upregulation by low O2 or CoCl2 was blocked by -amanitin, suggesting the 
requirement for transcription.  HIF proteins are stabilized at low O2 (Wang and Semenza, 1993), 
and activate transcription of targeted genes by interaction with specific HREs in the gene 
promoters (Semenza, 2003), along with transcriptional coactivators to form an initiation complex 
(Lisy and Peet, 2008).  We suspected that either HIF1A or HIF2A could be involved in the 
response of trophoblast cells to low O2, based on their accumulation under the influence of CoCl2 
or 2% O2, which was previously reported in JEG3 choriocarcinoma cells (Park et al., 2014). 
Interestingly, the transcriptome analysis revealed HSPA6/HSP70B’ as the most highly 
upregulated gene at 1-4 h, while no changes occurred in transcripts of metalloproteinases.  
Extraction of the HSPA6 promoter revealed two overlapping HREs on the sense and anti-sense 
strands.  HREs also appeared in the promoters of the eight other mRNAs that increased 1 h after 
exposure of trophoblast cells to low O2.  Interestingly, microarray analysis identifies only 216 
genes have HRE sites in the human genome (Ortiz-Barahona et al., 2010).  In rabbit 
chondrocytes and JEG3 cells increased expression of HIF1A under hypoxia (2%) or simulated 
hypoxia (CoCl2) resulted in an increases in HSP70 expression, which is was ablated by HIF1A 
inhibition or knockdown (Park et al., 2014; Tsuchida et al., 2014).  These data suggest that 
HSP70 transcription is induced by HIF1A signaling.  
Induction of heat shock proteins (HSPs) in response to cellular stress has been proposed 
as a potential strategy of eukaryotic cells to combat lethal conditions (Ananthan et al., 1986; 
Goff and Goldberg, 1985; Parsell and Sauer, 1989).  Within the HSP family, HSP70 functions in 
the recovery of cells from stress, and in guarding against further insults (Fulda et al., 2010).  
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HSP70 is a multigene family that includes the stress-inducible members HSPA6 and 
HSPA1A/HSP70-1 (Schwarz et al., 2003; Tavaria et al., 1996).  HSP70 protects stressed cells by 
recognizing nascent polypeptides, unstructured regions of protein, and exposed hydrophobic 
stretches of amino acid (Nollen and Morimoto, 2002).  The binding of exposed hydrophobic 
residues in unfolded or partially folded proteins is regulated by ATP-hydrolysis-induced 
conformational changes in the ATPase domain of HSP70, which is stimulated by co-chaperones 
(Nollen and Morimoto, 2002).  HSP70 is transcribed in response to stress due to activation of 
heat shock transcription factor (HSF) (Abravaya et al., 1992).  Abravaya et.al proposed a model 
suggesting that physiological stress creates misfolded proteins that compete with HSF for 
binding to HSP70, resulting in release of transcriptionally active, DNA-binding HSF to induce 
transcription of heat shock genes.  Baird et.al has shown that this HSF-mediated transcription is 
increased under low O2 due to direct binding of HIF1A to its HRE on the HSF intron (Baird et 
al., 2006).  These reports are consistent with a mechanism wherein HSP70 transcription is 
mediated by HSF or HIF1A at low O2 in trophoblast cells. 
HSP70 forms a molecular chaperone complex with HSP90, another highly conserved and 
essential HSP family member (Pratt et al., 2015; Pratt and Toft, 2003).  This molecular 
chaperone complex is dependent on the hydrolysis of ATP, and ADP/ATP exchange, and is 
mediated by association with HOP (Hsp70/Hsp90-organising protein)/STIP1 (stress-induced 
phosphoprotein 1) (Carrigan et al., 2006; Chen and Smith, 1998).  The HSP70/HSP90 molecular 
chaperone complex, optimized by HOP, coordinates interactions that ensure folding and 
conformational regulation of proteins under stress (Hernandez et al., 2002; Wegele et al., 2004). 
RNAi knockdown of HOP in pancreatic cancer cells decreases expression of MMP2 (Walsh et 
al., 2011).  Additionally, inhibition or depletion of HSP70 in the breast cancer cell line, MA-MB-
231, decreases cell migration and invasion due to a lack of MMP2 activation (Sims et al., 2011).  
47 
 
This suggests that molecular relationships between HSPs, various signaling proteins, and partner 
proteins mediate the integrity of signal transduction pathways (Nollen and Morimoto, 2002).  
Our data further supports the role for HSP70 in mediating MMP2 function, which is required in 
trophoblast cells for HBEGF survival signaling. 
The signaling cascade delineated in the present study (Figure 12) could influence 
multiple physiological processes that play a key role in placentation.  There is substantial 
evidence to support that HBEGF expression is altered in preeclampsia, and that its protein levels 
are decreased in preeclamptic placentas (Armant et al., 2015; Leach et al., 2002a). MMP2 
belongs to a family of extracellular matrix-remodeling enzymes that have been implicated in the 
regulation of vasculogenesis, which is disrupted in placental insufficiency disorders, such as 
preeclampsia.  There is compelling evidence that MMP2, but not MMP9, increases in women 
who subsequently develop preeclampsia (Eleuterio et al., 2015; Montagnana et al., 2009; Myers 
et al., 2005; Narumiya et al., 2001).  HSP70 also appears to be altered in adverse pregnancies. In 
a pilot study, higher levels of HSP70 were reported in patients with early onset of severe PE 
(Jirecek et al., 2002; Yung et al., 2014).  Fukushima et.al reported that serum levels of HSP70 
were constant throughout normal pregnancy, but increased significantly in women with 
preeclampsia (Fukushima et al., 2005; Molvarec et al., 2006) or preterm delivery (Fukushima et 
al., 2005).  Increased circulating HSP70 in preeclamptic patients could be due to systemic 
inflammation as a result of disease and increased oxidative stress (Ekambaram, 2011; Molvarec 
et al., 2009).  In term preeclamptic placentas, HIF1A and HSP70 are both elevated and, localized 
prominently in syncytiotrophoblasts and villous endothelial cells (Park et al., 2014). In another 
study of HSP70 in term placentas, both mRNA and protein increased in women with 
preeclampsia and intrauterine growth restriction (Liu et al., 2008).  However, there has been no 
information reported on the expression or role of placental HSP70 in the first trimester prior to 
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this study. 
Using an established trophoblast cell line and a villous explant model, we have 
established a role for HSPA6 (HSP70B’), a HIF-regulated gene, in the regulation of MMP2 
required for HBEGF shedding at low O2.  These findings suggest that trophoblast survival in the 
low O2 environment during early pregnancy requires this signaling pathway.  Disruption of any 
component during the first trimester could compromise trophoblast survival and function, 
leading to placental insufficiency and the resulting obstetrical complications of pregnancy. 
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CHAPTER 3 - REGULATION OF HBEGF BY MICRO-RNA FOR SURVIVAL OF 
DEVELOPING HUMAN TROPHOBLAST CELLS 
Abstract 
The growth factor HBEGF is upregulated post-transcriptionally in the low O2 
environment of the human placenta during the first 10 weeks of pregnancy.  We have examined 
the possible roles of HBEGF turnover and micro-RNA (miRNA) signaling in its regulation by O2 
in human first trimester trophoblast cells. HTR-8/SVneo trophoblast cells were cultured at 2% or 
20% O2 with vehicle, 10 µg/ml cyclohexamide, 1 µg/ml lactocystin, 100 µg/ml MG132, or 
siRNA to knockdown DGCR8 in the microprocessor.  HBEGF, DGCR8, and β–actin were 
examined by western blotting. HBEGF was quantified by ELISA. Protein turnover studies using 
cyclohexamide demonstrated faster HBEGF degradation at 20 % O2 than 2% O2 mediated by the 
proteasome.  However, proteasome inhibitors were insufficient to initiate HBEGF accumulation 
at 20% O2.  Trophoblast cells were transfected with a dual luciferase reporter construct 
(psiCHECK-2) containing no insert (control), the HBEGF 3’ untranslated region (3’UTR), or 
sub-regions of the 3’UTR.  Reporter activity relative to empty vector demonstrated that the intact 
HBEGF 3’ UTR inhibited expression (0.26), while fragments containing only its flanking 
regions increased reporter activity (3.15; 3.43).  RNA was extracted from trophoblast cells 
cultured at 2% O2 for 0-4 h for next-generation sequencing to quantify miRNAs.  Although, no 
differential expression of any miRNAs was found in trophoblast cells, nevertheless, HBEGF 
upregulation at 2% O2 was blocked when the miRNA-processing protein DGCR8 was silenced, 
suggesting a role for miRNA.  Our findings suggest involvement of flanking regions of the 
3’UTR in activating HBEGF protein synthesis in response to 2% O2, possibly through a miRNA-
mediated mechanism. 
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Introduction 
The epidermal growth factor (EGF) family member, heparin binding EGF-like growth 
factor, (HBEGF), is present in the uterus at the time of embryo implantation (Leach et al., 1999; 
Yoo et al., 1997).  In addition, its expression in trophoblast cells of the invading placenta 
indicates its central role in early implantation and subsequent placentation (Leach et al., 2002a).  
Since, the placenta is not fully oxygenated until after the 10th week of pregnancy, placentation 
proceeds in a low O2 (2%) environment.  In vitro work has demonstrated that HBEGF protein 
levels are upregulated in human first trimester trophoblast cells at low (2%) O2 (Armant et al., 
2006).  Furthermore, HBEGF protects trophoblast cells from apoptosis, and promotes their 
invasion (Leach et al., 2004; Leach et al., 2008).  Preeclampsia, in which trophoblast invasion is 
reduced and apoptosis elevated, is characterized by in vivo reduction of HBEGF expression, as 
well as disruption of and other regulatory components of EGF signaling system in TB cells 
(Armant et al., 2015; Leach et al., 2002b).  A mechanism for the regulation of HBEGF by O2 in 
TB cells is beginning to emerge, based on recent studies of a first trimester TB cell line.  
Transmembrane HBEGF cleavage in response to low O2 initiates autocrine signaling that 
increases HBEGF levels to a concentration that inhibits apoptosis (Armant et al., 2006).  The 
autocrine upregulation of HBEGF requires activation of its cognate receptors (ERBB1 and 
ERBB4), and downstream signaling through any one of three MAPK pathways initiated by 
MAPK 1/3, MAPK14 or MAPK8 (Jessmon et al., 2010).  Previous work has demonstrated that 
HBEGF is not transcriptionally regulated by O2, although its protein levels increase by over 100-
fold at low O2 (Armant et al., 2006).  HBEGF mRNA levels are high and remain unchanged by 
exposure to low O2. It remains to be determined that at what point downstream of HBEGF 
shedding HBEGF accumulation is regulated by this autocrine mechanism. 
Regulation of transcription and translation can be disparate processes, depending on the 
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gene and cellular context (DiFederico et al., 1999; Koritzinsky et al., 2005).  The abundance of 
specific proteins can be regulated post-translationally by altering their turnover rates (Kristensen 
et al., 2013).  Proteins with fast turnover rates are generally characterized as low abundance 
(Boisvert et al., 2012; Schwanhausser et al., 2011), intrinsically unstructured (Gsponer et al., 
2008; Prakash et al., 2004), or aggregation prone (De Baets et al., 2011; Gsponer and Babu, 
2012), and are mostly involved in signal transduction and transcriptional activation (Boisvert et 
al., 2012; Legewie et al., 2008; Yen et al., 2008). Alternatively, HBEGF downstream signaling 
could be involved in inhibiting its protein turnover to increase its abundance through its 
autocrine signaling (Figure 13).  Certain proteins can be regulated by either stabilization (Zhao et 
al., 2008) or destabilization (Baudouin-Legros et al., 2005; Phelps et al., 2006) of their mRNA.  
A prior study has shown that HBEGF mRNA is stabilized in HeLa cells exposed to a 
chemotherapeutic agent (Sorensen et al., 2006).  Because HBEGF transcript levels are not altered 
by O2 fluctuation (Armant et al., 2006), we hypothesized that mRNA translation is a factor 
contributing to its regulation.  There is evidence that microRNAs (miRNA) could directly or 
indirectly regulate protein expression by increasing translational rates (Baek et al., 2008; Selbach 
et al., 2008). 
MicroRNAs are ~22 nt endogenous small RNA species that primarily target the 3’ 
untranslated region (3’UTR) of mRNA transcripts, and are well known for their roles in 
suppressing translation or inducing degradation of mRNA (Kim and Nam, 2006; Pillai et al., 
2007).  DGCR8 is a gene within the “DiGeorge syndrome chromosomal region (DGCR)” at 
human chromosome 22q11 (Shiohama et al., 2003). DGCR8 combines with Drosha to form a 
stable microprocessor, or pri-miRNA processing complex (Gregory et al., 2004; Han et al., 2004; 
Landthaler et al., 2004).    MicroRNAs are transcribed as primary miRNA transcripts in the 
nucleus by RNA polymerase II and are subsequently processed by the microprocessor into 
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shorter pre-miRNA hairpin precursors.  The pre-miRNAs are exported into the cytoplasm and 
processed into their mature ~22 nt form by dicer (Bartel, 2004).  Mature miRNAs are 
incorporated into RNA-induced silencing complexes (RISCs) or miRNPs (miRNA 
ribonucleoproteins) where miRNAs target mRNAs by binding with perfect complementarity to a 
conserved 6-8 nt seed region in the 3’UTR.  MicroRNAs have the unique capacity to bind a 
specific target transcript and, due to imperfect base pairing at nucleotides 10-11, inhibit 
translation without inducing degradation of the mRNA (Bartel, 2004; Filipowicz et al., 2008; 
Pillai et al., 2007).  A miRNA-mediated mechanism could be responsible for the translational 
regulation of HBEGF by O2 concentrations.  
Specific miRNAs are expressed in placental tissue (Barad et al., 2004; Maccani and 
Marsit, 2009; Mouillet et al., 2011) and trophoblast cells (Donker et al., 2007; Spruce et al., 
2010).  When introduced into cariocarcinoma cell cultures, miRNAs target functional proteins.  
Mir-152 targets HLA-G in JEG3 cells (Zhu et al., 2010), miR-34a targets Notch1 and Jagged1 in 
HeLa and JAR cells (Pang et al., 2010), and miR-199b targets SET (protein phosphatase 2A 
inhibitor) in BeWo and JAR cells (Chao et al., 2010).  Donker et al. (Donker et al., 2007) 
demonstrated in primary trophoblast from term placenta that the miRNP machinery is present in 
cells cultured for 24-72 h at 20% or 2% O2, and silences MED1 (Mediator complex subunit 1) 
expression through differential regulation of miRNAs (Mouillet et al., 2010).  Regulated 
expression of miRNAs that target HBEGF mRNA could likewise provide evidence that its 
translational regulation at 2% O2 is mediated by miRNAs. 
In this study we have tested whether the regulation of HBEGF protein is mediated 
through its turnover rate, or if other post-transcriptional mechanisms are operative.  Specifically, 
we examined reporter expression under control of the 3’UTR of HBEGF, the role of differential 
miRNA expression in the trophoblast cells exposed to reduced O2, and the effect of global 
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miRNA silencing by DGCR8 knockdown.  Our findings suggest a role for miRNA in the 
upregulation of HBEGF at 2% O2 rather than its suppression at 20% O2.  We suggest that the 
RISC becomes altered to enable translation from constitutively expressed HBEGF message 
downstream of HBEGF signaling at 2% O2. 
Materials and Methods 
Cell Culture and Treatments 
The first trimester human cytotrophoblast cell line HTR-8/SVneo (Graham et al., 1993) 
was cultured at either 20% O2 or 2% O2 as previously described (Leach et al., 2004; Leach et al., 
2008).  Cells were cultured for the indicated times in 10 µg/ml cyclohexamide to block de novo 
translation (Sigma-Aldrich), 1 µg/ml lactocystin or 100 µg/ml MG132 to inhibit the proteasome 
(EMD Biosciences).  The HTR-8/SVneo cell line retains important characteristics of primary 
cultures of human first trimester cytotrophoblast cells (Kilburn et al., 2000), making it a suitable 
model for this study.  This cell line expresses the TB specific marker KRT7.  When grown on 
Matrigel, HTR-8/SVneo cells expresses another TB specific marker HLA-G, and expression of 
integrin alpha 1 is upregulated, while alpha 6 is downregulated.  The expression of KRT7, β-
hCG and HLA-G as well as lack of Vimentin is routinely checked and cells are maintained at 
passages 30-50. 
Western Blotting 
Western blots were performed as previously described (Kilburn et al., 2000).  Cellular 
lysates were lysed in SDS sample buffer containing 5% β-mercaptoethanol, run on precast 4%-
20% Tris-HCl gradient gels (BioRad), and transferred to nitrocellulose membranes.  Monoclonal 
mouse antibodies against DGCR8 (Proteintech) and GAPDH (Ambion) were diluted in 5% milk 
dissolved in TTBS to 0.3 µg/ml and 1 µg/ml, respectively.  A polyclonal antibody against 
HBEGF (R&D Systems) was diluted to 0.2 µg/ml in 5 mg/ml BSA in TTBS. 
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ELISA 
The HBEGF DuoSet ELISA Development kit (R&D systems) was used, as previously 
described (Armant et al., 2006; Leach et al., 2008).  The optical density of the final reaction 
product was determined at 450 nm, using a programmable multiplate spectrophotometer (Power 
Wave Workstation; Bio-Tek Instruments) with automatic wavelength correction. 
Generation of 3’UTR Luciferase Reporter Vectors 
Regions of the HBEGF 3’UTR were amplified by PCR.  Restriction sites for XhoI and 
NotI were added to forward and reverse primers (IDT DNA), respectively.  3’UTR regions 
(Figure 14) amplified by the primers and the expected amplicon sizes are listed in Table 4.  The 
PCR amplified 3’UTR regions were cloned into the psiCheck-2 vector (Promega), in which two 
luciferase genes (Firefly and Renilla) driven by separate promoters are present.  HBEGF 3’UTR 
inserts were cloned into a region immediately following the Renilla luciferase gene, which serves 
as the reporter, while the Firefly luciferase gene is an internal control.  After isolating RNA from 
trophoblast cells (miRNeasy, Qiagen), cDNA was generated using the Omniscript Reverse 
Transcription kit (Qiagen).  HBEGF 3’UTR fragments were amplified by endpoint PCR, using 
HotstarTaq Plus Master Mix kit (Qiagen), according to the manufacturer’s instructions.  In a total 
reaction volume of 50 µl, 0.5 µM of each primer and 50 ng of cDNA were combined.  PCR 
products were processed using Wizard SV Gel and PCR Clean-up Kit (Promega).  Cleaned 
amplicons and the PsiCheck2 vector (1 µg each) were digested with both XhoI and NotI 
restriction enzymes (Promega) for 1 h at 37ºC in a thermal cycler, followed by a 15 min 70ºC 
inactivation step.  Amplified 3’UTR fragments and PsiCheck2 vector were combined and 
ligated, using Promega’s LigaFast Rapid DNA Ligation System.  To verify ligation, 1 µl of 
ligated product was amplified by PCR, using primers that bind outside of the PsiCheck2 vector’s 
multiple restriction site, as indicated in Table 4.  The primers listed were used in various 
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combinations to target different regions of HBEGF 3’UTR. 
Table 4. Primer sequence for amplification of HBEGF 3’UTR and vector sequencing.  
Forward Primers Sequence Target Site on HBEGF mRNA 
HBEGF 3’UTR AAACTCGAGGGAGGTTATGATGTGGGAAAATGA 844 
HBEGF 3’UTR AAACTCGAGCCTTTGCCACAAAGCTAGGA 1644 
HBEGF 3’UTR AAACTCGAGTTGCCTAGGCGATTTTGTCT 1829 
HBEGF 3’UTR AAACTCGAGAACAGGGAACATTGGAGCTG 2137 
PsiCheck-2 vector AGGACGCTCCAGATGAAATG  
   
Reverse Primers Sequence Target Site on HBEGF mRNA 
HBEGF 3’UTR AAAGCGGCCGCAGATCCCTTGGTGGTACT 1363 
HBEGF 3’UTR AAAGCGGCCGCCAGGAAATTGCCAAAGTA 1603 
HBEGF 3’UTR AAAGCGGCCGCCCAAGTTAACCCCTACATCCTG 1778 
HBEGF 3’UTR AAAGCGGCCGCATGAACCAGGTTTGGAAATACA 2315 
PsiCheck-2 vector CAAACCCTAACCACCGCTTA  
 
Bacterial Transformations  
One microliter of the ligation reaction mixture or empty PsiCheck2 vector was placed on 
ice, combined with 50 µl of JM109 bacteria (Promega) and heat shocked.  Bacteria were 
incubated on an LB Agar plate containing AMP-100, X-GAL-80, IPTG-50 (Teknova) overnight 
at 37ºC.  Colonies were grown and expanded in 3 ml of LB broth (Becton, Dickinson & Co.) 
containing 100 µg/ml of Ampicillin.  Bacterial lysates were prepared and amplified by PCR with 
primers in Table 1 to select colonies that displayed a correctly-sized insert.  Vectors were 
isolated using the Wizard Plus SV Miniprep kits (Promega), and 100 ng were used for 
transfection reactions.  Vectors were sequenced using the same primers utilized to verify 
ligation, and aligned to the HBEGF mRNA sequence (PUBMED sequence NM_0001945.2) 
using Geneious (Kearse et al., 2012). 
Transfection and Luciferase Assay 
HTR-8/SVneo cells were grown to 75 % confluence and cultured for an additional 24 hr 
in 1 ml serum-free media (DMEM/F-12 with 5 mg/ml BSA) containing 3 µl of FuGene-6 and 1 
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µl of vector (100 ng).  The cells were lysed in 500 µl 1X passive lysis buffer (Promega).  Lysates 
(20 µl) was used in each dual luciferase reaction, conducted according to the manufacturer’s 
protocol (Dual Luciferase Reporter Kit, Promega).  Negative controls containing untransfected 
cells were included. Each sample received 100 µl of LARII reagent, and was read after adding 
100 µl Stop & Glo reagent (Promega) using a Veritas microplate luminometer (Turner 
Biosystems).  Renilla measurements were normalized to Firefly measurements. Each transfection 
experiment was repeated at least 3 times.  
Library Preparation for NGS 
Trophoblast cells maintained at 20% O2 were cultured at 2% O2 for 0-4 hrs and RNA was 
collected.  For RNA-seq, both long RNA and small RNA (sRNA) were isolated with the 
miRNeasy mini kit (Qiagen).  The long RNA fraction was used for transcriptomic analysis in 
Chapter 2. The sRNA fraction was quantified and its purity assessed, using an Agilent 2100 
Electrophoresis Microfluidics Analyzer.  A sRNA digital gene expression library was 
constructed by converting RNA into an adapter-ligated cDNA library, using a ScriptSeq Miner 
(Epicentre) and following the manufacturer’s protocol.  Each cDNA sample was bar-coded and 
the resulting 12 cDNA libraries (3 replicates for each O2 concentration) were combined for 
sequencing on Illumina’s Genome Analyzer II sequencer at the Wayne State University Applied 
Genomics Technology Center. 
Sequencing Data analysis 
Demultiplexing was performed using configure BclToFastq.pl script (CASAVA-1.8.2; 
Illumina Inc.) with default parameters for quality and index identification.  The sequencing data 
was aligned to the human genome build (HG19) and to the ribosomal sequences 18S and 28S 
using Genomatix mapping station (GMS).  The GMS generated tsv.files were exported to the 
Genomatix genome analyzer and subjected to the miRNA expression analysis tool to identify 
57 
 
differentially expressed miRNAs. 
DGCR8 Knockdown 
HTR-8/SVneo cells were tested for toxicity due to NeoFX transfection reagent (Ambion), 
using the Multitox-Fluor Multiplex Cytoxocity Assay Kit (Promega) to determine an optimal 
concentration for transfection, which was 0.75 µl of NeoFX reagent per well in a 96-well plate, 
(<10% toxicity after 48 hrs).  Cells were transfected in a 96-well plate (5,000 per well) for 48 hr 
with various concentrations of three siRNAs (s29061, s29062, s29063; Life Technologies) that 
target DGCR8.  Controls included no transfection, treatment with transfection agent only, 
transfection with a negative control siRNA and a GAPDH siRNA.  Cells were fixed with ice-
cold methanol for 10 min, permeabilized with 0.1% Triton-X100 for 15 min, stained overnight 
with primary antibody against DGCR8 (Santa Cruz Biotechnology, Inc.) at 4ºC, incubated for 1 
hr at room temperature with an anti-mouse/anti-rabbit labeled polymer (DAKO EnVision Dual 
Link), and visualized with DAB.  Based on preliminary experiments, 50 nM siRNA was chosen 
for DGCR8 knock down. 
qPCR 
RNA from HTR-8/SVneo cells was collected using the miRNeasy kit (Qiagen), 
according to the manufacturer’s protocol.  RNA concentration was determined using the 
NanoDrop spectrophotometer and purity was ascertained with a microfluidic Bioanalyzer 
(Agilent Technologies - 2100 Electrophoresis Bioanalyzer Instrument).  RNA was used in 
subsequent qPCR (Bustin et al., 2009) analysis.  Reverse transcription was performed using the 
Quantitect Reverse Transcription kit (Qiagen), and qPCR for HBEGF was conducted with the 
Quantitect SYBR Green PCR kit without UNG (Qiagen), in a final volume of 25 μl.  GAPDH 
was used as a housekeeping gene to normalize the data.  Semi-quantitative analysis was 
performed according to the ΔΔCt method (Pfaffl, 2001).  Primers for GAPDH and HBEGF were 
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obtained from Qiagen. 
Statistics 
All experiments were repeated at least 3 times and reported as mean ± SEM.  Statistical 
significance was determined at p<0.05 by ANOVA, Student-Newman-Keuls tests and Dunnett t-
test using SPSS version 12.0 statistics software (SPSS). 
Results 
HBEGF regulation by protein degradation  
The observed increase in HBEGF protein levels at low O2 could reflect a decrease in 
protein turnover rate at 2% O2.  HBEGF protein levels were elevated by culture at 2% O2 for 6 h 
and cultured for an additional 2 hours with cyclohexamide to arrest protein synthesis.  HBEGF 
levels remained unchanged (Figure 13 A), indicating a very low turnover rate.  In contrast, cells 
shifted to 20% O2 after 6 h at 2% O2 showed a marked destabilization of HBEGF protein, which 
declined significantly within 15 min (Figure 13 B).  HBEGF degradation was abrogated if cells 
were concomitantly treated with the proteasome inhibitors MG132 or lactocystin after shifting 
cells to 20% O2, suggesting that HBEGF turnover requires the proteasome.  However, HBEGF 
protein did not increase at 20% O2 when cells were treated with proteasome inhibitors (data not 
shown), suggesting that stabilization of HBEGF degradation is insufficient for its accumulation 
at 20% O2, and that its accumulation at 2% O2 requires activation of its translational from 
mRNA.  These finding indicate that destabilization by proteolysis through the proteasome clears 
HBEGF during reoxygenation.  
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Regulation by the HBEGF 3’UTR  
The differential regulation of HBEGF synthesis by O2 in human trophoblast cells could 
be the result of translational suppression at 20% O2, or activation of protein synthesis from its 
mRNA at 2% O2 under the direction of its large (1455bp) 3’UTR, a region of mRNA known to 
be involved in transcript stability (Mignone et al., 2002).  To determine whether the 3’UTR of 
HBEGF can control translation, a PsiCheck-2 luciferase reporter with 3’ inserts of the entire 
HBEGF 3’UTR or its subdomains was prepared and transfected into trophoblast cells cultured at 
Figure 13. Effect of O2 concentration on HBEGF
stability. HTR8S/Vneo cells were cultured for 6 h at
2% O2, allowing HBEGF protein to accumulate.
Afterwards, cells were (A) exposed to cyclohexamide
for up to 2 h in the absence or (B) presence of either 1 
µg/ml lactocystin (white circle) or 100 µg/ml MG132 
(triangle). Cell lysates were collected at the indicated 
times and HBEGF protein levels quantified by
ELISA. * p < 0.05 according to ANOVA and
Student-Newman-Keuls t-tests. 
A 
B 
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20% O2.  The presence of certain portions of the HBEGF 3’UTR altered Renilla Luciferase 
production, as compared to an empty vector control (Figure 14).  A vector containing the full-
length 3’UTR (844-2315) significantly (p=0.008) repressed reporter activity, as did 
vectorscontaining the 5’ subdomain (844-1778; p=0.031) or 3’ subdomain (1644-2315; 
p=0.019).  In contrast, the 134 bp region overlapped by the two larger domains did not regulate 
reporter activity.  Vectors containing regions 844-1603, 1644-1778, and 1829-2315 were also not 
active.  Vectors containing either the 5’ (844-1363) or 3’ (2137-2315) flanking regions of the 
3’UTR upregulated Renilla luciferase activity at both 20% O2 and 2% O2 (p<0.001 for both).  
The vectors containing the two flanking regions more significantly upregulated reporter at 20% 
O2 as compared to 2% O2 (t-test, p=0.022 and p<0.001, respectively).  Based on these 
Figure 14. Translational regulation by HBEGF 3’UTR. Dual luciferase assays used constructs containing
the indicated sequences of the HBEGF mRNA inserted 3’ to Renilla luciferase. The left panel shows activities
of the Renilla luciferase normalized to a constitutive firefly luciferase. N=3. *, p<0.05 vs empty vector control
(blue bar), ANOVA with Dunnett t-test. Right panel shows the locations of the inserts in colors indicating their
effect on translation; yellow, neutral; red, suppression; green, activation. A scale in base pairs is shown below.  
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observations, it appears that the two flanking domains of the 3’UTR increase translational 
activity in isolation from the central 3’UTR regions, while the presence of regions from 1363bp-
1644bp and 1778bp-1829bp instigated translational suppression.  These data are consistent with 
two opposing activities within the 3’UTR that respectively activate and suppress translation from 
the HBEGF transcript. 
Next generation sequencing to identify differentially expressed miRNAs 
To determine if HBEGF translation is regulated in response to O2 by differentially 
expressed miRNAs that interact with its 3’UTR, expression of miRNAs was examined globally 
by NGS.  Trophoblast cells cultured at 20% O2 were exposed to 2% O2 for 0, 1, 2 and 4 h, and
 
barcoded libraries were constructed for NGS.  The software analyzed a total of 2556 miRNAs 
based on the HG19.  A log-log plot of RPKM values comparing 0 h to later time points (Figure 
15), and statistical analysis by the Genomatix genome analyzer software, revealed that no 
A B 
C Figure 15. Effect of O2 on miRNA expression by
next generation sequencing: Log-log comparisons
of RPKM values for 2556 miRNAs  in
HTR8/SVneo cells after transfer from 20% O2 to
2% O2 for 0 h (x-axis, A-C) and y-axis 1 h (A), 2 h
(B) or 4 h (C). No miRNAs deviated significantly
from a straight line with slope of 1. 
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miRNAs were differentially expressed.  These findings suggest that if a mechanism involving 
miRNAs regulates HBEGF translation, it does not do so through changes in the expression of the 
miRNAs.  
Global inhibition of miRNA processing 
We further examined the potential role of miRNA in regulating HBEGF, using siRNA to 
silence DGCR8, which should globally suppress miRNA processing and deplete all miRNA 
(Landthaler et al., 2004).  DGCR8 was knocked down in HTR-8/SVneo cells by transfection for 
48 h with siRNA.  Controls included no transfection, treatment with transfection reagents only, 
and transfection with either a negative control siRNA or a GAPDH siRNA. Culture was either 
continued for 4 h at either 20% O2, or shifted to 2% O2.  Western blots for DGCR8 and toxicity 
assays were used to optimize conditions for knockdown (Figure 16A, B).  DGCR8 was greatly 
reduced in cells transfected with 50 nM of the targeting siRNA, but not in control treatments.  
Unexpectedly, HBEGF expression did not increase when DGCR8 was knocked down at 20% O2 
(Figure 16C), suggesting that HBEGF expression was not repressed by miRNA at high O2.  
Repression of translation by miRNA often occurs through degradation of message (Wilczynska 
and Bushell, 2015).  However, HBEGF mRNA was unchanged after DGCR8 knockdown and 
unaffected by O2 concentration (Table 5).  Surprisingly, the upregulation of HBEGF at 2% O2  
was inhibited in the DGCR8 knockdown compared to controls (Figure 16D).  These results were 
verified by ELISA to quantify HBEGF, which demonstrated levels near 0.01 pg/μg in all 
treatments at 20% O2 (Figure 16E).  At 2% O2, HBEGF levels rose to 5 pg/μg (range 4.2-6.4) in 
all controls, while cells transfected with 50 nM DGCR8 siRNA contained only 0.88 ± 0.22 pg/μg 
HBEGF (Figure 16F).  These findings indicate that HBEGF expression was not repressed by 
miRNA at high O2, and further suggest that miRNA is required for increased translation of 
HBEGF at 2% O2. 
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Table 5.  HBEGF mRNA in HTR-8/SVneo cells with or without (Control) exposure to 
DGCR8 siRNA measured by qPCR* 
20% O2 2% O2 
Control DGCR8 siRNA 50nM Control DGCR8 siRNA 50nM 
1.3 ± 0.26 0.92 ± 0.27 1.07 ± 0.30 1.39 ± 0.39 
*Relative expression of HBEGF mRNA normalized to GAPDH mRNA. Mean ± SE, n = 3. 
 
 
Discussion 
The present study demonstrates the complexity of HBEGF upregulation, and suggests the 
Figure 16. Effect of DGCR8 Knockdown on regulation of HBEGF by O2. Western blots of DGCR8
in lysates of HTR-8/SVneo cells treated for 48 hr with (A) 5 nM or 10 nM of three different DGCR8
siRNA and (B) different pairings of the three siRNA (5nM).  C-F. DGCR8 (~120kDa) , HBEGF
(~22kDa)  and -actin (~45kDa) were assessed in lysates of HTR-8/SVneo cells (control), cells treated
with transfection reagent only, or cells  transfected with GAPDH siRNA, 50 nM negative control siRNA,
and 5 nM and 50 nM DGCR8 siRNA. After 48 hrs, culture was continued for 4 hrs at 20% O2 (C, E) or
2% O2 (D, F). Lysates were assayed by western blot (C, D) or an ELISA for HBEGF (E, F). Untreated
trophoblast cells and trophoblast cells containing transfection reagent alone served as Control. *,
p<0.005, compared to Control. 
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potential role of miRNAs.  Blocking HBEGF degradation with proteasome inhibitors failed to 
instigate accumulation of HBEGF in trophoblast cells cultured at 20% O2, suggesting that the 
upregulation of HBEGF at low O2 is not due solely to decreased HBEGF turnover, but requires 
increased translation of abundant HBEGF mRNA.  HBEGF turnover was indeed strikingly faster 
at 20% than at 2% O2, which could facilitate clearance of the protein during reoxygenation. 
Given the lack of transcriptional regulation (Armant et al., 2006), it was hypothesized 
that HBEGF could be regulated translationally by its large (1461 bp) 3’UTR.  Luciferase 
reporters have been used to assess translational regulation by 3’UTRs (Pang et al., 2009) and 
provided evidence here that cloned regions of the HBEGF 3’UTR regulate its translation with 
domain-specific stimulatory or inhibitory activities.  Others have examined translational 
suppression by miRNA with cloned 3’UTR regions by transfecting with an additional vector that 
contains target miRNA in HEK293 cells (Jiao et al., 2010) and HTR-8/SVneo cells (Mouillet et 
al., 2010).  The methodology that we chose is advantageous because it more closely recapitulates 
in vivo conditions by relying upon endogenous miRNA and translational machinery.  Although 
there was no effect of changing O2 concentrations, the flanking regions of the 3’UTR (844-1363 
and 2317-2315) strongly upregulated luciferase activity, suggesting that these domains could 
have a role in elevating HBEGF translation at 2% O2.  In contrast, regions towards the center of 
the 3’UTR (1363-1603 and 1778-2315) repressed luciferase production, and are likely 
responsible for the overall repressive effect of the complete 3’UTR sequence.  Luciferase assays 
showed that discrete regions of the 3’UTR are sufficient to differentially regulate HBEGF.  
An unbiased NGS approach failed to find miRNAs that are differentially expressed at 
20% and 2% O2.  Therefore, HBEGF was apparently not regulated by changes in the levels of 
miRNAs that interact with its transcript, but other components of the RISC interacting with 
miRNAs could be involved.  The requirement for miRNA was further examined by blocking 
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miRNA synthesis in a DGCR8 knockdown experiment, realizing that it could interfere with other 
unrelated critical cellular processes.  Suh et al used Dgcr8 knockout mice to distinguish the 
effects of miRNA and endogenous siRNA during oocyte maturation and preimplantation 
development, comparing the effects on development and mRNA expression to oocytes and 
embryos deficient in Dicer (Suh et al., 2010).  During treatment with DGCR8 siRNA, the low 
expression of HBEGF at 20% O2 persisted.  However, HBEGF protein failed to increase at 2% 
O2, suggesting that miRNA is linked to increased HBEGF translation in either a positive or 
indirect manor at 2% O2 rather than through suppression at 20% O2.  This is consistent with the 
observation that HBEGF mRNA expression was unchanged by DGCR8 knockdown at either O2 
concentration.  Hence, miRNA could be responsible for facilitating the upregulation of HBEGF 
through changes in other components of the RISC at low O2 that increase the influence of the 
flanking regions of the 3’UTR (844-1363 and 2137-2315), or reduce the influence of the 
repressive central domains.  The regulatory activity of the RISC can be affected by structural 
changes in the 3’UTR, such as shortening.  For example, 3’ UTR shortening can occur due to 
cleavage of the alternative poly(A) sites on the 3’UTR of mRNA, and this can lead to changes in 
protein translation efficiency, mRNA stability, or mRNA localization (Fabian et al., 2010).  To 
see if this structural change was present in HBEGF 3’UTR, we examined the RNAseq data 
obtained in Chapter 2.  However, due to low sequencing depth we found no clear evidence of 
HBEGF 3’UTR shortening. 
Alternatively, miRNAs or other regulatory factors that bind regions outside the 3’UTR 
(for example, to the 5’UTR) could accelerate translation of HBEGF at 2% O2.  There is evidence 
that miR-10a binds to the 5’oligopyrimidine tract motif in the 5’UTR of ribosomal proteins in 
neural U87 cells and mediates translational upregulation (Orom et al., 2008). MiR-122 targets 
the 5’non-coding region of the hepatitis C viral genome to positively regulate accumulation of 
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viral RNA (Jopling et al., 2005) through requisite occupation of two miR-122 binding sites in 
hepatic cells (Jopling et al., 2008).  Hence, miRNA or other regulatory factors that bind regions 
outside the 3’UTR could integrate with regions in the 3’UTR to induce translation at 2% O2. 
In the absence of a change in miRNA profile, HBEGF translation could be controlled by 
other components of the RISC, including regulatory proteins activated downstream of MAPK 
signaling, which is required for HBEGF upregulation at 2% O2 (Jessmon et al., 2010).  Iwasaki 
et. al found that loading of sRNA duplexes into the RISC complex requires HSP70/HSP90 
chaperones activity (Iwasaki et al., 2010).  We find in trophoblast cells that HSP70 transcription 
is induced at low O2 (Jain et al., unpublished).  Alternatively, there is evidence that the stability 
of argonaute 2 (AGO2) in the RISC is enhanced by EGFR/ERBB1 through MAPK signaling in 
cancer cell line MDA-MB-231 (Adams et al., 2009).  EGFR induces phosphorylation of Y393 in 
AGO2 to inhibit miRNA maturation, leading to tumor cell survival (Shen et al., 2013).  Using 
mass spectrometry, multiple phosphorylation sites have been identified in AGO2 from HEK293 
cells (Rudel et al., 2011).  Phosphorylation of Y529 in the RNA-binding pocket results in 
inefficient binding of sRNA to the protein, suggesting a mechanism for the alternate binding and 
release of miRNAs.  Additionally, studies in Hela cells demonstrate that phosphorylation of 
AGO2 by AKT serine/threonine kinase 3 (AKT3) and MK2 at S387 upregulates miRNA-
mediated translational repression of endogenous miRNA targets (Horman et al., 2013).  Some 
RNAs can displace miRNAs from their target mRNAs.  An example is competing endogenous 
RNA (ceRNA) (Salmena et al., 2011) or the recently described circular RNA (circRNA)  
(Hentze and Preiss, 2013), where the RNAs not only manifest themselves in the sequestration of 
miRNAs, but also act through the direct or indirect binding of RNA-binding proteins. 
Genes other than HBEGF are also translationally regulated by O2.  For example, low O2 
increases ATF4 protein, but doesn’t affect its mRNA, in hippocampal neurons (Yukawa et al., 
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1999).  In addition, chemically-induced endoplasmic reticulum (ER) stress, comparable to effect 
of low O2, shifts ATF4 mRNA from monoribosomes to polyribosomes, indicating that its 
preexistent mRNA pool is inefficiently translated until cells experience ER stress.  This shift to 
polyribosomes was dependent on the presence of ER-resident eIF2alpha kinase/PERK, 
suggesting that eukaryotic initiation factor 2A (EIF2A) is phosphorylated prior to translation of 
ATF4 (Koumenis et al., 2002). 
Additional studies are necessary to fully understand the mechanism controlling HBEGF 
autocrine upregulation.  We have presented evidence that the RISC is a key site of regulation; 
therefore, proteomic analysis of the RISC could identify components that are altered in response 
to HBEGF downstream signaling.  Future studies involving Chip Seq (Park, 2009) could help to 
elucidate the role of RISC and its components in controlling the HBEGF autocrine loop.  
Alternatively, motif-binding prediction  tools such as Scansite (Obenauer et al., 2003) would 
help to elucidate the interaction of other molecules with the HEGF 3’UTR that could play a 
critical role in HBEGF upregulation.  The significance of this mechanism in vivo is unclear, 
because this investigation was conducted in a trophoblast cell line.  However, we have found that 
HBEGF is indeed upregulated at low O2 in villous explants (Chapter 2, Figure 12).  The 
development of an animal model to experimentally investigate the proposed mechanism would 
be useful to clarify understanding of HBEGF regulation by O2 in vivo. 
The present study demonstrates that HBEGF is post-transcriptionally regulated by O2 
through a mechanism involving interactions of miRNAs with its 3'UTR.  Luciferase assays 
identified discrete regions of the 3’UTR that differentially regulate HBEGF translation.  A role 
for miRNA was suggested by knocking down the miRNA-processing protein, DGCR8.  
Although no differentially expressed miRNAs were found, it can be speculated that miRNAs are 
required for translation of HBEGF, but not for its repression at low O2.  The regulation of 
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HBEGF through a targeted mechanism that increases its translation rate, putatively involving 
miRNA and the RISC, appears to be uncommon based on a paucity of similar reports in the 
literature.  The elucidation of this complex regulatory mechanism could provide important 
insights into trophoblast survival during early placentation, and its disruption in pregnancies with 
developmental pathologies. 
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CHAPTER 4 - FETAL GENOME PROFILING AT FIVE WEEKS OF GESTATION 
AFTER NONINVASIVE ISOLATION OF TROPHOBLAST CELLS FROM THE 
ENDOCERVICAL CANAL 
Abstract 
Single gene mutations account for over 6000 diseases, 10% of all pediatric hospital 
admissions, and 20% of infant deaths.  Down syndrome and other aneuploidies occur in over 
0.2% of births worldwide and are on the rise due to advanced reproductive age.  Birth defects of 
genetic origin can be diagnosed in utero after invasive extraction of fetal tissues, while 
noninvasive testing with circulating cell-free fetal DNA is limited by a low fetal DNA fraction.  
Both modalities are unavailable until the end of the first trimester.  We have isolated intact 
trophoblast cells from Papanicolaou smears collected non-invasively at 5-19 weeks of gestation 
for next-generation sequencing of fetal DNA.  Matched maternal, placental and fetal samples 
(n=20), were profiled by multiplex targeted DNA sequencing of 59 short tandem repeat and 94 
single nucleotide polymorphism sites across all 24 chromosomes.  The data revealed a fetal DNA 
fractions of 85-99.9% with 100% correct fetal haplotyping.  This noninvasive platform is capable 
of providing comprehensive fetal genomic profiling as early as 5 weeks of gestation. 
Introduction 
Current models for studying placental biology include ex vivo models like explant culture 
(Genbacev et al., 1992) and  in vivo  models involving cell lines (Orendi et al., 2011).  Although 
these models mimic the physiology of trophoblast cells, yet they are a mixed population of cells.  
Based on the research over decades, the current notion is that the disruption of function of extra-
villous trophoblast (EVT) cells leads to placental insufficiency and the root cause lying in the 
first trimester of pregnancy.  Both the ex vivo and in vivo models not only fail to represent a pure 
EVT population but are only based end point analysis.  Therefore, there is a need of a platform to 
assess the EVT cells in ongoing pregnancies to better understand their pathophysiology and their 
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role in the progression of disease.  Trophoblast retrieval and isolation from the cervix (TRIC) is 
an innovative and transformative technology to safely assess these cells (Bolnick et al., 2014).  
Fetal cells isolated by TRIC can provide the conceptual foundation to develop a reliable 
approach for interrogation of the pathophysiological status of pregnancy in vivo that will enhance 
research on the human placenta, and the ability to diagnosis perinatal disease.  Although it 
appears that cells obtained by TRIC are indeed of fetal origin based on lineage marker 
expression and Y chromosome detection by fluorescent in situ hybridization (FISH) when a male 
fetus is present (Bolnick et al., 2014), we rigorously tested this assumption by comparing the 
genotypes of maternal-fetal cell pairs from twenty pregnancies examined by TRIC in the study 
presented here. 
Prenatal testing for genetic disorders is currently performed invasively with a limited, but 
definite, risk using amniocentesis (earliest at 12 weeks) or chorionic villous sampling (CVS) 
(earliest at 9 weeks) (Mujezinovic and Alfirevic, 2007; Wapner, 2005).  In addition, 
preimplantation genetic screening is available as an adjunct to in vitro fertilization (Sermon et 
al., 2004).  In the past five decades, tremendous efforts have been made to develop reliable, 
noninvasive, early and safe prenatal testing techniques, using intact fetal erythrocytes, cell-free 
fetal DNA, and endocervical fetal cells (Chitty and Bianchi, 2013; Gil et al., 2015; Rodeck et al., 
1995).  These approaches have identified chromosomal abnormalities, sex-linked diseases, and 
RHD genotype in fetuses.  In addition, prenatal screening of cell-free fetal DNA in maternal 
blood (earliest at 8 weeks) has been implemented clinically with some restrictions.  The 
technology relies on fetal DNA fragments that accumulate and rapidly turn over in maternal 
blood, with analysis by massively parallel sequencing to distinguish fetal from maternal 
haplotypes (Gil et al., 2015; Wapner, 2005; Wong and Lo, 2016).  However, the small fetal 
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fraction (4-10% at 10 weeks of gestation) and fragmentation of degrading DNA (146 bp) in the 
circulation limit its reliability for probing a broad range of significant genetic anomalies (Wang 
et al., 2013; Wong and Lo, 2016).  The fetal fraction of DNA rises steadily with gestational age, 
but must exceed 4% for accurate and reliable assessment of specific trisomies (Wang et al., 
2013).  It is particularly challenging with a low fetal fraction to detect a fetal haplotype that is 
over-represented in the maternal fraction of DNA, such as a male fetus at risk for an X-linked 
disorder (Wong and Lo, 2016).  Digital polymerase chain reaction (PCR) assays can detect 
autosomal recessive sickle cell anemia (Barrett et al., 2012) and X-linked hemophilia (Tsui et al., 
2011), but rely on exact quantification of the fetal fraction, which can be problematic in the first 
trimester due to the overwhelming amount of co-purifying maternal DNA.  The American 
College of Obstetricians and Gynecologists recommends that positive cell-free DNA results 
should be verified by the invasive tests, CVS and amniocentesis, which are considered diagnostic 
(2015). 
A simple, reliable, and safe approach to fully interrogate the intact fetal genome early in 
the first trimester of pregnancy at single nucleotide resolution currently does not exist.  To 
address and close this gap, we developed a straightforward alternative that uses a Papanicolaou 
(Pap) smear to capture intact fetal cells in numbers sufficient for next generation sequencing as 
early as 5 weeks of gestation.  Fetal cells with a placenta (trophoblast) -like cellular phenotype 
are naturally shed from the conceptus into the reproductive tract by a poorly understood 
mechanism (Adinolfi and Sherlock, 1997; Imudia et al., 2010; Shettles, 1971).  Until now their 
presence offered little benefit for noninvasive testing due to low cell recovery, and a 2000-fold 
excess of maternal cells and DNA in endocervical specimens (Imudia et al., 2009).  We first 
reported that fetal cells can be purified to near homogeneity by TRIC (average 99%), using Pap 
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smears safely collected during early pregnancy with a nylon cytobrush from the lower segment 
of the endocervical canal (Bolnick et al., 2014).  Importantly, in contrast to cell free fetal DNA 
(Wang et al., 2013), we showed that provision of fetal cells by TRIC is unaffected by gestational 
age between 5 and 20 weeks of gestation, or by maternal obesity (Fritz et al., 2015b), thus 
providing a robust source of fetal DNA during a period of pregnancy when it is most useful 
clinically. 
Here, we report the development of a DNA isolation and genotyping protocol that 
provides a high fetal fraction from cervical fetal cells obtained by TRIC during ongoing 
pregnancies at 5-19 weeks of gestation (Figure 16). Fetal DNA was assessed in twenty 
specimens using multiplex targeted sequencing to distinguish it from maternal DNA, based on 
profiling of 153 short tandem repeat (STR) and single nucleotide polymorphism (SNP) sites 
across the entire genome.  
Materials and Methods 
Patient selection 
The institutional review board of Wayne State University approved this study, and each 
participating patient provided informed written consent.  Pregnant women between 5-19 weeks 
of gestation and undergoing pregnancy termination were recruited.  The patients were counseled 
for collection of endocervical specimens and placenta at the Safe and Sound for Women Clinic 
in Las Vegas, NV and the Northland Family Planning Centers of Michigan.  
Isolation of endocervical fetal trophoblast cells 
Endocervical sampling was performed as described previously (Imudia et al., 2009). 
Endocervical cells were immediately fixed post the Pap smear procedure, using a ThinPrep kit 
(Hologic, Marlborough, MA) to preserve cells, proteins, and nucleic acids.  Trophoblast cells 
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were isolated from each specimen using TRIC (Bolnick et al., 2014).  Briefly, cells were 
centrifuged and re-suspended in 10 mL phosphate buffered saline (PBS), washing them three 
times.  After a final resuspension in 1.5 mL PBS, anti-HLA-G-coated magnetic nanoparticles 
were added and incubated overnight at 4°C with mixing.  The non-bound (maternal) cells were 
collected after magnetic immobilization of HLA-G-positive cells, which were recovered after 
three washings in PBS. The HLA-G-positive (fetal) cells were assessed by immunofluorescence 
microscopy for expression of β-hCG, and the percentage of labeled cells was determined. 
Fluorescence in situ hybridization (FISH) 
Isolated fetal cells were mounted on slides and probed for X and Y chromosomes by 
FISH at the Detroit Medical Center Cytogenetics Laboratory, using the DYZ1 satellite III on the 
Y chromosome, and the DXZ1 alpha satellite on the X chromosome as fluorescently-labeled 
probes (Abbott Molecular).  Nuclei were counterstained with DAPI and scored for each 
chromosome to quantify cells that were XX or XY. 
Targeted sequencing 
DNA was obtained from fetal and maternal cells isolated by TRIC and tissue from the 
corresponding placenta.  Targeted sequencing was performed using pregnancies with both male 
and female fetuses (N=20). 
Nuclear isolation and DNA extraction 
Targeted sequencing was performed for 94 SNPs and 56 STRs listed in Table 6 after 
digestion of exogenous DNA.  Fetal and maternal cells obtained by TRIC were dropped on slides 
and allowed to dry. Prior to DNA extraction, the slides were immersed in pepsin solution (0.01g 
in 100 ml 0.1N HCl) for 11 mins, followed by a PBS wash for 5 mins to remove cell membranes 
and contaminating maternal DNA fragments.  Exogenous or circulating DNA was further 
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eliminated from the glass-bound nuclei by adding 10 µL of washed, immobilized DNase (DNase 
I, immobilized on matrix  F7M, MoBiTec,  Goettingen,  Germany) onto the pepsin-treated slides, 
Table 6: List of SNP’s and STR’s targeted by FORENSEQ.  
Sr.No SNP name Sr.No SNP name Sr.No STR name Sr.No STR name 
01   rs1490413 48    rs1498553 01   D1S1656 48  DYS438 
02   rs560681 49   rs901398 02   TPOX  49   DYS612 
03   rs1294331 50   rs10488710 03   D2S441 50   DYS390 
04   rs10495407 51   rs2076848 04   D2S1338 51   DYS643 
05   rs891700 52   rs2107612 05   D3S1358 52   DYS533 
06   rs1413212 53   rs2269355 06   D4S2408 53   Y- GATA- H4 
07   rs876724 54   rs2920816 07   FGA 54   DYS385a-b 
08   rs1109037 55   rs2111980 08   D5S818 55   DYS460 
09   rs993934 56   rs10773760 09   CSF1PO 56   DYS549 
10   rs12997453 57   rs1335873 10   D6S1043 57   DYS392 
11   rs907100 58   rs1886510 11   D7S820 58   DYS448 
12   rs1357617 59   rs1058083 12   D8S1179 59   DYF387S1 
13   rs4364205  60   rs354439 13   D9S1122   
14   rs2399332 61  rs1454361 14  D10S1248   
15   rs1355366 62   rs722290 15  TH01   
16   rs6444724 63   rs873196 16   vWA   
17   rs2046361 64   rs4530059 17   D12S391   
18   rs279844 65   rs1821380 18   D13S317   
19   rs6811238 66   rs8037429 19 PentaE   
20   rs1979255 67   rs1528460 20   D16S539   
21   rs717302 68   rs729172 21  D17S1301   
22   rs159606 69   rs2342747 22   D18S51   
23   rs13182883 70   rs430046 23   D19S433   
24   rs251934 71   rs1382387 24   D20S482   
25   rs338882 72   rs9905977 25   D21S11   
26   rs13218440 73   rs740910 26   PentaD   
27   rs1336071 74   rs938283 27  D22S1045   
28   rs214955 75   rs8078417 28  DXS10135   
29   rs727811 76   rs1493232 29   DXS8378   
30   rs6955448 77   rs9951171 30  AMELX   
31   rs917118 78   rs1736442 31   DXS7132    
32   rs321198 79   rs1024116 32   DXS10074   
33   rs737681 80   rs719366 33   DXS10103   
34   rs763869 81   rs576261  34   HPRTB   
35   rs10092491 82   rs1031825 35   DXS7423   
36   rs2056277 83   rs445251 36   DYS505   
37   rs4606077 84   rs1005533 37   DYS570   
38   rs1015250 85   rs1523537 38   DYS576   
39   rs7041158 86   rs722098 39   DYS522   
40   rs1463729 87   rs2830795 40   DYS481   
41   rs1360288 88   rs2831700 41   DYS19   
42   rs10776839 89   rs914165 42   DYS391   
43   rs826472 90   rs221956 43   DYS635   
44   rs735155 91   rs733164 44   DYS437   
45   rs3780962 92   rs987640 45   DYS439   
46  rs740598 93   rs2040411 46   DYS389I   
47  rs964681 94 rs1028528 47   DYS389II   
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and incubating for 3-5 mins at room temperature.  The slides were washed with PBS to remove 
the beads and terminate DNA digestion.  The nuclei were lysed by incubation overnight at 65C 
with 0.5 µL/cell of Arcturus PicoPure DNA lysis buffer (Applied Biosystems), and then 
inactivated at 95C for 30 min. 
Placental villi (20-25 mg) were dissected and suspended in 100 µL PBS. Ten µl of 
immobilized DNase was added and shaken for 10 min at room temperature to ensure efficient 
extracellular maternal and fetal DNA digestion.  DNase beads were removed by washing in PBS.  
DNA was extracted from the tissue, using the Qiagen DNeasy Blood & Tissue Kit. 
All DNA was purified using the Qiagen MinElute PCR purification kit, eluted in a final 
volume of 20 µL, and quantified using the PicoGreen assay. 
Library preparation for ForenSeq 
DNA libraries were prepared with the ForenSeq DNA Signature Prep Kit (Illumina), 
using primer mix A, as instructed by the manufacturer.  Individual samples were quantified by 
Qubit, and analyzed using Agilent high-sensitivity DNA chips prior to library normalization.  
The percentage of libraries between 200-1000 bp was calculated based on the library traces, and 
was mixed accordingly at the genomic core facility at the University of Illinois.  A pool size of 
200bp-1 kb was selected, and the size-selected negative controls were mixed into the pool.  The 
samples were sequenced on a MiSeq FGX system including positive and negative controls 
(Illumina).  
ForenSeq data analysis 
ForenSeq with primer mix A analyzes 94 SNP loci and 59 STR loci on all human 
chromosomes (Figure 17c, Table 6).  The ForenSeq Universal Analysis software provides a run 
quality report and detailed genotype. From this report, data was extracted and allele percentages 
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determined, using the read depth of each STR or SNP.  For STR data, the two dominant alleles 
with highest relative peaks were used for further analysis. 
To determine the purity of fetal DNA, the level of contamination with maternal DNA was 
calculated from the SNP data.  For each sample triad (fetal, maternal, placental), the homo- or 
heterozygosity of each SNP was determined, first in the placenta, then comparing to fetal, and 
the percentage deviation of the fetal DNA was calculated.  Deviations from homo- or 
heterozygosity were also calculated in the SNP profile of maternal DNA to determine a threshold 
of technical and/or biological variation.  Maternal and placental SNP profiles were then 
compared, and the non-informative SNPs (i.e., identical maternal and placental alleles) were 
filtered out.  For the informative SNPs, the deviations obtained from the maternal sample were 
subtracted from the fetal sample and multiplied by two (to account for two maternal alleles 
contributing to the fetal sample), yielding the percentage of maternal contamination. 
To investigate whether the fetal genotype could be accurately determined in the absence 
of reference DNA, autosomal STR’s were used.  The dominant alleles with highest relative peaks 
were summed, to establish the median and range, which discriminated the pure (<15% 
contamination) from impure samples.  Pure samples had median STR alleles >85%, while 
impure samples had median STR alleles <80%. To establish a cutoff for discriminating pure 
from impure samples, 82.5% was chosen.  The determined threshold for autosomal STR alleles 
then provided 100% correct calls for the fetal haplotype. 
For SNP analysis, a threshold of 10% allowed a maximal maternal contamination of 
approximately 20%.  Therefore, a homozygous SNP was only analyzed in fetal samples when the 
variant allele represented either 0-10% or 90-100% of the read depth, while heterozygous SNPs 
were only analyzed when the variant allele read depth was between 40 and 60%. 
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Results 
Isolation and characterization of fetal cells 
Using TRIC (Bolnick et al., 2014), maternal and fetal cells were isolated from 
endocervical specimens (n=20), as illustrated in Figure 17a, at gestational ages ranging from 5 to 
19 weeks (8.3 ± 3.6 weeks; Table 7).  Matched maternal cells, and placental tissues were used as 
references for analysis.  An average of 282 trophoblast cells (range, 170-410) were separated 
from maternal cells that were in excess of 200,000 cells.  Purity of fetal cells was assessed by 
staining for expression of the trophoblast-specific protein, human chorionic gonadotropin β 
subunit (β-hCG).  On average, 89.2% (± 5.0%) of the isolated fetal cells stained positive for β-
hCG, which was completely absent in maternal cells (Table 7, Figure 17a, lower panel).  The 
gender of the isolated cells was determined by fluorescence in situ hybridization (FISH) for the 
X and Y chromosomes.  In pregnancies with a male fetus, the fetal cells showed positive probe 
binding for both X and Y chromosomes, as expected, while the maternal cells were positive only 
for the X chromosome (Figure 17a, lower panel).  Fetal and maternal DNA was obtained from 
234 (± 75) and 335 (± 104) cells, respectively, using endocervical specimens (n=20) and small 
pieces of placental tissue. (Table 7).  For fetal cells, nuclear isolation combined with DNase 
treatment after TRIC (Figure 17, Material and Methods) was necessary to ensure high quality 
fetal DNA samples (Figure 18). 
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Figure 17. Trophoblast isolation, assessment of cell purity, and fetal DNA isolation for sequencing.
a, Endocervical specimen collection and immuno-magnetic separation of trophoblast cells, using anti-
HLA-G coated magnetic nanoparticles [1-6]. Below, trophoblast purity assessment by
immunofluorescence staining for β-hCG (green), maternal and IgG were negative (first three panels), and
screening for gender by fluorescent in situ hybridization (FISH) for the X and Y chromosomes (right
panel, male sample). b, Top panel illustrates nuclear DNA isolation from the fetal cells [1]. Maternal
DNA is blue, fetal cells and DNA are red [2]. Fetal nuclei remain adherent to slides after limited cell
proteolysis [3]. Nuclei are lysed [4], providing fetal DNA [5]. The lower panels show
immunofluorescence microscopic images of fetal cells during procedure. F-actin in green (FITC-
phalloidin), and nuclei in blue (DAPI). Pepsin digestion removed F-actin. DNase immobilized on beads
degraded residual maternal DNA. Nuclei were used for fetal DNA purification. c, Top panel illustrates the
steps for targeted sequencing using the Forenseq platform [1-4]. The lower panel shows the locations of
the 59 STR (blue) and 94 SNP (red) sites targeted across the human genome. Size bars, 100 μm 
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Table 7.  Overview of samples and results for targeted sequencing approach 
Sample 
ID 
Gestational 
Age 
Tropho‐
blast cell 
purity  
(% β‐hCG) 
Fetal 
Gender 
Autosomal STR alleles 
in TRIC 
% Fetal 
Fraction (% 
maternal 
fraction) 
# of Informative SNP’s 
Media
n  Range 
In sample 
triads (%) 
In Fetal cells 
after 
threshold (# 
total SNP’s 
detected) 
Incorrectly 
called in 
Fetal cells 
SA 5 wks 86 Male 94.8 85.6 - 100 97.6 (2.4) 41 (43.6)  41 (93) 0 
SB 5 wks 89 Female 85.5 75.1 – 100 92.2 (7.8) 44 (44.7) 31 (77) 0 
SC 5 wks 91 Female 89.1 73.5 – 100 87.2 (12.8) 51 (54.3) 39 (82) 0 
SD 6 wks 85 Female 91.9 80.8 – 98.7 95.2 (4.8) 42 (44.7) 40 (89) 0 
SE 6 wks 92 Male 86.4 85.7 – 96.9  85.6 (14.4) 30 (40.4) 25 (62) 0 
SF 6 wks 93 Male 88.1 73.2 - 99.4 75.6 (24.4) 49 (52.1) 11 (55) 0 
SG 6 wks 89 Male 93.3 84.9 – 100 93.9 (6.1) 48 (51.1) 45 (91) 0 
SH 6 wks 86 Female 92.7 77.8 - 98.5 98.6 (1.4) 51 (54.3) 47 (89) 0 
SI 6 wks 89 Male 95 88.9 – 100 100 (0.0) 38 (40.4) 35 (90) 0 
SJ 7 wks 92 Female 89 77.7 – 96.6 82.1 (17.9) 41 (43.6) 19 (68) 0 
SK 8 wks 80 Female 89 72.3 - 100 82.4 (17.6) 42 (44.7) 22 (74) 0 
SL 8 wks 96 Female 92 79.6 - 99.4 97.2 (2.8) 40 (42.6) 38 (87) 0 
SM 8 wks 96 Female 90.2 78.3 - 100 90.8 (9.2) 47 (50) 44 (91) 0 
SN 8.4 wks 92 Female 93.3 76.5 – 99.2 92.8 (7.2) 45 (47.9) 42 (90) 0 
SO 9 wks 85 Male 93.6 79.8 - 100 92.9 (7.1) 52 (55.3) 46 (90) 0 
SP 9 wks 94 Male 91.9 81.9 – 100 100 (0.0) 38 (40.4) 37 (92) 0 
SQ 11 wks 85 Female 91.9 73.8 - 97.6 95.9 (4.1) 41 (43.6) 39 (89) 0 
SR 13 wks 91 Male 87.4 77.7 - 100 91.9 (8.1) 57 (60.6) 41 (77) 0 
SS 14wks 90 Male 91.7 81.8 - 100 92.6 (7.4) 44 (46.8) 44 (93) 0 
ST 19 wks 80 Female 93.2  85.3 – 99.5 98.7 (1.3) 48 (51.5) 48 (92) 0 
 
 
Figure 18. Comparison of
fetal fractions obtained
with/without nuclear
isolation. The stack bar graph
for the distribution of co-
purifying maternal DNA
(calculated as percentages and
represented in gradient
shades) in TRIC cells among
informative SNPs. Samples
S1-3, sequenced without fetal
cell nuclear isolation show
high proportion of maternal
SNP’s. Samples S4-6 were
subjected to nuclear isolation
before sequencing and show
decreased detection of
maternal SNP’s. 
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Targeted multiplex next generation sequencing  
We determined whether fetal DNA obtained by TRIC possessed the fidelity for reliable 
detection of single nucleotide mutations, as well as small DNA insertions and deletions.  To do 
this, we utilized the ForenSeq platform to genotype and distinguish the fetus and mother, using 
small quantities of DNA (Churchill et al., 2016; Kidd et al., 2006; Sanchez et al., 2006) to target 
59 STRs (27 autosomal, 7 X, and 24 Y haplotype markers) and 94 SNPs on all 22 autosomes 
(Figure 17c; Table 6).  On average 1.9 ±0.9 ng DNA (n=20) from fetal cells and DNA from 
matched placental and maternal cells was sequenced. All 153 loci (Table 6) were sequenced at a 
mean sequencing depth of 5268 ± 1714 per STR and 760 ±218 per SNP.  The fetal nuclear 
isolation strategy developed here generated a high-resolution STR profiles, detailing multiple 
shared and discriminatory alleles between mother and fetus.  Detailed analysis revealed 
concordance between allelic profiles of fetal DNA obtained by TRIC and reference placental 
DNA, which were both distinct from maternal DNA, and provided 100% correct fetal gender 
identification in all samples compared to fetal reference DNA (Figure 19a and Table 7).  
We observed that all 94 SNP’s were detected in the fetal samples, and matched the 
placental reference DNA haplotypes (Figure 19c).  Discriminatory SNP analysis, comparing the 
maternal haplotype to the reference placental DNA and fetal haplotype (Figure 19 b, d, 
Methods), revealed an average fetal DNA fraction of 92.2 ± 6.5%, indicative of low levels of 
maternal DNA in the fetal samples (Table 7).  Additionally, all of the maternal and fetal 
haplotype pairs lacked forbidden combinations (AA/BB) at any allele (Figure 19b), consistent 
with unique individuals, related as parent and offspring.  Forbidden combinations were checked 
to ensure that in each of the samples at least one allele was derived from the mother thereby 
demonstrating that the fetus is related to the mother. 
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Accuracy of Haplotype Determinations  
Using a threshold filter derived from reference placental DNA to account for variant 
reads due to maternal DNA that co-purified with fetal DNA (Methods), homozygous SNPs were 
Figure 19. Targeted sequencing of fetal cells obtained by TRIC. a. d a, Graphical representation of 
STR profiles of DNA triads composed of maternal cells (Maternal), fetal cells (TRIC) and placental tissue
(Placenta) from sample SN (Table 2.0). For each DNA sample, the two dominant alleles with highest
relative peaks for a given STR were determined and compared. The adjacent mini-plots show distribution 
of shared STR’s (upper mini-plot) and discriminatory STR’s (middle and lower mini-plots). b-d, 
Comparisons of allelic frequencies for the sequenced 94 SNPs in sample SD (Table 2.0); b, fetal and 
maternal cells, c, fetal cells and placenta, d, maternal cells and placenta. 
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only called when the variant allele reads were within 0-10% or 90-100%, while heterozygous 
SNPs were only called between 40 and 60% (Methods).  We observed that even after the 
threshold was applied, we were able to call 89% ± 12% of all the 94 SNP’s in fetal samples 
(Table 7).  The haplotype of any SNP that passed the filter always matched the placental 
reference DNA and was, therefore, correctly determined.  The number of SNPs recovered after 
filtering correlated with the amount of co-purifying maternal DNA present.  Stratifying the 
twenty samples, we found that the presence of less than 5% maternal DNA (n=8) resulted in 95.4 
± 2.5% recovery of the SNPs available pre-filtering; for 6.1% to 9.2% maternal DNA (n=7), 
average recovery was 92.5 ± 7.3% of SNPs; whereas higher contamination (12.8% to 24.4%, 
n=5) reduced recovery of SNPs to 62.5 ± 15%. 
The data were further analyzed to determine when the purity of the fetal fraction was 
sufficient to call the correct fetal haplotypes in the absence of reference (e.g., placental) DNA.  
An internal quality control was established using the median summed autosomal STR allele 
percentage (Methods).  A median summed autosomal STR allele percentage greater than 82.5% 
(achieved in 15 of the 20 samples) was required to consider a sample adequately pure for precise 
single nucleotide resolution.  In general, any given SNP in any samples that passed the filter was 
correctly called. 
Discussion 
Genetic disorders pose a significant risk for the newborn.  After forty-five years of 
exploring the diagnostic utility of fetal trophoblast cells residing in the female reproductive tract 
(Imudia et al., 2010; Shettles, 1971), we report in this study that the entire fetal genome can be 
analyzed with a noninvasive and standardized procedure, beginning at three weeks post 
conception  (five  weeks  after  the previous  menses).   The  TRIC  protocol, followed by nuclear 
83 
 
 
Figure 20. Approaches to obtain fetal DNA for prenatal testing in ongoing pregnancies in
comparison to trophoblast retrieval and isolation from the cervix (TRIC). Sources of fetal DNA
throughout early pregnancy are illustrated at the maternal-fetal interface. Amniocentesis is available
beginning at 12-15 weeks of gestational age (GA) and is invasive, but provides intact fetal cells from
amniotic fluid for DNA isolation. Chorionic villous sampling (CVS), available at 9-10 weeks of GA,
provides fetal DNA from intact cells of a placental biopsy obtained invasively. Fetal cells are extremely
rare in maternal blood. However, fragments of fetal DNA released from degrading placental cells
accumulate in maternal blood with increasing GA as cell-free fetal DNA. This cell free fetal DNA can be
obtained non-invasively from maternal blood, beginning at 8-10 weeks of GA and can be analyzed using
multiple parallel sequencing combined with extensive computational analysis to distinguish it from cell-
free maternal DNA. Hundreds of intact trophoblast cells can be safely retrieved non-invasively in Pap
smears using a cytobrush. TRIC captures trophoblast cells migrating into the reproductive tract that
accumulate in the endocervical canal beginning at 5 weeks of GA without negative effects early GA or
maternal obesity found with cell free DNA. (Table 7) 
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isolation, provided access to the full, unfragmented fetal genome for analysis earlier in gestation 
than any procedure currently in practice (Figure 20).  
Previous studies have suggested genetic testing protocols using fetal cells captured from 
the cervix by size selection and laser micro dissection (Bussani et al., 2007; Bussani et al., 2002; 
Katz-Jaffe et al., 2005; Mantzaris and Cram, 2015; Pfeifer et al., 2016).  A critical obstacle was 
the inability to generate pure, well-characterized fetal cell populations.  The lack of sufficient 
quantities of fetal DNA for reliable molecular analysis limited DNA characterization and 
reproducibility.  As a result, those approaches have never been adapted for clinical use.  
To overcome these limitations, we have developed a rapid isolation protocol that 
provides fetal cells and DNA within one day, using immunomagnetic isolation of fetal cells 
(Bolnick et al., 2014).  Although trophoblast HLA-G expression decreases in women with 
placental disorders, such as preeclampsia (Goldman-Wohl et al., 2000), fetal cell yield is not 
significantly hindered in those pregnancies (Fritz et al., 2015b), which reduces dropouts due to 
lack of DNA.  Initial experiments that isolated DNA from fetal cell extracts (Figure 17) failed to 
reliably provide a high fetal DNA fraction that was adequate for clinical analysis, suggesting co-
purification of maternal DNA fragments bound to the fetal cells.  This complication has likely 
hindered comprehensive analysis of the fetal genome by other groups working with specimens 
collected from the reproductive tract.  Nuclear isolation eliminated the maternal DNA, resulting 
in unprecedented fetal DNA purity from transcervical specimens.  An average fetal fraction of 
91.5% was obtained before 10 weeks of gestation, with a fetal fraction up to 99.9% as early as 6 
weeks of gestation. 
Next generation sequencing is a powerful tool for both global analysis of the genome and 
targeted sequencing of selected loci.  Whole genome and exome sequencing have the advantage 
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of identifying chromosome structural anomalies, as well as de novo mutations.  However, those 
approaches require larger quantities of DNA for complete coverage and adequate read depth 
(>30x) in order to obtain single nucleotide resolution.  The small fraction of fetal DNA available 
in cell-free DNA limits its usefulness to chromosome copy number variance testing as a 
noninvasive perinatal screen.  However, approximately 90% of congenital defects are not caused 
by aneuploidies (Christianson and Modell, 2004).  By accessing intact fetal cells with entire 
genomes, the TRIC protocol reliably provides comprehensive fetal genetic analysis as 
demonstrated here using targeted sequencing. 
Targeted sequencing without whole genome amplification is currently the method of 
choice for diagnostic screening of specific genomic regions and gene mutations.  It requires less 
DNA, provides greater depth (>300x), and is therefore a reliable, low cost approach. 
Additionally, data is easier to analyze compared to whole genome sequencing due to the limited 
number of loci involved.  It avoids as well the potential of uncovering maternal disorders, 
including cancers that can be detected with the current NGS shotgun sequencing approaches 
(Bianchi et al., 2015).  
With as few as 125 cells, the exact fetal genotype was determined reliably by targeted 
multiplex sequencing of 157 loci across all chromosomes.  However, the limit at which cycle 
saturation would cause a bias is not currently known.  SNPs are naturally occurring single 
nucleotide variations in the genome that, from a technical standpoint, are comparable to 
pathogenic point mutations.  Similarly, STRs mimic small insertions and deletions in the genome 
that distinguish some clinically-relevant mutations.  Targeted sequencing of SNPs has been 
extended on a large scale for aneuploidy analysis of cell free fetal DNA (Wong and Lo, 2016).  
The ability to detect both SNPs and STRs is evidence that prenatal genotyping by TRIC is 
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capable of detecting any genetically-transmitted disease. 
Achievement a high fetal fraction through TRIC and nuclear isolation solves a critical 
problem in the detection of gene mutations in the first trimester of pregnancy.  Here, we provide 
proof that recessive, autosomal, single nucleotide polymorphisms in a male fetus can be easily 
detected without the need of paternal haplotyping, based on our analysis.  The approach used in 
this study can be effortlessly adjusted to test for any genetic variation or disorder.  If 
discriminatory SNPs or STRs are included in the targeted sequencing strategy, contaminating 
maternal DNA can be quantified and subtracted to determine the fetal haplotype.  Therefore, 
genotyping is straightforward and can be adjusted to established commercial pipelines.  With 
advances in targeted multiplex sequencing approaches, Nicolaides et al. have successfully used 
19,488 parallel reactions to detect aneuploidies in cell free DNA (Nicolaides et al., 2013), which 
should be feasible using fetal cells from the cervix to screen aneuploidies, as well as multiple 
genetic disorders.  
TRIC can potentially fill an important gap in current noninvasive prenatal testing with the 
precision of current invasive technology, but unhampered by limitations due to a large maternal 
DNA fraction, rapid fetal DNA catabolism, early gestational age or maternal obesity.  Due to its 
simplicity, TRIC will in the future enable prenatal genetic analysis in a diagnostic clinical setting 
without the necessity of complex bioinformatics for interpretation of massively parallel 
sequencing.  Isolation of fetal cells by TRIC holds not only promise for prenatal genetic testing, 
but also provides a novel approach to investigate trophoblast cells in ongoing pregnancies 
(Imudia et al., 2010), exploring their biology and relationship to the various placental 
insufficiency syndromes that jeopardize fetal and maternal health. 
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CHAPTER 5 - TRANSCRIPTOMIC PROFILING FOR CHARACTERIZATION OF 
CELLS ISOLATED BY TRIC 
Abstract 
The survival and differentiation of extravillous trophoblast (EVT) cells at the beginning 
of pregnancy is crucial, and deficiencies are linked to diseases of uteroplacental insufficiency, 
including early pregnancy loss, fetal growth restriction and preeclampsia.  It is anticipated that 
EVT gene expression in the first trimester is altered prior to the onset of overt disease in the third 
trimester.  Fetal cells that express EVT lineage proteins can be obtained from ongoing 
pregnancies by Trophoblast Retrieval and Isolation from the Cervix (TRIC), and provide a novel 
platform for examining gene expression.  Transcriptomic analysis using next-generation 
sequencing (NGS) offers as an unbiased approach to identify differentially expressed transcripts 
in these fetal cells during the first trimester from normal and pathologic pregnancies.  RNA 
isolated from the fetal cells was quantified and assessed for quality to establish its stability 
during TRIC.  NGS identified 409 genes differentially expressed between the fetal cells and 
maternal cells from the same cervical specimens.  However, no significant differences in gene 
expression were noted between replicate RNA aliquots, or between fetal cells from different 
patients.  Bioinformatics, including gene ontology pathway analysis and BioPython library 
demonstrated that 21 genes were EVT specific.  This study suggests that not only can RNA of 
adequate quality be isolated from cells obtained by TRIC, but it can be used to reliably 
interrogate the transcriptome.  TRIC and NGS could provide for the first time molecular profiles 
that reveal early pathophysiological events postulated to occur in EVT cells at the inception of 
pregnancies that develop uteroplacental insufficiencies and cause major obstetric disorders.  
Introduction 
The placenta is a multifunctional organ that not only provides a fetal-maternal interface, 
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but is also the site of exchange of nutrients, oxygen, metabolites and other molecules between 
the mother and the fetus (Dilworth and Sibley, 2013).  The placenta is important for the survival 
of the fetus, as well as health of the mother.  They are composite organs consisting of a 
trophoblast compartment that enables nutrient and gas exchange between the fetal and maternal 
blood circulations, and mesodermal lineages that form the umbilical cord and the fetal portion of 
the placental vasculature (Chaddha et al., 2004).  The trophoblast compartment consists of a 
population of villous cytotrophoblast cells that fuse into syncytiotrophoblast or proliferate along 
the fetal-maternal interface to form cell columns and undergo a well-defined differentiation into 
invasive extravillous trophoblast (EVT) cells.  The synctiotrophoblast layer is responsible for all 
nutrient and gas exchange between the maternal and fetal blood circulations (Knofler and 
Pollheimer, 2013).  EVT cells discharge through the maternal mucosal fluids after invading the 
uterine wall, where they are deployed to facilitate spiral artery remodeling and immune 
modulation at the fetal-maternal interface.  
Trophoblast Retrieval and Isolation from the Cervix (TRIC) is a novel experimental 
platform (Bolnick et al., 2014) that provides a novel approach to non-invasively acquire fetal 
cells hypothesized to be EVT that are central for proper placentation.  TRIC uses the EVT 
lineage protein, HLA-G, to efficiently separate maternal cells from fetal cells in endocervical 
specimens.  The isolated cells are positive for β-hCG (>98%), while the depleted maternal cells 
do not express this trophoblast product (Bolnick et al., 2014; Fritz et al., 2015a).  Cells 
isolated by TRIC are clearly fetal in origin, based on the presence of a Y chromosome when the 
fetus is male (Bolnick et al., 2014), and comparison of haplotypes between maternal and fetal 
cells isolated during TRIC (Chapter 4).  Two other trophoblast marker proteins, cytokeratin 7 
(KRT7) and placental lactogen (CSH1) are uniformly expressed in the isolated fetal cell fraction 
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(Bolnick et al., 2014).  The phenotype of the isolated fetal cells was investigated using ICC, 
demonstrating that they express several EVT markers (ITGA1, CDH5, PECAM1, MMP9, HLA-
G), but lack villous trophoblast markers (ITGA6, CH1, PSG1) (Bolnick et al., 2014).  
Uteroplacental insufficiency, defined as inadequate perfusion of the placenta, is a 
pathology associated with several perinatal disorders, including early pregnancy loss (EPL), 
intrauterine growth restriction (IUGR) and preeclampsia (PE) (Hossain and Paidas, 2007; 
Papageorghiou et al., 2004).  There is compelling evidence that uteroplacental insufficiency 
originates with the failure of EVT cells to properly differentiate, invade intravascularly, and 
convert the uterine spiral arteries to low resistance, high volume conduits of maternal blood into 
the intervillous space (Chaddha et al., 2004).  These events transpire during the first trimester, 
well before clinical symptoms of IUGR or PE occur.  However, direct evidence that the EVT 
cells are altered in the first trimester prior to development of those disorders is lacking.  Fritz et 
al examined a set of proteins associated with uteroplacental insufficiency in fetal cells obtained 
by TRIC between 5 and 10 weeks of gestational age (GA) and found significant differences in 
six of the seven proteins between control pregnancies and those ending in EPL (Fritz et al., 
2015a), suggesting that the molecular profiles of the EVT-like fetal cells reflect pregnancy 
status. 
It is hypothesized that fetal cells obtained from the cervix by TRIC have a similar 
phenotype and physiology to EVT cells residing in the basal plate and placental bed.  
Understanding the relationship between EVT cells in the placenta and cervix will establish the 
developmental significance of the cells, and their utility as an experimental paradigm to 
investigate placental pathophysiology.  As an initial assessment, the transcriptome of fetal cells 
obtained by TRIC will be compared to that of the maternal epithelial cells from the cervix to 
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establish their unique RNA profile and to determine if the differentially expressed genes are 
indicative of an EVT phenotype.  Because EVT invasion and conversion of the maternal spiral 
arteries occurs in the first and early second trimesters, it is hypothesized that comparison of fetal 
cells obtained by TRIC from pregnancies that develop severe placental insufficiency causing 
EPL with fetal cells isolated from pregnancies with healthy term deliveries will generate a 
unique set of differentially expressed genes associated with deficient trophoblast development, 
and could help identify novel disease biomarkers with very high sensitivity and specificity for 
future preclinical testing.  These studies will provide a clearer view of the utility of fetal cells 
obtained by TRIC from ongoing pregnancies for investigating early placentation and 
pathological etiologies, and the potential of TRIC as a platform for perinatal interrogation of the 
placenta to predict maternal risk of placenta-based disease. 
Materials and Methods 
Sample Collection 
Pregnant patients (N=50) were recruited at 5-20 weeks GA with informed consent and 
approval of the institutional review board of Wayne State University.  EVT cells were obtained 
with a ThinPrep kit (Hossain and Paidas, 2007) and immediately fixed during the PAP smear 
procedure, preserving proteins and nucleic acids, including RNA.  Prior to fetal cell isolation, all 
cells were pelleted to remove ThinPrep fixative and then cross-linked with 10 ml of 2% 
paraformaldehyde for 10 min.  This was followed by washing the cells 3 times with 10 ml of 
PBS by centrifugation and resuspension.  Fetal cells were then purified by immunomagnetic 
isolation with anti-HLA-G, according to the TRIC protocol (Bolnick et al., 2014). Recovery after 
immunomagnetic isolation averages 746 ± 59 (Bolnick et al., 2014) 
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RNA Extraction 
Fetal RNA was isolated after de-crosslinking, using a Qiagen FFPE RNA kit, incubating 
at 56ºC for 15 min and 80ºC for 15 min and incubating with 1500 Kunitz DNase for 15 min prior 
to RNA extraction.  Isolated RNA was quantified with the RNA Pico Kit (Agilent Technologies), 
and its purity assessed using an Agilent 2100 Electrophoresis Microfluidics Analyzer.  The 
amount of RNA per cell recovered is reported in Figure 21C (Results). 
Library Preparation 
Eleven patients were selected for RNAseq after outcomes were determined from patient 
medical records.  A control cohort of pregnancies with uncomplicated term deliveries (n=9) and 
adverse pregnancy cohort (n=2) were identified and selected for library preparation.  RNA 
libraries were prepared from both fetal and maternal cells isolated by TRIC using the ScriptSeq 
v2 RNA-Seq Library Preparation Kit (Epicenter) and 500 pg of fragmented RNA.  Uniquely 
barcoded adaptors were ligated to the RNA, followed by PCR amplification and library 
purification.  Each uniquely barcoded sample was quantified and its quality assessed, using the 
High Sensitivity DNA Chip (Agilent Technologies).  The cDNA was combined from barcoded 
individual libraries before multiplex sequencing, eliminating any sequencing lane effects.  
Paired-end sequencing was performed for 50 cycles using the Illumina HiSeq-2500 sequencer.  
Data Alignment & Mapping 
RNA sequencing data was first processed with demultiplexing software (Casava 1.8.2, 
Illumina). It was then aligned to the human genome build CRCh37.p7/hg19, using TopHat2 ver 
2.0.13 (Kim et al., 2013), and to the ribosomal sequences 18S and 28S, using the bioinformatics 
tool Novoalign (Novocraft, 2010).  Novoalign determined unique alignments that were used to 
generate 1000 reads per coding segment per sample.  The reads thus generated were converted 
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into bed.files and imported to the Genomatix Genome Analyzer (GGA) (Genomatix Software 
GmbH).  The GGA, using RNA-seq analysis, generated data in the form of Reads Per Kilobase 
of exon per Million fragments mapped (RPKM) for 25,000 genes in the database. A set of 
differentially expressed genes (DEGs) were identified with bioconductoR package DESeq2 
(Anders and Huber, 2010).  A gene was considered significantly altered if the adjusted p-value 
was < 0.05. p-values were calculated by the DeSeq2 program.  DEGs were subjected to Ingenuity 
Pathway Analysis (IPA) to identify the top functional interaction networks and key central 
regulatory genes.  The most significant network in which the differentially expressed genes were 
enriched was selected and illustrated. 
qPCR 
The quality of the fragmented RNA was validated by semi-quantitative qPCR for 
HBEGF, MMP2 and 18sRNA, using SYBR green and a CFX384 BioRad thermal cycler (Life 
Technologies).  NGS data was validated using qPCR with primers (IDT) for genes listed in Table 
8.  RNA for each of the samples used in NGS was converted to cDNA, using 4 µl iSCRIPT 
(BioRad) and pre-amplified for x cycles in a multiplexed reaction using all primers and 
SsoAdvanced PreAmp Supermix (BioRad).  Samples were then target-amplified with individual 
primers. After each of the samples was target-amplified, qPCR was quantified by delta (Bustin et 
al., 2009) analysis.  
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Table 8: Genes used for qPCR validation 
Gene name Forward Primer Reverse Primer  
HLA-G GTG TGG TAC TTT GTC 
TTG AGG A 
AGA GTA GCA GGA 
AGA GGG TT 
Trophoblast marker 
KRT7 GGT CAG CTT GAG 
GCA CTG 
ACC ACA AAC TCA 
TTC TCA GCA 
Trophoblast marker 
CDH5 AAG AAC TGG CCC 
TTG TGA C 
CAG CCT TTC TAC CAC 
TTC CAG 
Invasion/migration marker 
MMP9 CGT CGA AAT GGG 
CGT CT 
ACA TCG TCA TCC 
AGT TTG GTG 
Invasion/migration marker 
ITGA6 TTG GAC TCA GGG 
AAA GCT ATT G 
GAT CTC CAC TGA 
GGC AGT TAT G 
Epithelial marker 
CDH1 CTG AGG ATG GTG 
TAA GCG ATG 
GTC TGT CAT GGA 
AGG TGC TC 
Epithelial marker 
CD38 TCC GAA GAT GTG 
GAC TTG C 
TCT CCA TCC TCT CTT 
CAC CA 
Trophoblast specific genes 
upregulated in fetal cells when 
compared to maternal cells. CSF1 TCT TTC AAC TGT TCC 
TGG TCT AC 
TGT CGG AGT ACT 
GTA GCC A 
DDX39A CAC CGA AGA ACA 
CAG ACA CC 
TCA ACG GAC AGG 
TGA CG 
RBM15 TCT TCT TGT TCT CAT 
ACC TAA CTC C 
AGT TCT CCC AGC 
AGT TCC T 
TLR1 AGA CAT TCC TAA 
AGG TAG AAG CTG 
GAA GAA ATC AGG 
ATA ACA AAG GCA 
AMBP GTA TCT GTT TTC TCA 
TAA GCT CCA G 
GAC AGG ATG ACA 
GTG AGC AC 
Trophoblast specific genes 
downregulated in fetal cells when 
compared to maternal cells. FGF23 TAT CTT CTG CTC ATC 
ACA CCT G 
GCC AGG AAC AGC 
TAC CAC 
KCNQ5 CTT CCT TGC CAT CCT 
CTA TAT CG 
AGT GTT TTC TAC CAT 
CCC TGA G 
NUNDT9 TTC TGT AAG GAG 
TTG GA GCT TC 
AAG GAA AGA CTG 
TGG AGA ATG G 
TRPC7 CAT CAA AGT AAG 
ACA GCC AGA GT 
TGC TCA ACA TGC 
TAA TAG CCA 
C3 TGT TAA ATG GCT 
GAT CCT GGA G 
GCC ATG TCT TTC TCG 
TTG TTG 
Genes upregulated in fetal EPL 
cells when compared to fetal 
normal CCND1 GTT CCA CTT GAG CTT 
GTT CAC 
GCT GTG CAT CTA 
CAC CGA 
FGF2 GCC AGG AAC AGC 
TAC CAC 
TAT CTT CTG CTC ATC 
ACA CCT G 
HSP90B1 AAG GAC TAC TGC 
ACC AGA ATG 
TGT TTC CGA AGA 
CGT TCC AC 
PRDX6 TGT GAC AGC TCG 
TGT GGT GT 
GTC AGC TGG AGA 
GAG ATG AC 
SUMO2 CCT GCA CAG TTG 
GAA ATG GAG G 
AGT AGA CAC CTC 
CCG TCG TCT GCT 
DUSP1 ACC ATC TTC CAT GCT 
TAC CAC 
AAC TTG GCA CTG 
CAT TTT GG 
Genes downregulated in fetal 
EPL cells when compared to fetal 
normal FOS ACA CTC CAA GCG 
GAG ACA GA 
CTG AGC TGC CAG 
GAT GAA CT 
IL1B TGG CCT TGG GCC 
TCA AGG A 
CTA CAC TCT CCA GCT 
GTA GAG 
IL8 TGT CTG GAC CCC 
AAG GAA 
CAT CTT CAC TGA TTC 
TTG GAT ACC 
JUNB CGG ATG TGC ACT 
AAA ATG GAA C 
GGT TTC AGG AGT 
TTG TAG TCG T 
NFKBIA CAG GAG ACG TGA 
AGA TGC TG 
AGT TGA GAA TGA 
AGG TGG ATG A 
SOC3 CAA GGA CGG AGA 
CTT CGA TTC 
GGA AAC TTG CTG 
TGG GTG A 
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Results 
TRIC provides stable RNA from isolated cells 
To assess RNA stability during TRIC, the HTR-8/SVneo cell line was treated similarly to 
cervical specimens collected in the ThinPrep fixative.  Both fresh cells and cells fixed in 
ThinPrep produced intact RNA, however, after a series of PBS washes or incubations to mimic 
the TRIC protocol at both 4C and room temperature degradation of RNA was apparent (Figure 
21A), possibly due to introduction of endogenous RNases.  
Formaldehyde covalently binds proteins and nucleic acids by reacting with primary 
amino groups, and prevents loss of highly soluble nucleic acids by inactivating endogenous 
RNases.  Aldehyde crosslinkers are reversible by heat and salt treatment (Niranjanakumari et al., 
2002).  TRIC was modified to incorporate formaldehyde crosslinking prior to removal of cells 
from the ThinPrep fixative to preserve RNA integrity.  Fetal and maternal RNA was extracted 
after de-crosslinking, which resulted in fragmented RNA (Figure 21B).  RNA extracted from 
ThinPrep-fixed cells prior to TRIC (crude) and maternal or fetal cells separated by TRIC using 
the crosslinking and de-crosslinking protocols produced equal amount of RNA/cell (Figure 21C).  
This finding suggests that the formaldehyde cross-linking prevents RNA degradation. qPCR for 
several known mRNAs in the isolated maternal and fetal cells produced Ct values comparable to 
RNA isolated from the crude cells (Figure 21D), suggesting that fragmentation following de-
crosslinking does not impact the over-all quality of the RNA extracted after TRIC for use in 
mRNA quantification.  The fragmented RNA is ideal for downstream NGS (Head et al., 2014). 
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Transcriptomic analysis of cells isolated by TRIC from normal term pregnancies 
Total RNA was prepared after TRIC, using the formaldehyde crosslinking and 
decrosslinking protocol from cervical samples obtained from patients with normal full term 
Figure 21. Assessment of RNA quality and integrity. A and B. Gel Images (Agilent 2100 Bioanalyzer)
of total RNA. A. RNA extracted from HTR-S/Vneo cells was immediately examined (Fresh), or fixed
with ThinPrep (Fixed), washed in PBS (Fixed + Wash) and processed by the TRIC protocol (Separation)
at either 4C (Cold) or room temperature (RT). High-quality samples (Fresh and Fixed) produced two
distinct bands corresponding to the 18S and 28S ribosomal RNAs. Smearing in the other lanes was
indicative of RNA degradation. B. RNA extracted from fetal (F) and maternal (M) cells isolated using the
formaldehyde crosslinking  protocol showed smearing and strong bands at ~200 bp, indicative of
fragmentation. C. RNA recoveries, quantified by Agilent Bioanalyzer, were determined from crude cells
in ThinPrep fixative and maternal and fetal cells separated by TRIC using the formaldehyde crosslinking
protocol (N = 48 cervical specimens. D. cDNA made from equal amounts of RNA in C was assayed by
qPCR with primers for the indicated RNAs 
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deliveries (n=9, Table 9).  The transcriptome was analyzed by RNA sequencing and 
bioinformatics to identify genes differentially expressed between the isolated fetal and maternal 
cells.  A total of 428 differentially expressed transcripts were obtained.  Analysis of transcripts 
by DESEQ2 for 2.0-fold up or down regulation, generated 209 up and 219 downregulated 
transcripts (Figure 22A).  Each of the differentially regulated transcripts appeared in MA (Figure 
22A) and volcano (Figure 22B) plots, demonstrating at least a 2-fold change and a p-value of 
<0.05, respectively as determined by the DESeq2 program.  
Table 9. Patient and specimen characteristics 
Characteristics Control EPL1 EPL2 
Number, n (% of total) 9 (81) 1 (9.5) 1 (9.5) 
Maternal age in years, median (IQR) 26 (22-28) 26 29 
Ethnicity   
Caucasian, n (%) 0 (0) 0 (0) 1 (100) 
African, n (%) 9 (100) 1 (100) 0 (0) 
Asian, n (%) 0 (0) 0 (0) 0 (0) 
Hispanic, n (%) 0 (0) 0 (0) 0 (0) 
Unknown, n (%) 0 (0) 0 (0) 0 (0) 
Gestational age at the time of sampling in weeks, median (IQR) 8 (7.6-11.6) 5 7.5 
Gravidity, median (IQR) 2 (1 - 2) 3 1 
Parity   
Nulliparous, n (%)  7 (78) 0 (0) 0 (0) 
Parous, n (%) 1 (11) 0 (0) 0 (0) 
Unknown, n (%) 1 (11) 1 1 
Delivery mode   
Normal Spontaneous Vaginal Delivery (NSVD), n (%) 7 (78) 0 (0) 0 (0) 
Cesarean section (CS), n (%) 2 (22) 0 (0) 0 (0) 
Unknown, n (%) 0 (0) 1 (100) 1 (100) 
Recovered fetal cells    
Purity (percentage of β-hCG positive cells), median (IQR) 100 (98-100) 90% 97% 
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Figure 22. Two visualizations of the comparative transcript expression profiles between fetal and
maternal cells A) A) Scatterplot (MA plot) of the log2-fold change in genes expressed in fetal cells
compared to maternal cells generated by DESeq2 on the y-axis, versus baseMean of normalized counts on
the x-axis. The differentially expressed genes (DEGs) (p-values <0.05) were indicated by bold red dots.
The black dots reflect genes with no significant change. B) Volcano plot of RNA-seq data represented by 
log2-fold change (x-axis), versus −log10 p-value. The light colored dots represent DEGs (p-value <0.05) 
in fetal compared to maternal cells. Among DEGs, 5 up-regulated (red) and 5 down-regulated (blue) genes 
were selected for further validation by PCR (see Fig. 23B and C). 
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Characterization of cells isolated by TRIC 
To characterize the two isolated cell populations (fetal, maternal) the expressions of 8 
genes known as markers for trophoblast, epithelial, and invasion/migration were selected and 
were examined by real-time qPCR in RNA from all 9 samples.  Comparison between cervical 
fetal and maternal cells showed expression of trophoblast markers in high abundance in the fetal 
cells (Figure 23A).  HLA-G and KRT7 were highly expressed compared to the maternal cells. 
HLA-G was most highly expressed in fetal cells, which were isolated using anti-HLA-G 
immune-separation.  CDH5 and MMP9, which are invasion/migration markers were expressed 
more in fetal cells than maternal cells.  E-Cadherin (CDH1) and integrin alpha 6 (ITGA6), both 
epithelial markers, were found in maternal cells, but were very low in the fetal cells, as expected 
of the most penetrating EVT (Zhou et al., 1997).  Of the differentially regulated genes, ten were 
selected based on their association with trophoblast based on a literature search, using BioPython 
(Cock et al., 2009).  Indeed, transcripts that were upregulated in the fetal cells based on NGS 
showed significantly higher mRNA expression by qPCR in fetal RNA compared to maternal 
RNA (Figure 23B).  Similarly, transcripts that were downregulated in the fetal cells according to 
RNAseq showed lower mRNA expression in fetal RNA than maternal RNA (Figure 23C), 
validating the NGS data and further confirming that the fetal cells are in fact of trophoblastic 
origin. 
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Gene Ontology Consortium, analysis for fetal and maternal DEGs in normal pregnancies 
For gene ontology (GO) analysis, the differentially expressed transcripts (p<0.05) 
Figure 23. Validation of RNAseq by qPCR. A. To characterize the isolated fetal and maternal cell
populations), the expression of 6 genes known as markers for trophoblast, epithelial, and
invasion/migration were selected and examined by qPCR for the 9 control pregnancies. The
expression values are presented as whisker-box plots. Transcript levels of 5 up-regulated (B) and 5
down-regulated (C) genes in the fetal transcriptome identified by RNA-Seq were also validated by
real-time qPCR. * p<0.05; The boxes represent the 25th to 75th percentiles, and horizontal red lines
within the boxes indicate the medians. The whiskers are drawn to indicate 1.5 × Inter Quartile Range
(3rd quartile – 1st quartile). 
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between the fetal and maternal cells were analyzed using Ingenuity pathway analysis (IPA).  For 
this analysis, biological processes were analyzed.  IPA generated the top protein-protein 
interaction network with a score of 32 comprising of 27 differentially expressed genes that were 
involved in invasion and migration differentiation and proliferation (Figure 24).  The prominence 
of these pathways suggests that the fetal cells isolated by TRIC have an EVT phenotype. 
 
Transcriptomic analysis and validation of cells isolated by TRIC in Early pregnancy loss  
After the pregnancy outcomes were known, 2 cases of early pregnancy loss (EPL) were 
identified and compared by NGS to 2 selected control pregnancies (EPL, 5 and 7.5 weeks, Table 
Figure 24. Protein-protein interaction network. Among the potential regulatory networks identified by
Ingenuity pathway analysis for the genes differentially expressed between fetal and maternal cells
(p<0.05), the top protein-protein interaction network is shown. It contains the key regulatory genes
involved in invasion and migration, differentiation and proliferation. Green symbols indicate genes
downregulated, and red symbols indicate genes upregulated in the in our study. 
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9).  Libraries were prepared for both the fetal and maternal cell populations from the EPL 
samples and sequenced.  Analysis of the sequencing data identified 348 genes differentially 
expressed between the fetal cells from control and EPL pregnancies.  Out of the 348 
differentially expressed genes, 69 were upregulated and 279 were downregulated, each with a p-
value <0.05 (Figure 25, Tables 10 & 11).  Of the differentially expressed transcripts, both up and 
downregulated genes were randomly selected for validation by qPCR.  Transcripts that were 
upregulated in RNAseq data had a higher mRNA expression level in the qPCR analysis (Figure 
26A), and those that were downregulated had a higher expression in the normal group (Figure 
26B).  However, because there were only two EPL samples, statistical analysis should be 
interpreted cautiously. Nevertheless, both the NGS and qPCR data show a similar pattern. 
 
Figure 25. Volcano plot presentation of transcripts in EPL versus control fetal cells. The light dots
represent significantly up- and down-regulated genes at two significant levels (p<0.05 and p<0.01)
shown in the legend to the right. Of all differentially expressed genes, 6 down-regulated (blue dots) and 7
up-regulated (red dots) were chosen for qPCR validation.   
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Table 10. Upregulated fetal genes in EPL compared to normal pregnancy 
 
 
Gene id log2fold change Symbol  Gene id log2fold change Symbol 
2353 3.189 FOS  5209 1.799 PFKFB3 
3553 3.147 IL1B  4792 1.79 NFKBIA 
8794 2.999 TNFRSF10C  366 1.784 AQP9 
6688 2.868 SPI1  54210 1.784 TREM1 
3577 2.712 CXCR1  2214 1.771 FCGR3A 
2215 2.606 FCGR3B  6648 1.767 SOD2 
23135 2.581 KDM6B  5329 1.747 PLAUR 
1958 2.504 EGR1  23645 1.737 PPP1R15A 
5008 2.502 OSM  3985 1.729 LIMK2 
4046 2.489 LSP1  5341 1.702 PLEK 
50486 2.455 G0S2  57580 1.685 PREX1 
1439 2.401 CSF2RB  2180 1.683 ACSL1 
8843 2.392 HCAR3  64744 1.669 SMAP2 
4688 2.372 NCF2  7133 1.619 TNFRSF1B 
7832 2.314 BTG2  6515 1.597 SLC2A3 
55911 2.287 APOBR  3579 1.574 CXCR2 
1843 2.276 DUSP1  6402 1.551 SELL 
3936 2.26 LCP1  3059 1.484 HCLS1 
3576 2.116 IL8  3937 1.477 LCP2 
338442 2.092 HCAR2  2495 1.357 FTH1 
4332 2.058 MNDA  7439 1.316 BEST1 
5552 2.023 SRGN     
3851 2.023 KRT4     
1230 1.981 CCR1     
8291 1.98 DYSF     
3133 1.964 HLA-E     
3106 1.96 HLA-B     
7128 1.955 TNFAIP3     
1441 1.932 CSF3R     
2212 1.905 FCGR2A     
7408 1.868 VASP     
7538 1.849 ZFP36     
3726 1.848 JUNB     
10135 1.845 NAMPT     
4542 1.808 MYO1F     
9021 1.806 SOCS3     
5997 1.806 RGS2     
9516 1.803 LITAF     
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Table11. Downregulated fetal genes in EPL compared to normal pregnancy 
Gene id log2fold change Symbol  Gene id log2fold change Symbol 
6206 -3.665 RPS12  3799 -2.493 KIF5B 
595 -3.539 CCND1  3308 -2.484 HSPA4 
6181 -3.311 RPLP2  7416 -2.462 VDAC1 
7184 -3.284 HSP90B1  1982 -2.461 EIF4G2 
10963 -3.186 STIP1  10959 -2.445 TMED2 
302 -3.183 ANXA2  6222 -2.436 RPS18 
1915 -3.155 EEF1A1  54443 -2.426 ANLN 
6124 -3.13 RPL4  5885 -2.422 RAD21 
9349 -3.102 RPL23  6152 -2.417 RPL24 
6205 -3.102 RPS11  7027 -2.417 TFDP1 
3182 -2.992 HNRNPAB  2280 -2.414 FKBP1A 
6188 -2.94 RPS3  3939 -2.383 LDHA 
7531 -2.886 YWHAE  3326 -2.382 HSP90AB1 
811 -2.846 CALR  6176 -2.372 RPLP1 
4904 -2.844 YBX1  6232 -2.362 RPS27 
5315 -2.84 PKM  1.01E+08 -2.349 RPS10-NUDT3 
304 -2.84 ANXA2P2  6160 -2.339 RPL31 
6125 -2.788 RPL5  3843 -2.337 IPO5 
594839 -2.781 SNORA33  5757 -2.329 PTMA 
10594 -2.764 PRPF8  3313 -2.323 HSPA9 
7052 -2.723 TGM2  7169 -2.315 TPM2 
6135 -2.718 RPL11  22974 -2.31 TPX2 
6185 -2.708 RPN2  6194 -2.309 RPS6 
821 -2.703 CANX  23193 -2.309 GANAB 
1938 -2.691 EEF2  11167 -2.299 FSTL1 
654364 -2.647 NME1-NME2  6210 -2.296 RPS15A 
6204 -2.63 RPS10  23521 -2.294 RPL13A 
3015 -2.617 H2AFZ  3608 -2.294 ILF2 
64710 -2.615 NUCKS1  908 -2.285 CCT6A 
22948 -2.608 CCT5  2923 -2.279 PDIA3 
6128 -2.601 RPL6  93621 -2.278 MRFAP1 
6167 -2.599 RPL37  284119 -2.275 PTRF 
60674 -2.588 GAS5  6129 -2.269 RPL7 
3945 -2.561 LDHB  9761 -2.253 MLEC 
6191 -2.547 RPS4X  351 -2.25 APP 
2597 -2.546 GAPDH  1937 -2.25 EEF1G 
308 -2.54 ANXA5  5901 -2.245 RAN 
3688 -2.513 ITGB1  7431 -2.245 VIM 
6143 -2.502 RPL19  22836 -2.242 RHOBTB3 
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Gene id log2fold change Symbol  Gene id log2fold change Symbol 
8754 -2.226 ADAM9  124801 -1.992 LSM12 
629 -2.224 CFB  7913 -1.991 DEK 
813 -2.218 CALU  11222 -1.987 MRPL3 
2288 -2.21 FKBP4  4288 -1.978 MKI67 
619564 -2.206 SNORD72  2195 -1.977 FAT1 
5718 -2.191 PSMD12  3069 -1.971 HDLBP 
372 -2.19 ARCN1  1.01E+08 -1.971 SENP3-EIF4A1 
10112 -2.188 KIF20A  6590 -1.971 SLPI 
6155 -2.185 RPL27  84154 -1.967 RPF2 
4628 -2.172 MYH10  718 -1.967 C3 
29789 -2.165 OLA1  857 -1.967 CAV1 
6169 -2.151 RPL38  23435 -1.962 TARDBP 
47 -2.151 ACLY  2547 -1.959 XRCC6 
5478 -2.147 PPIA  58517 -1.958 RBM25 
51406 -2.14 NOL7  1973 -1.958 EIF4A1 
6122 -2.136 RPL3  6790 -1.958 AURKA 
6130 -2.128 RPL7A  6189 -1.953 RPS3A 
125144 -2.126 C17orf76-AS1  2247 -1.947 FGF2 
3181 -2.124 HNRNPA2B1  9588 -1.944 PRDX6 
2201 -2.123 FBN2  5591 -1.936 PRKDC 
4430 -2.122 MYO1B  1282 -1.934 COL4A1 
10606 -2.12 PAICS  6134 -1.93 RPL10 
10562 -2.117 OLFM4  10568 -1.928 SLC34A2 
6233 -2.111 RPS27A  476 -1.924 ATP1A1 
6175 -2.106 RPLP0  6133 -1.924 RPL9 
8872 -2.104 CDC123  140609 -1.922 NEK7 
10197 -2.098 PSME3  6289 -1.921 SAA2 
5688 -2.094 PSMA7  7529 -1.92 YWHAB 
6217 -2.09 RPS16  805 -1.916 CALM2 
488 -2.081 ATP2A2  6171 -1.915 RPL41 
6780 -2.067 STAU1  1786 -1.914 DNMT1 
1662 -2.065 DDX10  5962 -1.914 RDX 
826 -2.054 CAPNS1  7178 -1.911 TPT1 
56910 -2.052 STARD7  2131 -1.911 EXT1 
7520 -2.013 XRCC5  7812 -1.907 CSDE1 
5707 -2.01 PSMD1  23215 -1.907 PRRC2C 
3998 -2.007 LMAN1  23028 -1.904 KDM1A 
3875 -1.994 KRT18  9805 -1.898 SCRN1 
9052 -1.993 GPRC5A  80014 -1.897 WWC2 
51400 -1.992 PPME1  6228 -1.895 RPS23 
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Gene id log2fold change Symbol  Gene id log2fold change Symbol 
967 -1.893 CD63  689 -1.77 BTF3 
3915 -1.89 LAMC1  8886 -1.768 DDX18 
3187 -1.886 HNRNPH1  10399 -1.767 GNB2L1 
6599 -1.886 SMARCC1  2058 -1.765 EPRS 
6613 -1.879 SUMO2  51495 -1.765 PTPLAD1 
9221 -1.878 NOLC1  114908 -1.764 TMEM123 
51747 -1.874 LUC7L3  10250 -1.762 SRRM1 
9897 -1.873 KIAA0196  9793 -1.76 CKAP5 
9669 -1.866 EIF5B  23603 -1.756 CORO1C 
6136 -1.865 RPL12  8615 -1.751 USO1 
6229 -1.865 RPS24  10199 -1.75 MPHOSPH10 
1173 -1.862 AP2M1  5411 -1.748 PNN 
9055 -1.855 PRC1  6147 -1.746 RPL23A 
1984 -1.849 EIF5A  2746 -1.74 GLUD1 
4436 -1.847 MSH2  23367 -1.739 LARP1 
3184 -1.844 HNRNPD  23524 -1.737 SRRM2 
79026 -1.843 AHNAK  4670 -1.736 HNRNPM 
6202 -1.839 RPS8  51474 -1.734 LIMA1 
11014 -1.838 KDELR2  9987 -1.726 HNRNPDL 
54407 -1.837 SLC38A2  10128 -1.723 LRPPRC 
26585 -1.835 GREM1  26135 -1.72 SERBP1 
7057 -1.832 THBS1  5955 -1.713 RCN2 
2935 -1.83 GSPT1  2956 -1.71 MSH6 
1315 -1.826 COPB1  27101 -1.709 CACYBP 
1E+08 -1.808 MTRNR2L8  6154 -1.707 RPL26 
1457 -1.807 CSNK2A1  3192 -1.699 HNRNPU 
9045 -1.804 RPL14  445815 -1.696 PALM2-AKAP2 
1431 -1.802 CS  214 -1.694 ALCAM 
7266 -1.8 DNAJC7  8394 -1.694 PIP5K1A 
4673 -1.798 NAP1L1  3376 -1.691 IARS 
4057 -1.796 LTF  23020 -1.681 SNRNP200 
7414 -1.795 VCL  4144 -1.679 MAT2A 
10521 -1.793 DDX17  3178 -1.676 HNRNPA1 
94025 -1.791 MUC16  1965 -1.67 EIF2S1 
2335 -1.791 FN1  6059 -1.669 ABCE1 
10769 -1.779 PLK2  26509 -1.668 MYOF 
7082 -1.775 TJP1  1303 -1.668 COL12A1 
27316 -1.773 RBMX  1933 -1.668 EEF1B2 
11217 -1.771 AKAP2  9804 -1.654 TOMM20 
9126 -1.771 SMC3  7430 -1.649 EZR 
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Gene id log2fold change Symbol  Gene id log2fold change Symbol 
55706 -1.642 NDC1  22872 -1.574 SEC31A 
10276 -1.64 NET1  7874 -1.573 USP7 
2040 -1.635 STOM  7415 -1.553 VCP 
9879 -1.635 DDX46  1778 -1.53 DYNC1H1 
667 -1.634 DST  10490 -1.527 VTI1B 
6421 -1.628 SFPQ  9908 -1.522 G3BP2 
6385 -1.626 SDC4  8500 -1.512 PPFIA1 
6201 -1.624 RPS7  6709 -1.501 SPTAN1 
7037 -1.619 TFRC  1981 -1.5 EIF4G1 
4076 -1.615 CAPRIN1  1495 -1.488 CTNNA1 
4735 -1.591 2-Sep  51280 -1.482 GOLM1 
3655 -1.577 ITGA6  79832 -1.477 QSER1 
1213 -1.576 CLTC  6651 -1.472 SON 
3646 -1.575 EIF3E     
 
 
Gene Ontology Consortium analysis for DEGs in EPL 
For gene ontology (GO) analysis the differentially expressed transcripts between the fetal 
Figure 26: Real-time qPCR validation of selected differentially expressed genes. Shown are 6
down-regulated (A) and 7 up-regulated (B) genes in EPL (n=2) compared to control (n=2) pregnancies
for fetal cells. The trends match that predicted by RNAseq results for each of the genes.  
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cells from EPL and fetal normal pregnancies were analyzed using Genomatix pathway analysis.  
The analysis generated pathways such as apoptosis (Figure 27A), inflammation (Figure 27B) and 
placental disease (Figure 27C) that are expected to be involved in placental insufficiency and 
EPL.  This result supports our hypothesis that cells isolated by TRIC are EVT like fetal cells that 
accurately reflect pathologies of pregnancy associated with placental EVT deficiencies.  Due to 
the small number of subjects (n=2) for the EPL group, Genomatix was used for initial analysis. 
Discussion 
Uteroplacental insufficiency is at least in part caused by defects affecting all EVT cells 
independently of their location at either the implantation site or cervix.  Recent published 
findings (Fritz et al., 2015a) reveal a strong correlation early in gestation between cervical EVT 
expression patterns of several proteins suspected of involvement in uteroplacental insufficiency 
and adverse pregnancy outcomes such as EPL (Fritz et al., 2015a).  The exact origin and biology 
of EVT-like cells residing in the cervix, and their relationship to the human placenta and 
pregnancy outcomes, are widely unknown.  Based the information gathered so far, it can be 
hypothesized that, as the placenta grows, EVT cells are naturally shed into the cervical canal, and 
their overall phenotype is comparable to the EVT cells residing in the placenta.  Any differences 
found in their RNA expression profiles could reflect the influences of the respective local 
environments.  Previously, investigators have tried to harness the cervical cells, but have failed 
to get a pure population.  In this study, for the first time using TRIC it has been possible to study 
the transcriptomic signature of EVT like fetal cells that were obtained in a noninvasive fashion 
as early as 5 week of gestation and utilize them as an experimental paradigm to investigate 
placental pathophysiology.  
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Figure 27. Pathway Analysis for EPL.  Potential regulatory networks identified by Genomatix pathway
analysis for genes differentially expressed between fetal EPL and control pregnancies. A. Apoptosis. B.
Inflammation. C. Placental disease. Upregulated genes represented in red, downregulated in blue, and no
regulation in orange, according to the key at bottom of figure. 
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TRIC provides ample RNA from isolated EVT cells for extensive transcriptomic 
analysis.  Statistical analysis of TRIC/RNAseq data revealed 428 genes differed significantly 
(Figure 22) between cervical EVT and maternal cells of which trophoblast specific genes were 
validated using RT-PCR.  mRNA expression of cervical EVT cells showed not only higher 
expression trophoblast markers such as HLA-G and KRT7 but also a higher expression of 
invasion/migration markers like CDH5 and MMP9.  Additionally, lower expression of epithelial 
markers like CDH1 and ITGA6 was also seen in these EVT like fetal cells.  
Expression of trophoblast specific markers, trophoblast invasion/migration markers and 
epithelial markers suggests an epithelial -mesenchymal transition (EMT).  During implantation 
and subsequent placentation cells of the trophectoderm that are known to be precursors of 
cytotrophoblast undergo EMT that induces trophoblast invasion and anchoring of the villi into 
maternal decidua to promote nutrient and gas exchange (Aplin et al., 1998; Bischof et al., 2006; 
Vicovac and Aplin, 1996). EMT results in the loss of junction and polarity of epithelial cells 
results in a reorganization of their cytoskeleton, reprogramming of gene expression and initiation 
of increased motility and invasive phenotype (Thiery et al., 2009; Thiery and Sleeman, 2006).  
Interestingly, bioinformatics analysis on the differentially regulated genes between the maternal 
and EVT like fetal cells generated pathways involved in invasion, migration and proliferation as 
the top scored (Figure 24).  Based on the mRNA expression of cells isolated by TRIC it can 
therefore be hypothesized that the isolated cells are indeed EVT like and could have undergone 
EMT. 
Overall, this data indicated the expected phenotypic similarities of the two trophoblast 
populations, and suggested that cervical EVT were mostly fully differentiated EVT.  Based on 
these findings, we conclude that cDNA libraries can be constructed from RNA isolated cervical 
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EVT cells and reproducibly sequenced by NGS.  Furthermore, libraries produced from different 
cell types show expected differences.  Significant differences were measured in gene expression 
between first trimester samples with early pregnancy loss and normal term deliveries (Figure25).  
A comparison of the EVT like fetal cells from normal term deliveries and those from early 
pregnancy loss generated a total of 348 differentially expressed genes.  Of these some of the 
genes upregulated in the EPL group such as FOS (Sitras et al., 2009), IL1B (Hefler et al., 2001), 
IL8 (Shimoya et al., 1999) and NFƘB(Vaughan and Walsh, 2012) have been reported to be 
associated with placental insufficiencies such as PE, IUGR and recurrent pregnancy loss based 
on studies done using placental tissue or from maternal serum.  Bioinformatics pathway analysis 
of the differentially expressed genes in pregnancies with EPL represented several interesting 
pathways, including inflammation, apoptosis and placental disease (Figure 27).  These are not 
unexpected findings, and they support the validity of our data.  TRIC provides the platform to 
now study these genes on a global aspect.  Transcriptome signatures associated with poor 
placentation will identify novel targets for preclinical testing with very high sensitivity and 
specificity.  This avenue of translational investigation will significantly accelerate our ability to 
diagnose and monitor perinatal disease, and is likely to facilitate experimental and clinical 
breakthroughs beneficial to patients who succumb to obstetrical disorders that arise from 
uteroplacental insufficiency.  
Due to the fact that EVT invasion and conversion of maternal spiral arteries occurs in the 
first and early second trimesters, the unique transcriptomes of patients with disease arising from 
poor placentation will help to identify new biomarkers for assessment of disease risk.  Though, 
the heterogeneous nature of these pathologies and variations in patient genetics and 
environmental factors gives rise to differences in expression of some genes among individual 
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specimens within each cohort.  Yet this platform has, for the first time, made it possible to tract 
the changes in EVT physiology and identifies many new potential biomarkers.  This study will 
help unravel molecular mechanisms governing uteroplacental insufficiency and the lay the 
foundation for subsequent studies to evaluate larger cohorts. TRIC is a novel platform for 
noninvasive, real time placental assessment, and pre-clinical prediction of specific abnormal 
pregnancy outcomes.  It provides the means to identify patients at high risk for disease as a 
research tool for evaluating first trimester interventions and new patient management strategies.  
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CHAPTER 6 - CONCLUSION 
Two approaches were undertaken to investigate the etiology of placental insufficiency.  
The first involved a focused study of HBEGF, which was known to regulate trophoblast survival 
and invasion, and becomes dysregulated in PE (Brosens et al., 1972; DiFederico et al., 1999).  
Secondly, an unbiased global approach based on NGS and systems biology to explore the EVT 
transcriptome by leveraging a novel, innovative approach to capture EVT like cells non-
invasively from ongoing pregnancies.   
Previous studies indicated that HBEGF is post-transcriptionally regulated by O2 through 
a dual mechanism in which proHBEGF is cleaved by metalloproteinases at low O2, and the 
released sHBEGF induces downstream signaling through MAPKs to mobilize its dormant 
mRNA (Armant et al., 2006; Jessmon et al., 2010).  Using an established trophoblast cell line 
and a villous explant model, we have established a role for HSPA6 (HSP70B’), a HIF-regulated 
gene, in the upregulation of MMP2 required for HBEGF shedding and subsequent survival 
signaling at low O2 (Chapter 2).  These key components of the trophoblast survival pathway 
could be required during early placentation and their disruption could contribute to placental 
insufficiency.  
To further investigate the upregulation of HBEGF by low O2, we examined the pathway 
downstream of its shedding, which autoregulates its accumulation.  The goal was to determine 
how dormant HBEGF mRNA becomes translated, hypothesizing that miRNA is involved.  
Global analysis of miRNA by RNAseq demonstrated that the mechanism did not involve a 
change in miRNA expression.  Demonstration for a role of the miRNA through DGCR8 
knockdown with siRNA suggested that other components of the RISC could contribute to the 
regulation of HBEGF mRNA translation (Chapter 3).  The elucidation of this complex regulatory 
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mechanism could provide important insights into trophoblast survival during early placentation, 
and its disruption in pregnancies with developmental pathologies.  However, HBEGF and other 
components of the EGF signaling system are disrupted in placentas of women with PE (Armant 
et al., 2015; Leach et al., 2002a).  Previous studies have shown that the survival and invasive 
function of EVT cells is under the regulation of numerous pathways involving growth factors, 
cell surface proteins and extracellular matrix components (Cross et al., 1994; Fritz et al., 2014; 
Lala and Hamilton, 1996).  Therefore, there is need to study trophoblast development using a 
global platform. 
TRIC is a novel approach to non-invasively acquire EVT cells hypothesized to be central 
for proper placentation during the first half of pregnancy.  Using rigorous genetic analysis of 
cells isolated by TRIC, we have shown that they are indeed fetal in origin (Chapter 4).  
Additionally, isolation of fetal cells by TRIC followed by NGS provides an advantageous 
platform for perinatal diagnostics as that is the first to offer noninvasive fetal genetic and 
perinatal disease testing as early as 5 weeks of gestation, which compares favorably to the 
current available options.  
We applied the TRIC platform to investigate the transcriptome of fetal cells from 
ongoing pregnancies with known outcomes as a strategy to identify molecules contributing to 
placental insufficiencies (Chapter 5).  Evidence was provided that cells obtained by TRIC 
expressed many known trophoblast markers, indicating an EVT phenotype.  Therefore, TRIC 
can provide a novel window into the molecular mechanisms controlling EVT cells during 
development and pathology.  Based on their expression of genes associated with the EVT 
phenotype, it is interesting to note that displacement to the cervix has not greatly altered these 
cells due to a new environment.  Further analysis by direct comparison to authentic EVT cells is 
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necessary to establish the extent of impact from this dislocation.  Our pilot study provides an 
initial view of transcripts that are differentially expressed between EVT cells of normal term 
pregnancies and those that end in an EPL.  Here, we postulate that EPL is the result of severe 
placental insufficiency.  In using TRIC, we are the first to examine EVT cells in the first 
trimester from pregnancies with known outcomes.  We can report, based on the altered 
expression of 348 genes, that the EVT cells are indeed disrupted in placental insufficiencies, as 
long hypothesized (Burton and Jauniaux, 2004). 
Fritz et al, found a half-dozen proteins that altered in EVT cells from the cervix of 
patients that had an EPL, compared to those with a normal term pregnancy (Fritz et al., 2015a), 
confirming expectations based on published changes in serum levels of those proteins at much 
later times during gestation.  Recent studies demonstrated the same protein changes in cervical 
EVT cells from patients that later developed FGR or PE (Bolnick et al., in press), suggesting a 
relationship between those proteins and EVT failure to remodel the spiral arteries prior to 
placental insufficiency.  It would be interesting to determine global molecular changes in EVT 
cells associated with disease, using transcriptomic, proteomic and other systems biology 
approaches.  Here, we have found through bioinformatics differences between EVT and maternal 
cells indicative of EMT.  Additionally, the differentially expressed genes in pregnancies with 
EPL represented several interesting pathways, including inflammation, apoptosis, placental 
disease and gestation trophoblastic disease.  These are not unexpected findings, and they support 
the validity of our data.  Future pre-clinical studies with greater sample numbers should be 
conducted to firmly establish molecular profiles of control and disease pregnancies to provide 
insight into changes in signaling pathways associated with placental insufficiencies.  
Comparisons among cohorts of EVT cells obtained by TRIC that are associated with 
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normal or adverse pregnancy outcomes could provide an in-depth validation that these cells 
accurately reflect pathologies arising from EVT deficiencies, as supported by our data.  These 
studies will provide a clearer view of the utility of EVT cells as a platform for perinatal testing to 
predict maternal risk of placenta-based disease.  The current choice of biomarkers for adverse 
outcomes is limited to a few found in serum, usually late in gestation.  Screening the fetal 
genome, proteome and transcriptome by TRIC during the first trimester will expand the pool of 
potential biomarkers by several orders of magnitude. 
Although neither HBEGF nor MMP2 gene expression was altered by EPL, we did find a 
decrease in expression of HSP90B. HSP90 works with HSP70 (Hernandez et al., 2002; Wegele 
et al., 2004), a critical gene in HBEGF upregulation (Chapter 2).  Based on findings in Chapters 
2 and 3, we know that HBEGF is post-transcriptionally regulated. In the future, proteomics could 
be used to investigate components of the RISC affected by placental insufficiency that could be 
involved in HBEGF regulation.  While the studies in this dissertation have raised many 
questions, the findings provide a way forward towards understanding mechanisms that regulate 
trophoblast survival and differentiation using the TRIC platform in conjunction with a systems 
biology approach. 
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HBEGF, is present in the uterus at the time of embryo implantation and protects first 
trimester TB cells from apoptosis and promotes their invasion.  The hypertensive disease, PE, in 
which TB invasion of the uterine arteries is reduced and TB apoptosis is elevated, is 
characterized by a reduction in HBEGF expression.  In this study using a first trimester cell line 
and villous explant culture key components involved in HBEGF survival signaling pathway were 
identified.  Specific MMP inhibitors established the requirement for MMP2 in HBEGF shedding 
and upregulation. NGS identified a HIF regulated gene, HSPA6 (HSP70B’) and using specific 
inhibitors it was established that HSP70 regulates MMP2 mediated shedding of HBEGF at low 
O2 and is functional upstream of MAPKs signaling cascade.  To further investigate HBEGF 
upregulation at low O2 using NGS and siRNA knockdown of DGCR8 it was demonstrated that 
other components of RISC may be involved in regulation of HBEGF mRNA translation.  These 
findings suggest that trophoblast survival during early pregnancy requires this signaling pathway 
and disruption of any component could lead to placental insufficiency.  However, a global 
platform is needed to study the pathophysiology of trophoblast cells and their role in placental 
insufficiency.  
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TRIC is an innovative platform to noninvasively acquire fetal cells.  DNA was extracted 
from fetal cells isolated from 20 specimens with gestational age as early at 5 weeks to 19 weeks.  
This was followed by targeted sequencing using the Forenseq (Illumina) platform to identify 
informative SNPs.  Using the Forenseq software 89% ± 12% of the 94 SNPs were called 
correctly in the fetal samples.  Using the STR analysis out of the 20 fetal samples, 9 males were 
confirmed.  Therefore, TRIC not only provides fetal cells but also opens new venues of perinatal 
testing. 
TRIC provides ample RNA from isolated fetal cells for extensive transcriptomic analysis.  
Using qPCR it was demonstrated that the fetal cells have higher expression for EVT specific 
markers such as HLA-G and KRT7 and markers for invasion/migration such as CDH5 and 
MMP9, whereas the maternal cells have a higher expression for epithelial markers such as CDH1 
and ITGA6. This suggests that not only are the fetal cells EVT like but may also undergo an 
epithelial mesenchymal transition.  Comparison of fetal and maternal cells from normal group 
using NGS identified 409 genes, of which top 5 upregulated and downregulated genes were 
validated by qPCR.  Pathway analysis of the differentially regulated identified pathways related 
to invasion/migration, proliferation and differentiation, further suggesting the EVT like 
expression of the fetal cells.  NGS revealed 348 differential expressed genes on comparison of 
the EVT like fetal cells from the EPL group to those from the normal group that were further 
validated by qPCR.  Bioinformatic analysis identified pathways related to apoptosis, 
inflammation and placental disease.  
The exact origin and biology of cervical EVT cells, and their relationship to the human 
placenta and pregnancy outcomes, are widely unknown.  Based on our study so far it can be 
hypothesized that as the placenta grows, EVT cells are naturally shed into the cervical canal, and 
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their overall phenotype is comparable to the EVT cells residing in the placenta.  These studies 
will provide a clearer view of the utility of EVT cells obtained by TRIC from ongoing 
pregnancies for investigating early placentation and mechanisms of pathology, and their potential 
as a platform for prenatal tests to predict maternal risk of placenta-based disease.  
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05/2015 Presented a poster at the Annual Mott Centre Retreat held on May 8th, 2015. 
05/2015 Awarded the 2015-2016 Thomas C. Rumble University Graduate Fellowship WSU  
03/2016 Awarded 3rd prize at WSU-Graduate Research Symposium held on Mar 23rd 2016 
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